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Cellular communication by WNT signalling is crucial for growth, patterning, and tissue homeo-
stasis of metazoan animals and has been associated with various human diseases, such as 
cancer. The different branches of this signalling cascade are induced after the secretion of 
WNT ligands by the WNT cargo protein evenness interrupted/Wntless (EVI/WLS). The availa-
bility and stability of many proteins involved in the WNT signalling pathways is regulated by 
post-translational mechanisms. In the absence of WNTs, EVI/WLS is modified with ubiquitin 
and subjected to endoplasmic reticulum (ER)-associated degradation (ERAD) by the pro-
teasome. ERAD is well known to remove misfolded proteins from the ER but can also affect 
cellular signalling by degrading mature proteins associated with secretory routes. However, 
the latter type of regulation is not well studied in mammals. In addition, the mechanisms leading 
to the recognition, ubiquitination, and proteasomal targeting of EVI/WLS remain largely elusive. 
To gain insights into how ERAD and ubiquitination components regulate EVI/WLS, I 
performed a RNAi-based screen on EVI/WLS protein stability and used biochemical and cell 
biological methods in human cells with diverse genetic backgrounds. I discovered that the ER-
membrane associated proteins ERLIN2, FAF2, and UBXN4 are novel components of the 
EVI/WLS ‘destruction complex’. Mechanistically, ERLIN2 links EVI/WLS to the ubiquitination 
machinery, while FAF2 and UBXN4 interact with EVI/WLS and VCP, potentially to mediate its 
extraction from the ER membrane. Surprisingly, I also found that EVI/WLS is ubiquitinated and 
degraded in cells irrespective of their WNT activity. This K11-, K48-, and K63-linked ubiquitina-
tion is mediated by the E2 ubiquitin conjugating enzymes UBE2J2, UBE2K, and UBE2N and 
leads not only to the regulation of EVI/WLS protein levels, but also influences WNT secre-
tion. Analysing the functional impact of EVI/WLS abundance revealed that EVI/WLS protein 
levels and the secretion of WNT11 influence the invasive capacity of malignant melanoma cells. 
This suggests that the adaptive regulation of EVI/WLS can be important for the phenotypic 
manifestation and presumably progression of human malignancies. 
In summary, my data shows an unanticipated complex ubiquitination pattern of 
EVI/WLS and three novel interaction partners, thus providing important details on the post-
translational modification and fate of an endogenous ERAD substrate in mammalian cells. The 
abundance of EVI/WLS is essential for context-dependent WNT ligand secretion and thus gov-
erns the malignancy of several tumours, among them melanoma. Targeting EVI/WLS protein 










Die Zellkommunikation mittels WNT Signalwegen ist notwendig für das Wachstum, die Musterbil-
dung und die Gewebehomöostase aller vielzelligen Tiere. Störungen oder Veränderungen in WNT 
Signalwegen tragen zu der Entstehung zahlreicher Krankheiten bei, wie beispielsweise Krebs. Die 
Initiation der WNT Signalkaskaden geschieht durch die Sekretion von WNT Liganden mit Hilfe des 
Transportproteins evenness interrupted/Wntless (EVI/WLS), wobei viele der beteiligten Proteine 
posttranslational reguliert werden können. Sind keine WNT Liganden vorhanden, wird EVI/WLS 
ubiquitiniert und durch den endoplasmatischen Retikulum (ER)-assoziierten Abbau (engl. ER-
associated degradation, ERAD) dem Proteasom zugeführt. ERAD dient normalerweise dazu, fehl-
gefaltete Proteine aus dem ER zu entfernen, kann aber durch den Abbau funktionaler Proteine auch 
Signaltransduktionswege beeinflussen. Diese Art der Regulation wurde allerdings in Säugetierzel-
len bisher nur wenig untersucht und auch bezüglich der Erkennung, der Ubiquitinierung und der 
Überführung von EVI/WLS an das Proteasom bleiben viele Fragen offen. 
Um die Regulation von EVI/WLS durch Ubiquitinierung und ERAD besser verstehen zu kön-
nen, habe ich einen RNAi-basierten Screen von zahlreichen ERAD-assoziierten Faktoren durchge-
führt und die Ergebnisse durch biochemische und zellbiologische Experimente in verschiedenen 
genetischen Hintergründen validiert. Ich habe herausgefunden, dass ERLIN2, FAF2 und UBXN4 
am Abbau von EVI/WLS beteiligt sind. ERLIN2 verbindet EVI/WLS mit dem Ubiquitinsystem, wohin-
gegen FAF2 und UBXN4 mit EVI/WLS und der ATPase VCP interagieren, vermutlich um EVI/WLS 
aus der ER Membran zu entfernen. Überraschenderweise wurde EVI/WLS in Zellen unabhängig 
von deren WNT Aktivität ubiquitiniert und abgebaut. Diese K11-, K48-, und K63-verbundene 
Ubiquitinierung wurde durch die E2 Ubiquitin-konjugierenden Enzyme UBE2J2, UBE2K und UBE2N 
gewährleistet und beeinflusste nicht nur die Verfügbarkeit von EVI/WLS, sondern auch die Sekre-
tion von WNT Liganden. Weitere Untersuchungen zur Funktionalität von EVI/WLS ergaben, dass 
die Verfügbarkeit von EVI/WLS und die Sekretion von WNT11 einen Einfluss auf die Invasivität von 
Melanomzellen hatten. Dies lässt vermuten, dass die Feinregulation von EVI/WLS möglicherweise 
wichtig für den Verlauf von menschlichen Krankheiten sein kann. 
Zusammengefasst zeigen meine Daten ein unerwartet komplexes Muster der EVI/WLS-
Ubiquitinierung sowie drei neue EVI/WLS Interaktionspartner, wodurch neue Erkenntnisse hinsicht-
lich der posttranslationalen Modifizierung und Verarbeitung von endogenen ERAD Substraten in 
Säugetierzellen geliefert werden. Dabei ist die Menge an EVI/WLS Protein nicht nur entscheidend 
für die kontextabhängige Sekretion von WNT Liganden, sondern letztlich für die Malignität verschie-
dener Tumoren, wie dem Melanom. Die posttranslationale Regulation von EVI/WLS könnte deshalb 








To maintain protein homeostasis is a major challenge for all organisms and changes in protein 
abundance can alter cellular physiology and lead to diseases. Both the adequate synthesis and 
the organised removal of proteins are essential to avert cellular stress. Importantly, quality con-
trol mechanisms can also impact on a cell’s signalling by regulating protein quantity. A better 
understanding of these processes, their components, and their interplay will advance basic 
research and can potentially help to find novel treatment possibilities for diseases dependent 
on these signalling pathways. 
The WNT pathways are well-known signalling cascades which can be regulated by pro-
tein abundance. For example, β-catenin, which is one of their major effectors, is degraded by 
the proteasome in the absence of WNT ligands, thus blocking downstream effects. In this PhD 
thesis, I present novel insights into ubiquitination and endoplasmic reticulum (ER)-associated 
degradation of the WNT cargo protein evenness interrupted/Wntless (EVI/WLS) and discuss 
possible implications for cancer progression and treatment. 
2.1   The WNT signalling pathways and cancer 
Cellular communication and intercellular signalling are the cornerstones of metazoan life. 
Growth and patterning during development and tissue homeostasis in adults require well reg-
ulated, coordinated action of proteins over short and long ranges and on organismal level. 
Delineating signalling cascades, their interaction and regulation, allows us to better understand 
the logic behind cellular activity and to draw informed conclusions about their deregulation in 
diseases, such as cancer. Many developmental signalling programmes are reactivated during 
malignant transformation and offer potential targets for tumour therapy. 
2.1.1   Intercellular communication 
The exchange of information between cells is complex and relies on various different mecha-
nisms (Alberts et al., 2008). Information units can be transmitted between cells directly through 
a continuous, porous link (e.g. electrical signals passing through gap junctions between heart 
muscle cells) or by the exchange of molecules between cells, which are released from one cell 
and detected by receptors on the receiving cell (also referred to as ‘chemical synapse’). The 
three major modes of action of secreted signalling molecules are distinguished by their range: 
(i) autocrine messages are produced and received by the same cell, e.g. during clonal T cell 
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expansion after antigen recognition, (ii) paracrine signals instruct cells within immediate vicinity 
to the source signal, for instance during Wingless (Wg)-mediated patterning of the Drosophila 
wing imaginal disc, and (iii) endocrine signalling affects tissues far away from the molecule’s 
origin, as do for example hormones after release in the blood stream. The three most common 
types of cell surface receptors are ligand-gated ion channels (for example the acetylcholine 
receptors at the neuromuscular junction), guanine nucleotide-binding (G) protein-coupled re-
ceptors (which can be activated upstream of the phosphatidylinositol signal pathway) and en-
zyme-linked receptors, such as the epidermal growth factor receptor (EGFR), which dimerises 
upon ligand binding, causing the intracellular domains to phosphorylate each other. After re-
ception, the message of these signals is transduced inside the cell via a coordinated interaction 
of downstream proteins to evoke a cellular response. In many cases, signal transduction is 
propagated by reciprocal phosphorylation of proteins and eventually results in the activation 
of specific transcription factors that activate or repress the transcription of target genes. An 
example is the mitogen-activated protein kinase (MAPK) pathway downstream of exempli gra-
tia (e.g.) EGFR activation. This results in the subsequent phosphorylation and activation of rat 
sarcoma (RAS), rapidly accelerated fibrosarcoma (RAF), MAPK/extracellular signal-regulated 
kinase (ERK) kinase (MEK), and finally ERK/MAPK, which in turn regulates several transcription 
factors and other downstream effects (Schadendorf et al., 2015). 
2.1.2   WNT ligands are conserved morphogens 
Tight spatiotemporal regulation of gene expression is imperative to ensure proper growth and 
patterning during development. A common mechanism among metazoans to achieve this are 
morphogens, conserved secreted signalling cues that build opposing gradients in the early 
embryo and govern target gene transcription through availability and activity in combination 
with underlying transcription networks (Briscoe & Small, 2015). An important family of morpho-
gens are Wnt ligands, which are involved in the pattering of the vertebrate neural tube or the 
drosophila wing, for example (Briscoe & Small, 2015; Wiese et al., 2018). Though it is still under 
debate whether Wnt ligand gradient formation or spreading in the drosophila wing imaginal 
disc is necessary for wing development, the importance of Wnt signalling itself is undisputed 
(Alexandre et al., 2014; Ewen-Campen et al., 2020; J. J. S. Yu et al., 2020). In adults, Wnt 
ligands play an important role in tissue homeostasis, turnover, and repair by regulating the 
adult stem cell populations of various tissues (Nusse & Clevers, 2017; T. Sato et al., 2009). Wnt 
ligands are secreted glycoproteins which often carry a lipid-modification. They can be grouped 
in 13 subfamilies with high vertical conservation and are encoded in the genomes of most 
 
   2   Introduction 
3 
 
animals, but are absent from unicellular organisms, as well as from plants and fungi (Holstein, 
2012). 
Binding to a distinct subset of receptors and co-receptors on the Wnt receiving cell sets 
several intracellular signal transduction cascades in motion, which can be grouped functionally 
in β-catenin dependent (‘canonical’) or independent (‘non-canonical’) pathways (see 2.1.4 and 
2.1.5). In this regard, the human WNT ligands WNT1, WNT3/3A, and WNT10A/B are classified 
as ‘canonical’ and have very well-defined physiological roles and receptor binding partners, 
whereas WNT5A and WNT11 induce the less well studied ‘non-canonical’ WNT- Frizzled 
(FZD)/planar cell polarity (PCP) and the WNT/Ca2+ pathways (Niehrs, 2012; Nusse & Clevers, 
2017; Voloshanenko et al., 2017; Zhan et al., 2017). The cellular response depends on the 
specific pair of WNT ligand and receptor, the cell-type and the tight interplay with other path-
ways, such as MAPK or hedgehog signalling (Ishitani et al., 2003; Ouspenskaia et al., 2016; 
Zhan et al., 2019). Mutations in components of the WNT signalling pathways can lead to he-
reditary diseases, such as Robinow syndrome, delays in development (Mancini et al., 2020), or 
lead to cancer (Afzal et al., 2000; Nusse & Clevers, 2017; van Bokhoven et al., 2000). 
2.1.3   WNT ligand maturation and secretion 
The expression of each of the 19 human WNT ligands is tightly regulated and induced in a 
context and tissue-dependent manner in the WNT secreting cell. WNTs are about 40 kDa large, 
cysteine rich proteins, which are co-translationally imported into the ER, where they are glyco-
sylated and lipid-modified by the protein-serine O-palmitoleoyltransferase porcupine (PORCN) 
on a conserved serine (Siegfried et al., 1994; Takada et al., 2006; Willert et al., 2003). This 
modification allows their interaction with the WNT cargo protein EVI/WLS, which helps in the 
anterograde transport of WNTs to the extracellular space (Bänziger et al., 2006; Bartscherer et 
al., 2006; Goodman et al., 2006). Furthermore, the lipid modification is important for the binding 
of WNTs to the cysteine-rich domain (CRD) of FZD receptors on their target cell (Janda et al., 
2012). It was also recently reported that several non-acylated WNTs could induce downstream 
signalling (Speer et al., 2019), however, this study awaits further independent confirmation. 
Surprisingly for a pathway this intricate, the secretion and activity of most WNT ligands was 
hitherto reported to depend on the lipid-modification and the interaction with EVI/WLS, the only 
exception being the distantly related Drosophila WntD (Ching et al., 2008). This in turn allows 
researchers to block all WNT signalling pathways by inhibiting either EVI/WLS or PORCN, for 
example with the small-molecule PORCN inhibitor LGK974 (J. Liu et al., 2013). LGK974 and 
several other WNT signalling inhibitory agents are the focus of multiple ongoing clinical trials 
in liquid and solid cancers, but systemic inhibition of WNT signalling results in side effects such 
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as decreased bone mass and strength or loss of taste sensation (Jung & Park, 2020; L.-S. 
Zhang & Lum, 2018). 
2.1.3.1   WNT ligand secretion 
Mature WNT ligands associate with EVI/WLS in the ER and are recruited into coat protein com-
plex (COP) II vesicles by association with secretion associated RAS related GTPase 1 (SAR1) 
and the help of transmembrane p24 trafficking proteins (Buechling et al., 2011; Port et al., 2011; 
Jiaxin Sun et al., 2017; J. Yu et al., 2014). They are then transported to the Golgi and to the 
plasma membrane in an RAS-associated binding (RAB) 8A dependent mechanism (Das et al., 
2015). Subsequent free diffusion of WNTs in the extracellular space without any binding part-
ner is unlikely due to their lipid modification. Therefore, several distinct routes have been pro-
posed to explain how WNT ligands are delivered to the target cell over short and long distances 
(Figure 1). It is conceivable that these routes are used in parallel and in an organism and con-
text dependent manner. One proposed mechanism to stabilise lipidated WNTs in the extracel-
lular space are glypicans, plasma membrane associated heparan sulphate proteoglycans 
Figure 1. WNT ligand secretion is coupled to 
EVI/WLS and its recycling 
WNT ligands are co-translationally imported into 
the endoplasmic reticulum (ER), where they are 
lipid-modified by the acyl-transferase Porcupine 
and associate with the cargo protein EVI/WLS. 
From the ER, WNTs and EVI/WLS travel to the 
Golgi apparatus with coat protein complex (COP) 
II vesicles and then to the plasma membrane. 
Several mechanisms for WNT ligand secretion or 
presentation on the cell surface with or without 
EVI/WLS have been proposed and it is conceiv-
able that they operate in a context dependent 
manner. EVI/WLS is re-internalised from the 
plasma membrane with the help of clathrin and 
AP2 and shuttled back to the Golgi in a retromer-
dependent process. From there, it is recycled 
back to the ER by ADP-ribosylation factor (ARF), 
endoplasmic reticulum-Golgi intermediate com-
partment protein 2 (ERGIC2) and COP I vesicles. 
In the ER, EVI/WLS can engage again with WNT 
ligands and assist in their secretion. See main 
text for further details and abbreviations. 
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(Routledge & Scholpp, 2019). Other observed ways for short-range signalling rely on the 
transport of WNTs in a cell membrane-bound manner by cell division (Farin et al., 2016) and 
through signalling filopodia, so-called cytonemes (Mattes et al., 2018). 
It was also shown that active WNTs bound to EVI/WLS (or WNT or EVI/WLS alone) are 
secreted on exosomes after sorting to multivesicular bodies with the help of the endosomal 
sorting complexes required for transport (ESCRT) complex and the synaptobrevin homolog 
YKT6 (Gross et al., 2012; Korkut et al., 2009). This process was dependent on retromer and 
depletion of retromer led to the sorting of EVI/WLS to lysosomes (Gross et al., 2012). In general, 
several mechanism have been proposed that explain WNT long range transport by association 
of WNTs with other proteins or particles, ranging from transport on microvesicles and lipopro-
tein particles (LPP) to multimere formation and association with lipid-binding proteins, e.g. se-
creted wingless-interacting molecule (SWIM) or soluble FZD related proteins (sFRP, Routledge 
& Scholpp, 2019). Nevertheless, it remains unclear how WNTs are ‘handed-over’ to their re-
ceptor after they arrive at their target cell. This process probably involves several conforma-
tional changes (Routledge & Scholpp, 2019). 
2.1.3.2   The WNT cargo protein EVI/WLS 
It is commonly accepted that the transport of lipid-modified WNT ligands in the secreting cell 
depends on EVI/WLS, the only known dedicated WNT cargo protein (Najdi et al., 2012). Indeed, 
several examples demonstrate that WNT protein secretion is regulated by the availability of 
EVI/WLS protein (Galli et al., 2014, 2016; Glaeser et al., 2018). Despite this important function, 
only little is known about the structure and regulation of EVI/WLS. The human EVI/WLS gene 
(Genecode transcript: ENST00000262348.9) is located on the minus strand of chromosome 1. 
It encodes 12 exons and three different transcript variants with presumably overlapping but 
not identical functions (Petko et al., 2019). The canonical sequence (Uniprot ID: Q5T9L3-1) 
encodes a protein that is 541 amino acids in length and has a predicted mass of 63 kDa. How-
ever, the detected size of EVI/WLS in Western blots ranges rather from 35 kDa to 45 kDa and 
the difference remains unexplained. 
EVI/WLS gene expression is regulated by SOX2 in human embryonic stem cells (Zhou 
et al., 2016), and while one early study also described EVI/WLS as being transcriptionally reg-
ulated by canonical WNT signalling in mice (Fu et al., 2009), this could not be confirmed in flies 
or humans (Glaeser et al., 2018; Herr & Basler, 2012). By contrast, Glaeser et al., 2018, showed 
that EVI/WLS protein levels increase after overexpression of WNT ligands due to posttransla-
tional stabilisation through inhibition of ERAD. EVI/WLS is ubiquitinated by UBE2J2 and cell 
growth regulator with really interesting new gene (RING) finger domain protein 1 (CGRRF1), 
but the knock-down of both enzymes did not completely abolish EVI/WLS ubiquitination, 
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indicating the involvement of further proteins or residual enzyme activity (Glaeser et al., 2018). 
The degradation of EVI/WLS was mediated by a complex containing EVI/WLS, PORCN, and 
Valosin-containing protein (VCP/p97, Cdc48 in yeast), but it is still unclear how VCP is recruited 
to the complex or if additional interaction partners are involved (Glaeser et al., 2018). A recent 
study in Caenorhabditis elegans (C. elegans) found that K63-linked Ubiquitin was important for 
the transport and function of EVI/WLS, however without directly showing its ubiquitination or 
the presence of other linkage types (J. Zhang et al., 2018). Beside ubiquitination, EVI/WLS is 
also posttranslationally modified with N-linked oligosaccharides, but the exact amino acid po-
sition(s) of either modification have not been fully elucidated (Jin, Morse, et al., 2010). 
 
Figure 2. Protein structure of EVI/WLS with reported ubiquitination sites 
EVI/WLS is an 8-pass transmembrane protein with a large, unstructured luminal loop close to its N-terminus. This loop is important 
for its binding to lipid modified WNTs (salmon colour). The first 42 amino acids (orange colour) were predicted to be the signal 
peptide (Das et al., 2012), but studies showed that it is not cleaved off (Jin, Morse, et al., 2010). The third cytosolic loop contains 
the internalisation motif YEGL (yellow colour) and the FLM motif (brown colour), which is important for the interaction with the 
retromer complex. The KEAQE sequence (teal colour) at the C-terminus is the signal for retrograde transport to the ER. Numbers 
indicate amino acid positions, TM = transmembrane domain, Ub = ubiquitin, topology according to UniProt ID:  Q5T9L3, entry 
version 133 
The N-terminus of EVI/WLS contains a putative signalling peptide which presumably 
regulates its co-translational insertion into the ER membrane (Figure 2). This sequence does 
not contain a cleavage site and experiments with N-terminal protein tags suggest that the ‘sig-
nal peptide’ is indeed not cleaved and still present in the mature protein, forming the first of 
eight transmembrane domains (Bartscherer et al., 2006; Jin, Morse, et al., 2010). This notion 
is supported by analyses that show that both the N- and the C-terminus face the cytoplasm, 
suggesting an even number of transmembrane domains (Jin, Morse, et al., 2010; Korkut et al., 
2009). The first ER-luminal or extracellular loop at the N-terminus contains an unstructured 
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region required for the interaction of EVI/WLS with lipidated WNTs (Coombs et al., 2010; Fu et 
al., 2009; Herr & Basler, 2012). Modelling of this region by Coombs et al., 2010, suggested it 
had a structure similar to the lipocalin-family fold, however analysis in our lab could not reca-
pitulate this (Michaela Holzem, personal communication). Additional important structural fea-
tures are the YEGL and the FLM tripeptide motif in the third intracellular loop (Figure 2). 
The former is recognised by adaptor protein 2 (AP-2) to initiate clathrin- and casein 
kinase (CK) 2-mediated internalisation of EVI/WLS from the plasma membrane (de Groot et al., 
2014; Gasnereau et al., 2011; Pan et al., 2008). These carriers are destined to fuse with early 
endosomes, which play a major role in cargo sorting to either lysosomal degradation or recy-
cling. The latter motif, FLM, is thought to be important for the interaction of EVI/WLS with the 
conserved heterotrimeric peripheral membrane protein complex retromer (Belenkaya et al., 
2008; Franch-Marro et al., 2008; Port et al., 2008; P.-T. Yang et al., 2008). Under physiological 
conditions, EVI/WLS is recruited into recycling vesicles already at early endosomes by its in-
teraction with the sorting nexin 3 (SNX3) retromer complex in a phosphatidylinositol-3-phos-
phate dependent manner (Harterink et al., 2011; Lorenowicz et al., 2014; P. Zhang et al., 2011). 
This special retromer variant requires a membrane remodelling complex composed of MON2, 
DOPEY2, and probable phospholipid-transporting ATPase IIA (ATP9A) to form transport carri-
ers (McGough et al., 2018; Zhao et al., 2020). After retromer-dependent retrieval of EVI/WLS 
to the trans-Golgi network, it is recycled back to the ER by endoplasmic reticulum-Golgi inter-
mediate compartment protein 2 (ERGIC2) and the COP I vesicle regulator ADP-ribosylation 
factor (ARF) in a process dependent on the KEAQE sequence at its C-terminus (see Figures 1 
and 2, J. Yu et al., 2014). 
The requirement of WNT signalling for development and homeostasis of multiple em-
bryonic and adult tissue types explains the broad expression pattern of mammalian EVI/WLS 
(Jin, Morse, et al., 2010) and why its homozygous knock-out is embryonic lethal in mouse mod-
els (Carpenter et al., 2010; Fu et al., 2009). Conditional, tissue specific mouse models were 
developed and confirmed the importance of EIV/WLS for liver growth (Leibing et al., 2018), 
development of the pulmonary vasculature (Cornett et al., 2013; Jiang et al., 2013), or mam-
mary development (Maruyama et al., 2013), among others. EVI/WLS was even implicated in 
drug addiction through its interaction with the mu-opioid receptor (Jin, Kittanakom, et al., 2010). 
Importantly, it is frequently overexpressed in various types of cancer (Augustin et al., 2012; 
Glaeser et al., 2018; Seo et al., 2018; Voloshanenko et al., 2013; H. Xu et al., 2016), and also 
regulates immune cell recruitment (Augustin et al., 2016). Conversely, EVI/WLS was found to 
be decreased in melanoma cell lines and patient samples compared to non-malignant controls 
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and its downregulation induced metastasis formation in a xenograft melanoma mouse model 
(P.-T. Yang et al., 2012). 
2.1.4   β-catenin-dependent/canonical WNT signalling 
β-catenin has two distinct cellular functions: on the one hand, it is part of the cadherin cell 
adhesion system at the plasma membrane (Peifer et al., 1992), on the other hand it is an im-
portant signalling molecule in the cytoplasm that can translocate into the nucleus (Behrens et 
al., 1996; Molenaar et al., 1996). β-catenin can be exchanged between these two pools (Gross-
mann et al., 2013) and is additionally constantly replenished by newly translated protein. The 
best-studied WNT-dependent signalling pathway, the ‘canonical’ pathway (Figure 3), relies on 
the accumulation of β-catenin in the cytoplasm and the subsequent activation of target gene 
expression in a tissue and context dependent manner. It mainly activates proliferation or dif-
ferentiation, for example via the proto-oncogene MYC (He et al., 1998). A universal target gene 
is axis inhibition protein (AXIN) 2, which is also commonly used as a read-out for β-catenin-
dependent WNT signalling activation (Lustig et al., 2002; Nusse & Clevers, 2017). In the ab-
sence of WNT ligands, cytoplasmic β-catenin is constantly targeted for degradation by the ‘de-
struction complex’ grouped around the scaffold protein AXIN (Ikeda et al., 1998; L. Zeng et al., 
1997). AXIN and its interaction partners, most notably AXIN2, adenomatous polyposis coli 
(APC), and the two serine/threonine kinases glycogen synthase kinase-3 (GSK-3α/β) and CK 
1α/δ, bind β-catenin and mediate its N-terminal phosphorylation (Behrens et al., 1998; Ikeda et 
al., 1998; Chunming Liu et al., 2002; Munemitsu et al., 1996). Phosphorylated β-catenin is rec-
ognised and ubiquitinated by β-transducin repeat-containing protein (β-TrCP), and subse-
quently degraded by the proteasome (Aberle et al., 1997; Kitagawa et al., 1999; Winston et al., 
1999). Additionally, β-catenin can be ubiquitinated by other proteins and cause context-de-
pendent effects (Chenxi Gao et al., 2014). In the absence of β-catenin in the nucleus, the tran-
scription factors T cell factor (TCF) and lymphoid enhancer factor (LEF) repress transcription 
of their target sites by interaction with transducin-like enhancer protein (TLE, Groucho in Dro-
sophila), among others (Cavallo et al., 1998; Roose et al., 1998). 
Binding of canonical WNT ligands to FZD receptors and low-density lipoprotein-recep-
tor-related proteins 5/6 (LRP5/6) induces the phosphorylation of LRP5/6 by GSK3 and CK1γ 
(Davidson et al., 2005; X. Zeng et al., 2005) and the recruitment of Dishevelled (DVL) to FZD 
(Tauriello et al., 2012). Thus, AXIN and other components of the destruction complex are re-
cruited to the cell membrane and inhibited (Fiedler et al., 2011; Zhan et al., 2017). The hereby 
stabilised cytosolic β-catenin can then translocate into the nucleus, where it interacts with 
TCF/LEF and converts their repressive function transiently into transcriptional activation, 
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together with additional binding partners, e.g. B-cell lymphoma 9 (BCL9, J. Behrens et al., 1996; 
Kramps et al., 2002; Molenaar et al., 1996). 
The abundance of FZD receptors at the plasma membrane determines WNT signalling 
and they are important targets of posttranslational regulation. The two homologous transmem-
brane Ub ligases RING finger protein (RNF) 43 and zinc and RING finger 3 (ZNRF3) ubiquitinate 
FZD receptors and LRP6 and thus initiate their lysosomal degradation. Secreted R-Spondin 
(RSPO) inhibits these two ligases by recruiting them to complexes with leucine-rich repeat 
containing G protein-coupled receptor 4/5 (LGR4/5), resulting in increased responsiveness of 
the cell towards WNT ligands (H.-X. Hao et al., 2012; Koo et al., 2012; Nusse & Clevers, 2017). 
WNT signalling can also be inhibited by secreted antagonists. Dickkopf (DKK) and Sclerostin 
(SOST) bind to LRP5/6, possibly interrupting the interaction with FZD receptors, and sFRP and 
WNT inhibitory protein (WIF) can interfere with WNTs directly (Glinka et al., 1998; Nusse & 
Clevers, 2017). 
Figure 3. The canonical/β-catenin dependent WNT signalling pathway 
The binding of WNT ligands to Frizzled and LRP5/6 receptors on the cellular surface of a WNT responsive cell leads to several 
downstream events and the inhibition of the β-catenin destruction complex, consisting of AXIN, APC, GSK3, and CK1. Subse-
quently, β-catenin accumulates in the cytoplasm and translocates into the nucleus to interact with TCF/LEF, thus activating tran-
scription of cell type specific and context-dependent target genes. In the absence of WNT ligands, the destruction complex phos-
phorylates β-catenin, thus allowing its binding to the E3 ligase complex β-TrCP/SRC and its polyubiquitination and proteasomal 
degradation. Other inhibitors of canonical WNT signalling include the secreted factors DKK, SOST, WIF, and sFRP, which  have 
various distinct modes of action. An important enhancer of the displayed signalling cascade is RSPO, which can bind to LGR4/5 
and the E3 ligases RNF43 and ZNRF3, thus inhibiting the ubiquitination and degradation of Frizzled receptors and leading to 
increased abundance of the receptors. See main text or 6.4.1 for protein name abbreviations. 
Importantly, the inhibition of GSK3 after the engagement of FZD and LRP5/6 with WNTs 
does not only activate β-catenin dependent signalling. In addition, it also prevents the phos-
phorylation, ubiquitination, and degradation of other GSK3 substrates and thus has an im-
portant role in various cellular processes, such as cell-cycle progression. This effect is called 
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WNT-dependent stabilisation of proteins (WNT/STOP) and is one of several alternative 
branches of this intricate pathway (Acebron & Niehrs, 2016). 
2.1.5   Non-canonical WNT signalling by WNT5A and WNT11 
In contrast to canonical WNT signalling, several so-called ‘non-canonical’ signalling pathways 
exist, which act downstream of FZD and DVL but do not primarily result in the stabilisation of 
β-catenin (Chan Gao & Chen, 2010). They have important instructive or permissive roles during 
embryonal pattern formation or cell migration, among others (Y. Yang & Mlodzik, 2015). In 
general, these pathways have no well-defined molecular endpoint and are therefore more dif-
ficult to analyse and less well studied (Voloshanenko et al., 2018). The best characterised non-
canonical WNT ligands in vertebrates are WNT5A and WNT11. Notably, WNT5A can also reg-
ulate β-catenin, demonstrating the high degree of overlap and complexity of the WNT pathways 
(van Amerongen et al., 2012). To exemplify the function of non-canonical WNT signalling, the 
two most investigated branches, WNT-FZD/PCP and WNT/Ca2+, are described in more detail 
below (Figure 4). 
PCP is essential to break symmetry during embryonal development and to pattern func-
tional complex organ structures. To achieve this, the core PCP components establish an asym-
metric network of protein complexes across the membranes of neighbouring cells by simulta-
neously inhibiting each other within the same cell and stabilising each other in bordering cells. 
These core PCP components are FZD, Vang-like protein (VANGL), Cadherin EGF LAG seven-
pass G-type receptor (CELSR), Prickle-like protein (PK), and DVL (Y. Yang & Mlodzik, 2015). 
In addition to this short-range signalling, the PCP components FZD and VANGL can also trans-
duce long-range cues. To do so, WNT5A or WNT11 bind FZD and its co-receptors receptor 
tyrosine kinase like orphan receptor (ROR) 1/2, receptor like tyrosine kinase (RYK), or protein 
tyrosine kinase (PTK) 7 to recruit and activate DVL, which in turn relieves repression of the 
cytoplasmic protein DVL associated activator of morphogenesis 1 (DAAM1) and associates 
with small GTPases of the RAS homolog family (Rho, especially with RHOA and RAC1). They 
then trigger Rho-associated protein kinase (ROCK) and rearrangements of the cytoskeleton as 
well as JUN N-terminal kinase (JNK) and transcriptional regulation, for example by cyclic AMP-
dependent transcription factor 2 (ATF2) and JUN phosphorylation (Boutros et al., 1998; Y. 
Yang & Mlodzik, 2015; Zhan et al., 2017). 
WNT5A binding to ROR2 also activates VANGL by phosphorylation (Y. Yang & Mlodzik, 
2015). Previously, it was suggested that the formation of a WNT ligand gradient was required 
for PCP during Drosophila wing development and that several WNTs had redundant functions 
in this process (J. Wu et al., 2013). However, recent studies described the formation of PCP in 
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the wing in the absence of WNT ligands, indicating that many of the underlying processes are 
still only rudimentary understood and suggesting that it might be important to reconsider the 
general role of WNT in PCP (Ewen-Campen et al., 2020; J. J. S. Yu et al., 2020). 
Figure 4. The ‘non-canonical’ WNT signalling pathways 
The so-called ‘non-canonical’ WNT signalling pathways act downstream of Frizzled and  Dishevelled (DVL) and do not primarily 
result in the stabilisation of β-catenin but have important roles during embryonal pattern formation or cell migration, amongst 
others. The core WNT/Planar Cell Polarity (PCP) components Frizzled, VANGL, CELSR, PK, DVL and the Diego o rthologs Inversin 
and Diversin establish an asymmetric network of protein complexes by inhibiting each other in the same cell and stabilising each 
other in neighbouring cells. They can also transduce long-range signalling by WNT5A or WNT11 and ROR1/2, RYK, or PTK7. The 
subsequent recruitment and activation of DVL, DAAM1, Diego and several members of the Ras homolog family (especially RHOA 
and RAC1) leads to ROCK-dependent rearrangements of the cytoskeleton or JNK mediated transcriptional regulation. 
WNT/Ca2+ signalling is initiated by WNT interaction with Frizzled and RYK, ROR1, or ROR2, which results in the intracellular acti-
vation of G protein and cleavage of PIP2 by PLC into IP3 and DAG. Binding of IP3 with its receptor at the ER membrane triggers the 
release of Ca2+ and activation of PKC and CAM. This leads to actin rearrangements by CDC42 and the activation of transcriptional 
programmes via NFAT and NLK, which can inhibit the transcription factor TCF/LEF and canonical/β-catenin dependent signalling. 
See main text or 6.4.1 for protein name abbreviations and further details. 
FZD proteins belong to the group of G protein-coupled receptors, and its attached het-
erotrimeric G protein is implicated in the recruitment of DVL and in various branches of 
WNT/FZD signalling, among them the WNT/Ca2+ pathway (Chan Gao & Chen, 2010; Xianjun 
Zhang et al., 2018). Engagement of WNT5A with FZD and non-canonical co-receptors (e.g. 
ROR2) results in the intracellular activation of G protein and subsequent cleavage of phospha-
tidylinositol-4,5-bisphosphate (PIP2) by phospholipase C (PLC) into inositol 1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG). Binding of IP3 with its receptor at the ER membrane triggers the 
release of Ca2+ and thus initiates further downstream events, such as conformational changes 
of protein kinase C (PKC) and calmodulin (CAM, Sheldahl et al., 2003; Slusarski et al., 1997). 
The activation of PKC by Ca2+ together with its binding to DAG at the plasma membrane leads 
to the polymerisation of actin through the GTPase cell division control protein 42 (CDC42) and 
also has major effects on mechanocoupling between endothelial cells (Carvalho et al., 2019; 
Schlessinger et al., 2007). CAM can in turn activate calcineurin, a Ca2+-dependent 
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phosphatase, and the Ca2+/CAM-dependent kinase II (CAMKII). Calcineurin dephosphorylates 
nuclear factor of activated T cells (NFAT), thus stimulating its translocation into the nucleus, 
where it controls various signalling programmes. The interaction of NFAT with deoxyribonu-
cleic acid (DNA) is inhibited by GSK3β-mediated phosphorylation (J. W. Neal & Clipstone, 
2001). It plays an important role in cancer, for example by mediating resistance to apoptosis 
or dedifferentiation (Griesmann et al., 2013; Perotti et al., 2016). CAMKII activates nemo-like 
kinase (NLK), which can inhibit the transcription factor TCF/LEF by phosphorylation in the nu-
cleus and thus impacts on canonical/β-catenin dependent signalling (Ishitani et al., 2003). 
2.1.6   Deregulated WNT signalling and melanoma 
Multi-layered misappropriation of autocrine, paracrine, or even endocrine cellular communica-
tion is cause or consequence of many ‘hallmarks of cancer’, for example when the tumour 
sustains its own proliferative signalling, activates invasion and metastasis, or escapes immune 
surveillance (Hanahan & Weinberg, 2011). WNT1 itself was first discovered as a proto-onco-
gene in mouse mammary tumours (Nusse & Varmus, 1982) and WNT signalling was later im-
plicated in the pathogenesis of various tumours, most prominently in colorectal cancer, where 
nearly all cases harbour alterations in WNT signalling components (Schatoff et al., 2017; Zhan 
et al., 2017). In contrast, the role of WNT signalling in melanoma seems to be less causative 
and more modulatory but is still only incompletely understood and requires further investiga-
tion (Webster et al., 2015). 
2.1.6.1   Cutaneous melanoma  
Cutaneous melanoma is a type of non-epithelial skin cancer that originates from melanocytes, 
neural crest derived cells that reside (among other locations) in the skin’s epidermis with close 
connection to the basement membrane and are responsible for skin colour (Schadendorf et 
al., 2015; J. X. Wang et al., 2016). Cutaneous melanoma is a common disease with an incidence 
of 10.2 and 13.8 per 100 000 person-years in 2012 in the European Union and North America, 
respectively, and responsible for the majority of skin cancer-related deaths (ca. 60 % in the 
United States of America, USA, in 2020, excluding basal-cell and squamous cell carcinoma, 
Schadendorf et al., 2018; Siegel et al., 2020). This is surprising, considering that clinical diag-
nosis and surgical management of patients with non-metastatic melanoma are at a very high 
level in central Europe and the USA, which results in a favourable outcome with a 5-year sur-
vival rate after primary diagnosis of over 90 % (Schadendorf et al., 2015; Siegel et al., 2020). 
However, patients with metastatic melanoma faced very poor prognosis and a median survival 
of only 6 months to 12 months until the early 2010s (Schadendorf et al., 2015). In the USA, the 
overall mortality rate of cutaneous melanoma dropped by 6.4 % in the years 2013 to 2017 
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(Siegel et al., 2020) and the 5-year overall survival rates for melanoma with distant metastasis 
increased from below 10 % to up to 40 % or higher by 2018 (Schadendorf et al., 2018). This 
unprecedented improvement in melanoma patient care is mainly attributed to better under-
standing of the molecular mechanisms of melanoma carcinogenesis and the according devel-
opment and approval of targeted therapies. 
The development of melanocytic neoplasms is driven by the sequential accumulation 
of point mutations and copy-number alterations. In many cases, the activating BRAF p.V600E 
mutation can already be found in benign precursor lesions and is accompanied in later inter-
mediate stages by mutations in the telomerase reverse-transcriptase (TERT) promotor and by 
the biallelic inactivation of cyclin-dependent kinase-inhibitor 2A (CDKN2A) in invasive mela-
noma. Metastatic melanoma is additionally characterised by mutations in phosphatase-and-
tensin homologue (PTEN) and tumour-protein p53 (Hodis et al., 2012; Schadendorf et al., 2018; 
Shain et al., 2015). In general, the point mutation burden and the number of mutations with 
ultraviolet (UV) radiation signature (e.g. C → T nucleobase exchange) is particularly high in 
many cutaneous melanomas compared to other cancers and reflect sun-induced damage (Ale-
xandrov et al., 2013; Shain et al., 2015). The hyperactivation of the MAPK pathway is the main 
driver of melanomas and only 10 % of cases do not harbour mutations in either BRAF (ca. 50 % 
of melanoma cases), the RAS genes (NRAS, KRAS, HRAS, ca. 25 % of melanoma cases), or 
Neurofibromin-1 (ca. 15 % of melanoma cases), which is a negative regulator of RAS (Schaden-
dorf et al., 2018). Another important characteristic of melanoma cells is immune evasion by 
inhibiting the antitumour immune response, for example by activating the programmed cell 
death protein 1 (PD-1) immune checkpoint through the expression of PD-1 ligands (Hassel et 
al., 2017). Accordingly, a combination therapy of BRAF and MEK inhibitors are now routinely 
used in the clinics to target the MAPK pathway and several immune checkpoint inhibitors are 
being implemented with great success (Schadendorf et al., 2018). However, not all patients 
benefit from these exciting developments and there are only few treatment options available 
for patients without overactivation of the MAPK pathway. Moreover, many patients develop 
resistance against BRAF- and MEK-inhibitors, leading to rapid relapse. Recent studies indicate 
that a large subset of patients do not respond to checkpoint inhibition and/or develop severe 
adverse events (Schadendorf et al., 2018; Wagle et al., 2011). This shows that the treatment of 
metastatic melanoma remains a major challenge and that further investigations of underlying 
pathomechanisms are required. 
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2.1.6.2   WNT signalling and phenotype switching in melanoma cells 
Melanocytes are neural crest derived cells that require WNT/β-catenin signalling for their em-
bryonic induction and depend on WNT/PCP signalling via WNT5A and WNT11 for their migra-
tion to the target tissue (Baker et al., 1997; De Calisto et al., 2005; Ikeya et al., 1997; Ji et al., 
2019; Ossipova & Sokol, 2011). Later during development, WNT/β-catenin signalling is im-
portant for melanocyte lineage specification by regulation of the transcription of microphthal-
mia-associated transcription factor (MITF) and its downstream targets, such as premelano-
some protein (PMEL), melan-A (MLANA), and tyrosinase (TYR, Gajos-Michniewicz & Czyz, 
2020; Hari et al., 2002; Kawakami & Fisher, 2017; Steingrímsson et al., 2004; Widlund et al., 
2002). Additionally, adult epidermal keratinocytes can secrete the canonical WNT7A ligand 
upon UV-light irradiation to induce the differentiation of melanocytes from multipotent, dermal 
precursor cells (J. X. Wang et al., 2016). 
Considering that WNT signalling is required for melanocyte differentiation and migra-
tion, it is not surprising that its role in melanoma tumorigenesis has also become more and 
more apparent, albeit it is far from being understood. In general, the occurrence of mutations 
in the β-catenin gene (CTNNB1) or other WNT signalling pathway components are low and 
thus, they are not considered to be main drivers of melanoma progression (Gajos-Michniewicz 
& Czyz, 2020). Nevertheless, researchers have unravelled a highly sophisticated dependency 
of melanoma on canonical and non-canonical WNT signalling in different stages of the disease. 
Canonical WNT3A signalling is assumed to be necessary for melanoma initiation but it inhibits 
disease progression in later stages. Furthermore, switching from canonical to non-canonical 
signalling (e.g. via WNT5A expression) has been demonstrated to allow metastasising of the 
tumour (Grossmann et al., 2013; M. P. O’Connell et al., 2010; O’Connell & Weeraratna, 2009; 
Weeraratna et al., 2002). This so-called ‘phenotype switching’ hypothesis (Figure 5) affects not 
only WNT signalling, but general transcriptional networks in melanoma cells (Hoek et al., 2008). 
It has replaced the idea of cancer stem cells in melanoma after it was shown that a large pro-
portion (25 % to 28 %) of melanoma cells have tumourigenic potential and no hierarchical or-
ganisation (Quintana et al., 2010, 2008; Restivo et al., 2017). In contrast to these findings 
Figure 5. The phenotype switching 
model of melanoma pathogenesis 
Melanoma cells can rewire their signalling 
programmes according to external cues 
and thus adopt a more ‘proliferative’ or 
‘migratory/invasive’ state. This so called 
‘phenotype switching’ is associated with 
the expression of canonical WNT3A or 
non-canonical WNT5A and respective 
gain or loss of microphthalmia-associated 
transcription factor (MITF) expression. 
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concerning WNT ligand expression, studies on the role of WNT secretion demonstrated that 
cell proliferation and metastasis formation is enhanced upon EVI/WLS knock-down (and re-
duced secretion of WNT5A) in a mouse xenograft model using the A375 cell line (P.-T. Yang 
et al., 2012). The authors further show decreased EVI/WLS levels in patient tumours and mel-
anoma cell lines compared to healthy controls (P.-T. Yang et al., 2012). This apparent discrep-
ancy remains mostly unexplained. 
The role of β-catenin in melanoma is controversial: several studies indicated a positive 
correlation of nuclear β-catenin, dependent on WNT3A, with patient survival (Chien et al., 2009) 
and a reduction of β-catenin-dependent activity of MITF with a more invasive phenotype and 
poor prognosis (Carreira et al., 2006; Hartman & Czyz, 2015). By contrast, other studies argue 
that β-catenin dependent signalling is associated with the formation of metastases and a more 
aggressive disease (Damsky et al., 2011). Grossman et al., 2013, used a gelatin degradation 
assay to show that stabilisation of β-catenin increased melanoma cell invasiveness. This assay 
relies on the formation of actin-based, proteolytic protrusions that are called podosomes in 
healthy cells or invadopodia in cancer (Paterson & Courtneidge, 2018). The pathophysiological 
activity of these protrusions is reflected by the amount of degraded underlying extracellular 
matrix after the formation of F-actin, cortactin, and SH3 And PX Domains 2A 
(SH3PXD2A/TKS5) positive puncta and the secretion of matrix metalloproteases (MMPs, Iizuka 
et al., 2016; Paterson & Courtneidge, 2018). In melanoma, invadopodia formation and activity 
is regulated by activation of the MAPK signalling pathway through BRAF p.V600E, CDC42, and 
SH3PXD2A/TKS5, which suggests the convergence of various signalling pathways (Gross-
mann et al., 2013; Iizuka et al., 2016; H. Lu et al., 2016; Nakahara et al., 2003). Furthermore, 
the efficacy of checkpoint inhibitors depends on the tumour-infiltrating lymphocytes and it was 
shown that T cell exclusion is regulated by tumour cell mediated WNT/β-catenin signalling 
(Spranger et al., 2015). These partly contradictory results most likely originate from context-
dependent differences and an insufficient mechanistic knowledge of the cross-regulation of 
canonical and non-canonical WNT pathways in melanoma. 
2.2   Ubiquitin and Ubiquitination 
Post-translational modifications (PTMs) of proteins are a powerful, dynamic way to regulate 
signalling, protein turnover and other fundamental cellular processes. A plethora of PTMs has 
been identified that ranges molecularly from covalent attachment of small chemical modifica-
tions, for example phosphate groups, to sugars or lipids, and to polypeptides and small pro-
teins, among them Ubiquitin (Ub). Ub and Ub-like proteins, such as Small Ub-like Modifier 
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(SUMO) or Neural Precursor Cell Expressed Developmentally Down-regulated Protein 8 
(NEDD8), have been intensively studied in the past, and current research still continues to 
unravel novel insights into their role in signal transduction, disease, and their reciprocal inter-
action and regulation, among others (Baek et al., 2020; Barysch et al., 2019; Tatham et al., 
2008). 
2.2.1   Ub and Ub-binding domains 
The discovery of Ub (Goldstein et al., 1975) and its covalent attachment to other proteins 
(Goldknopf & Busch, 1977; Hunt & Dayhoff, 1977), a process known as ubiquitination, were 
seminal findings that changed how researchers perceive PTMs. Since then, ubiquitination has 
been implicated in most cellular functions, among them cell cycle progression, endocytosis, 
and protein degradation (Dikic et al., 2009; Komander & Rape, 2012). 
Ub consists of 76 amino acids and is conserved among eukaryotes, with only 3 amino 
acid changes between yeast and human (Ciechanover et al., 1984; Özkaynak et al., 1984). 
Various hydrogen bonds and a hydrophobic core mediate its very stable β-grasp fold (see 
Figure 7), while the exposed, flexible C-terminus can bind covalently to target proteins or to 
other Ub molecules (Komander & Rape, 2012; Vijay-Kumar et al., 1987). Ub moieties are recy-
cled after use to replenish the free cellular Ub pool or synthesised de-novo from four mamma-
lian Ub precursor genes (Clague et al., 2019; Grou et al., 2015). 
A multitude of Ub-binding domain (UBD) containing proteins interact non-covalently 
with mono- or poly-Ub modifications and channel downstream effects through the induction of 
conformational changes (Dikic et al., 2009). 
2.2.2   The ubiquitination cascade 
Ubiquitination of target proteins is a multi-step process involving three separate enzyme 
activities: E1, E2, and E3 (Figure 6). In a first endothermic reaction, the Ub activating enzyme 
(E1) forms a thioester with the C-terminus of Ub (Ciechanover et al., 1981). Then, Ub is trans-
thiolated to a cysteine in the active site of the Ub conjugating enzyme (E2~Ub) and finally to its 
target substrate with the help of a Ub ligase (E3, Hershko et al., 1983; Metzger et al., 2012). 
Typically, the ε-amino group of a lysine in the target polypeptide forms a stable isopeptide bond 
with the carboxy group at Ub’s C-terminus after a nucleophilic attack. However, ubiquitination 
can also occur at other nucleophilic amino acids (threonine, serine, cysteine) or at the N-ter-
minus of proteins (Metzger et al., 2012). 
Up to now, the vertebrate genome was found to encode 2 E1s (Jin et al., 2007) that 
load about 35 E2s with Ub (van Wijk et al., 2009), which interact with over 600 E3s. E3s are 
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particularly numerous and determine the exquisite substrate specificity of the ubiquitination 
machinery (W. Li et al., 2008; J. Weber et al., 2019). Three families of E3s have been defined 
based on their mode of action: RING-type/U-box ligases essentially build a scaffold to enable 
the transfer of Ub from E2 to the substrate. They are the most numerous type of E3s in verte-
brates (W. Li et al., 2008). Homologous to E6AP carboxy-terminus (HECT)-type E3s function 
by first receiving the Ub from the E2 to their active site and then passing it on to the target 
protein (Metzger et al., 2012). RING between RING (RBR)-type ligases are a hybrid of the other 
two (Zheng & Shabek, 2017). Additionally, multiubiquitin chain assembly can be catalysed by 
so-called E4 enzymes (e.g. UBE4A/UBE4B), which elongate Ub-chains by forming branching 
points (Koegl et al., 1999; Chao Liu et al., 2017). Some E2, e.g. UBE2K, possess the ability to 
transfer Ub to client proteins without the involvement of an E3 (Z. Chen & Pickart, 1990; Mid-
dleton & Day, 2015). It is worth noting that the initial attachment of Ub to the target substrate 
(priming) is mechanistically different from the elongation of Ub chains and can involve different 
enzymes (Deol et al., 2019; A. Weber et al., 2016). 
Figure 6. The ubiquitination cascade 
Ubiquitin (Ub) is conjugated to target substrates by the coordinated action of enzymes with three main activities: E1, E2 and E3. 
First, the Ub activating enzyme (E1) uses adenosine triphosphate (ATP) as source of energy to form a thioester with the C-terminus 
of Ub, which is then transferred to the Ub conjugating enzyme (E2) and to the substrate with the help of the Ub ligase E3. Repeating 
this process several times can lead to the formation of polyubiquitin chains. This can have various outcomes, one of which is  
proteasomal degradation of the substrate and recycling of Ub. Deubiquitinating enzymes (DUBs) can remove Ub from substrates 
or conjoined Ub molecules, thus influencing the substrate’s fate. AMP = adenosine monophosphate, P-P = pyrophosphate 
Ubiquitination is a reversible PTM and about 100 deubiquitinating enzymes (DUBs) 
have been described, which can hydrolyse the (iso)peptide bond between Ub and the modified 
protein or conjoined Ub molecules. Thus, Ub can be recycled and the target protein can be 
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channelled to different routes (Figure 6). DUB proteases are mainly classified as cysteine pro-
teases or, less common, zinc-dependent metalloproteinases, and some DUBs only cleave se-
lected linkage types and can be used for molecular analysis (Clague et al., 2019). 
The target protein’s fate is decided by the interplay of ubiquitination, de-ubiquitination, 
and interaction with Ub-binding proteins and their balance is crucial for cellular homeostasis. 
2.2.3   Linkage types and non-lysine ubiquitination 
Ub modifies and interacts with various proteins to achieve its diverse repertoire of downstream 
effects. Monoubiquitination, the modification with a single Ub molecule, is very common and it 
is estimated to engage about 60 % of all cellular Ub in HEK293 cells, representing a commonly 
used human cellular model (Clague et al., 2015). It can regulate protein interactions and local-
isation of target proteins, e.g. of EGFR (Haglund et al., 2003; Huang et al., 2007). Importantly, 
Ub can be conjugated to other Ub molecules and form poly-Ub chains via seven internal lysine 
(K) residues (K6, K11, K27, K29, K33, K48, and K63) or its N-terminus (Figure 7A). Ub bound 
in such chains comprise about 11 % of total cellular Ub in HEK293 cells (Clague et al., 2015). 
These Ub-chains can be homotypic and only contain one linkage type or heterotypic when 
linkage types are mixed (Swatek & Komander, 2016). 
Figure 7. Ubiquitin linkage types and chemical bonds 
A. Ribbon representation of ubiquitin (Ub), with lysine (K) residues K48 and K63 highlighted in pink. They are most frequently used 
to form poly-Ub chains (Protein Data Bank, PDB, identifier 1UBQ). 
B, C. Surface and ribbon representations of tetra-Ub polymers with K48- (B, PDB identifier 2O6V) or K63 linkage (C, PDB identifier 
3HM3) show distinct spatial orientation. The C-terminal glycine (pink) and linked K residues (orange) are  highlighted. 
D. Ub is linked to its substrates via distinct chemical bonds, depending on the involved amino acid or protein structure.  
Molecule representations based on crystallographic data using PyMOL. N-terminus = amino terminus, C-terminus = carboxy ter-
minus, C = cysteine, S = serine, T = threonine  
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The linkage type strongly affects the spatial orientation of Ub chains (Figure 7A,B,C) 
and thus allows or excludes their interaction with UBD containing proteins and mediates down-
stream effects (Dikic et al., 2009). The two most common Ub-chain types observed in cells are 
linked via K48 or K63 (Clague et al., 2015) and historically, they were described to be either 
proteolytic (K48) or involved in signal transduction and endocytosis (K63). However, more re-
cent studies showed that multiple linkage types can cause protein degradation, including K63-
linked chains, or have various other roles in cell physiology (Swatek & Komander, 2016). 
The type of Ub-Ub linkage is mostly determined by the E2 enzyme and how E2, E3, Ub, 
and substrate are sterically oriented (Deol et al., 2019). Some E2s specifically catalyse a certain 
linkage type, e.g. UBE2K forms K48-linked poly-Ub chains while UBE2N cooperates with the 
catalytically inactive UBE2V1 or UBE2V2 to make K63-linked chains (Andersen et al., 2005; 
Clague et al., 2015). One Ub moiety can even be conjugated to two Ubs, thus leading to 
branched or forked chains (H. T. Kim et al., 2007). Mass-spectrometry based quantification 
approaches demonstrated that chains with K48-K63 branched linkages are common in mam-
malian cells and can influence cellular signalling and protein degradation (Ohtake et al., 2016, 
2018). 
To increase complexity, ubiquitination can occur at non-lysine residues, e.g. when the 
E2 enzyme UBE2J2 catalyses the formation of an oxyester bond (Figure 7D) between Ub and 
the hydroxylated amino acids serine or threonine (Cadwell & Coscoy, 2005; X. Wang et al., 
2009; A. Weber et al., 2016). Recently, such non-lysine Ub modifications were reported for the 
first time in higher eukaryotes (Pao et al., 2018). Furthermore, Ub can carry other PTMs, such 
as phosphorylation or acetylation (Clague et al., 2019). The above mentioned factors are col-
lectively referred to as the ‘Ub Code’ (in the style of the ‘histone code’) and govern distinct 
cellular consequences for the Ub-labelled substrates (Komander & Rape, 2012). 
2.3   Ub-mediated protein degradation 
The concept of energy-dependent protein turnover dates back to early studies in the 1940s 
and 1950s (Schoenheimer, 1942; Simpson, 1953), but did not attract a lot of attention at first. 
Many years later, the physiological role of protein degradation in cellular homeostasis was 
demonstrated in experiments about muscle atrophy (Goldberg, 1969a, 1969b), followed by 
many methodological innovations (Etlinger & Goldberg, 1977). These helped Aaron Ciechano-
ver, Avram Hershko and Irwin Rose to overcome the notion that Ub itself (which they called 
APF-1, Active Principle of Fraction 1) was an adenosine triphosphate (ATP)-dependent prote-
ase. Rather, energy is used to conjugate Ub to target substrates or other Ub-molecules, 
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followed by protein degradation (Ciechanover et al., 1980, 1978; Hershko et al., 1980). For this 
discovery, they were awarded the Noble Prize in Chemistry for 2004 (Karigar & Murthy, 2005). 
Nowadays, two main protein degradation machineries are distinguished that function inde-
pendently but are interlinked: the Ub-proteasome system and autophagy (Pohl & Dikic, 2019). 
2.3.1   The Ub-proteasome system (UPS) 
Whereas the autophagic degradation system is mainly in charge of large, cytosolic structures, 
the UPS is the destination of single, short-lived polypeptides (Dikic, 2017; Pohl & Dikic, 2019). 
It was estimated that the proteasome degrades up to 30 % of newly translated proteins, which 
do not fulfil the cellular quality control standards (Kleiger & Mayor, 2014). The proteasome 
mostly used in mammals is the 26 S proteasome and consists of the 20 S proteasome core 
subunit and the 19 S regulatory subunit. The regulatory component’s main tasks are to recog-
nise and bind substrates with Ub tag and prepare them for proteolysis by ATP-dependent un-
folding and cleaving off of the Ub modifications. The minimal Ub signal for proteasomal target-
ing is currently under debate and the ‘Ub threshold’ model was proposed to explain the obser-
vation that the number of substrate-conjugated Ub molecules seems to be more important than 
the prevalent linkage type (Swatek & Komander, 2016). After being threaded into the enclosed 
cavity of the core particle, the substrate is digested into 2 to 24 amino acid long peptides by 
three catalytically active subunits (Dikic, 2017). 
Proteasomal degradation is required for several essential cellular functions: (i) elimina-
tion of key regulatory proteins (e.g. β-catenin), and thus regulating signalling, transcription, cell 
cycle progression, and cell survival, (ii) removal of misfolded or damaged proteins, (iii) recy-
cling of amino acids, (iv) generation of peptides for antigen presentation by major histocom-
patibility complex (MHC) class I molecules (Dikic, 2017; Rock et al., 1994). 
The development of selective proteasome inhibitors, such as MG132 (Rock et al., 
1994), greatly advanced our current understanding of the proteasome as a primary proteolytic 
route and its role for proteome integrity. Another proteasome inhibitor, Bortezomid, is also used 
in the clinics to treat multiple myeloma, because malignant plasma cells produce high amounts 
of antibodies without control and therefore have a higher level of ER stress than healthy cells. 
Inhibiting the proteasome increases this stress and the subsequent stress response leads to 
cell death (Dikic, 2017; Hungria et al., 2019). 
2.3.2   ER-associated degradation (ERAD) 
Proteomic studies suggest that one-fourth to one-third of eukaryotic proteins belong to the 
secretory pathways and are co-translationally translocated into the ER or its membrane 
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(Ghaemmaghami et al., 2003; Juszkiewicz & Hegde, 2018; Thul et al., 2017). These proteins 
often undergo elaborate and error prone folding and assembly steps before they reach ma-
turity. Extensive ER quality control mechanisms are important to help them fold in their correct 
structure or recognise and remove terminally misfolded or unassembled polypeptides. The 
extraction and destruction of such potentially dangerous proteins is a highly sophisticated pro-
cess called ERAD and it relies on a network of functionally diverse proteins in different cellular 
compartments, including the UPS. As shown in Figure 8, the most important steps are: (i) 
recognition of clients, followed by their (ii) ubiquitination, (iii) dislocation from the ER membrane 
into the cytosol, (iv) delivery to the proteasome, and (v) proteasomal degradation (Christianson 
& Ye, 2014; Hirsch et al., 2009). 
Importantly, the removal of proteins from the ER can also influence cellular signalling if 
it affects functionally mature proteins and thus controls their abundance and availability. This 
mechanism is called regulatory ERAD and presumably functions similar as ERAD of misfolded 
proteins. The underlying concepts, and some of the involved proteins, are functionally con-
served in related degradation mechanisms, for example the recently discovered endosome 
and Golgi‐associated degradation (EGAD, Schmidt et al., 2019). Furthermore, some misfolded 
proteins elude the ERAD machinery, e.g. by forming large aggregates that cannot pass the ER 
membrane. These so-called ‘ERAD-resistant proteins’ can be cleared from the ER by autoph-
agy and lysosomal degradation (Fregno & Molinari, 2019). ‘ER-phagy’, the process of au-
tophagic degradation of ER components, was shown to be an important part of the ER stress 
response and likely plays a role in several diseases, including cancer (Hübner & Dikic, 2020). 
Potential substrates that escape from the ER and reach the Golgi can be subjected to 
‘Golgi quality control’ mechanisms and face degradation by proteasomes or lysosomes. After 
the Golgi, only quality control mechanisms at the plasma membrane (leading to lysosomal deg-
radation) can catch misfolded or overabundant client proteins. It should be noted that sub-
strates are constantly shuttled between these compartments and many open questions remain 
regarding the underlying processes of these distinct but overlapping control mechanisms (Z. 
Sun & Brodsky, 2019). 
 




Figure 8. Components of the endoplasmic reticulum (ER) associated degradation (ERAD) pathways 
(refer to next page for figure legend) 
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◄ previous page │Figure 8. Components of the endoplasmic reticulum (ER) associated degradation (ERAD) pathways 
Proteins within the secretory routes or transmembrane domain containing proteins are imported into the ER co-translationally. 
Polypeptides that do not acquire their native fold in a timely manner and thus fail to pass scrutiny by the ER resident protein quality 
control mechanisms are targeted to ERAD by the proteasome in the cytoplasm. By passing misfolded proteins through an elabo-
rate network of various interaction partners, this process ensures safe and accurate delivery of its substrates. Recurrent protein 
domains mark the various steps of this process. The five major steps include (1) client recognition, (2) ubiquitination, (3) disloca-
tion/retrotranslocation, (4) targeting to the proteasome, and (5) degradation. According to the substrate, these steps depend on 
each other and/or presumably occur in parallel (e.g. ubiquitination and dislocation or proteasomal targeting and degradation).  
However, different substrates can take distinct routes out of the ER and interact only with a subset of the indicated proteins, which 
is not always well defined. Importantly, mature and properly folded proteins can undergo quantity control by ERAD which regulates 
cellular signalling, a process called regulatory ERAD. See main text or 6.4.1 for protein name abbreviations and further details. 
 
2.3.2.1   Protein folding and recognition of ERAD clients 
In the ER, newly synthesized polypeptides interact with chaperones and proteins associated 
with oligosaccharides already during translation and translocation. Directly after ER entry, oli-
gosaccharyltransferases (OSTs) attach a 14-part sugar modification to most polypeptides on 
an asparagine-residue (N) in a short consensus sequence (Hebert & Molinari, 2012). Sequen-
tial trimming of the oligosaccharide moieties and concurrent binding of different ER-resident 
proteins, for example the lectins calnexin (CNX) and calreticulin (CLR), or heat shock protein 
70 kDa (HSC70)-like chaperons (such as binding immunoglobin protein, BiP), help the poly-
peptide to reach its native form and bury exposed hydrophobic patches (Daniels et al., 2003; 
Hirsch et al., 2009). Proteins with correct folding are shuttled to their final destination by the 
export machinery. 
Glycoproteins that linger in the ER for too long and do not acquire their native fold are 
processed by ER-resident mannosidases, e.g. members of the ER degradation-enhancing α-
mannosidase-like 1 protein (EDEM) family and others. The consecutive removal of mannose 
molecules from the initial 14-part oligosaccharide exposes binding motifs for amplified in oste-
osarcoma 9 (OS-9, Yos9 in yeast) and ER lectin 1 (ERLEC1/XTP3-B), which in turn bind to the 
adaptor protein suppressor of lin-12-like protein 1 (SEL1L) via their mannose 6-phosphate re-
ceptor homology (MRH) domains (Christianson et al., 2008; Cormier et al., 2009; Hebert & 
Molinari, 2012). SEL1L is part of a supramolecular protein complex including the membrane-
bound ERAD E3 ligase synoviolin (SYVN1/HRD1), which can mediate the poly-ubiquitination of 
substrates and their dislocation back into the cytoplasm (Hebert & Molinari, 2012). There are 
further studies suggesting that SEL1L and others might be themselves substrate of ERAD in a 
process called ERAD tuning (Hebert & Molinari, 2012). 
2.3.2.2   ERAD-associated E3 Ub ligase complexes and their E2 partners 
In yeast, only two E3 ligase complexes are responsible for the degradation of most client pro-
teins from the ER: degradation of α2 protein (Doa10) and β-hydroxy β-methylglutaryl coenzyme 
A (HMG-CoA) reductase degradation protein 1 (Hrd1). Additionally, the amino acid sensor-
independent (Asi) complex controls protein quality at the nuclear envelope, which is 
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continuous with the ER membrane. However, no mammalian ortholog has been identified for 
this yeast complex (Hampton et al., 1996; Mehrtash & Hochstrasser, 2019). The best studied 
E3 complexes in mammals are the Doa10 ortholog membrane-associated RING-CH protein VI 
(MARCH6) and the two orthologs of Hrd1, SYVN1/HRD1 and glycoprotein 78 (AMFR/GP78), 
but so far at least 25 ER membrane-bound E3 ligases were identified in human cells (Fenech 
et al., 2020). A recent proteomic-based screen uncovered over 450 interaction partners of 
these E3s, many of them previously unknown. Considering that these interaction networks vary 
greatly between different E3, it is very likely that their modes of action also differ substantially 
from the well-studied SYVN1/HRD1 (Fenech et al., 2020). As one result of this study, it was 
discovered that the WNT cargo protein EVI/WLS is degraded via ERAD with the help of 
CGRRF1, an ER-membrane resident E3 ligase (Glaeser et al., 2018). CGRRF1 was later also 
implicated in the ubiquitination and degradation of EGFR (Lee et al., 2019) and in the general 
ER-stress response (Fenech et al., 2020). 
The main ERAD associated E2 Ub conjugating enzymes in yeast are the membrane 
tethered Ubc6 (human UBE2J1 and UBE2J2) and the cytosolic Ubc7 (human UBE2G1 and 
UBE2G2), which binds the ER-membrane anchored coupling of Ub conjugation to ER degra-
dation 1 (Cue1) and catalyses the formation of K48-linked Ub chains, which are transferred to 
substrates en bloc (Deol et al., 2019; Hirsch et al., 2009; Mehrtash & Hochstrasser, 2019). A 
recent functional genetic screen in human cells found that UBE2G2 was involved in the degra-
dation of all investigated ERAD substrates (Leto et al., 2019) and it was shown to interact with 
AMFR/GP78 and MARCH6 (Mehrtash & Hochstrasser, 2019). Ubc6/UBE2J2 seems to be inef-
ficient in making long polyubiquitin chains, but it is indispensable for priming a broad range of 
substrates with monoubiquitin or K11-linked Ub dimers, due to its ability to ubiquitinate not only 
lysine, but also hydroxylated amino acids such as serine or threonine. These short modifica-
tions can then be elongated by Ubc7/UBE2G2 in cooperation with Doa10 (X. Wang et al., 2009; 
A. Weber et al., 2016; P. Xu et al., 2009). Notably, other cytosolic E2 enzymes without perma-
nent ER-membrane association are also involved in ERAD of various substrates, such as 
UBE2D3, which was reported to act together with MARCH6 and UBE2J2 (Stefanovic‐Barrett et 
al., 2018). Ubc1 (human UBE2K) is the most prominent example, which can elongate initial 
primed Ub with K48-linked chains, even in the absence of a E3 (Middleton & Day, 2015; Ro-
drigo-Brenni & Morgan, 2007). Ub side chains can be cleaved and modified by several ERAD-
associated DUBs, for example Ub-specific protease (USP) 25 or USP50 (Lemus & Goder, 
2014). 
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2.3.2.3   VCP/Cdc48 provides energy for retrotranslocation 
The conserved ATPases associated with a variety of cellular activities (AAA ATPase) VCP is 
involved in various cellular processes including the separation of ubiquitinated substrates from 
membranes, chromatin, or macromolecular complexes, often followed by their proteasomal 
degradation (Bodnar & Rapoport, 2017). VCP is a circular homohexamer with a central pore 
and three distinct domains: the N domain composed of the N-termini of the six monomers, and 
two AAA ATPase domains (D1 and D2). Various binding partners and cofactors associate with 
VCP via their Ub regulatory X (UBX) or VCP-interacting/binding motifs (VIM/VBM) domains 
(Meyer & Weihl, 2014). Most prominently, VCP makes a ternary complex with Ub recognition 
factor in ER-associated degradation protein 1 (UFD1) and nuclear protein localization protein 
4 homolog (NPLOC4), which both bind VCP via its N domain and help to recruit and bind Ub-
chains, e.g. during ERAD (Ye et al., 2001). It is not clear what the minimal Ub signal for recog-
nition by VCP-UFD1-NPLOC4 is, but it was suggested that poly-Ub chains of at least four or 
five Ub molecules with K48-linkage would be necessary (Bodnar & Rapoport, 2017). 
Other UBX domain containing proteins are essential to recruit VCP to the ER mem-
brane, such as FAS-associated factor 2 (FAF2/ETEA/UBXD8) and UBX domain-containing pro-
tein 4 (UBXN4/ERASIN/UBXD2). They function in recruiting as much as in mechanical anchor-
ing of VCP at the ER-membrane (Hirsch et al., 2009). These cytosolic proteins use an in-
tramembrane domain as anchor within the ER lipid bilayer, which results in both their N- and 
C-termini facing the cytoplasm. They are both part of large complexes involved in recruiting 
VCP and proteasomes to ERAD substrates: UBXN4 and FAF2 interact with Ubiquilin (UBQLN1-
4) and FAF2 interacts with SEL1L and ER lipid raft-associated protein 2 (ERLIN2), among oth-
ers. Additionally, FAF2 can bind to ubiquitinated proteins via its Ub-associated (UBA) domain 
(Christianson et al., 2012; Liang et al., 2006; P. J. Lim et al., 2009; Mueller et al., 2008; Schu-
berth & Buchberger, 2008). Recent cryo-electron microscopy data contributed to clarifying the 
mechanism of how substrates are then processed by VCP: energy from ATP hydrolysis is used 
to unfold a Ub molecule and pull it through the central lumen of VCP, followed by the unfolded 
substrate (Twomey et al., 2019). 
2.3.2.4   Retrotranslocation – shuttling ERAD substrates back to the cytoplasm 
Since the ER-lumen does not contain any components of the UPS, all ERAD clients have to be 
ubiquitinated and degraded in the cytoplasm. Integral membrane substrates of ERAD can be 
modified with Ub at domains exposed to the cytosol, but luminal substrates need to be trans-
ported across the ER membrane before they can face the UPS machinery (Christianson & Ye, 
2014). The physical removal of ERAD substrates either from or across the lipid bilayer of the 
ER membrane poses a significant energy barrier. Recent cryo- experiments in yeast provided 
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insights into the mechanism for substrates without a transmembrane domain: Yos9 and Hrd1 
form a luminal binding site for misfolded glycoproteins and a loop of the polypeptide is then 
inserted into the membrane by two ‘half-channels’ made by Hrd1 and its binding partner deg-
radation in the endoplasmic reticulum protein 1 (Der1, a member of the derlin family). Hrd1 
and Der1 are linked by U1 SNP1-associating protein 1 (Usa1, HERPUD in mammals), shield 
the hydrophilic polypeptide from the lipids and distort the membrane to make it thinner and 
easier to cross (X. Wu et al., 2020). In line with this, it was recently discovered that the rhomboid 
fold of Der1 itself distorts lipids in its vicinity (Kreutzberger et al., 2019). The loop exposed to 
the cytoplasm is subsequently ubiquitinated and can serve as ‘handle’ to facilitate the sub-
strate’s extraction from the ER with the help of VCP. However, it remains to be investigated 
whether this mechanism is universal for all luminal ERAD substrates. 
Several mechanisms were proposed for the retrotranslocation of integral ER membrane 
proteins, a process often referred to as ‘dislocation’. In parallel to the mechanism described 
for luminal substrates, additional possibilities are lateral gated protein channels, again poten-
tially including the Derlin family or the ERAD-associated E3 complexes themselves, such as 
Hrd1 (B. K. Sato et al., 2009). Single-pass integral membrane proteins with transmembrane 
domains of low hydrophobicity can engage with the luminal ERAD machinery after complete 
translocation into the ER, as was shown for the T cell receptor α (TCRα) and others (Feige & 
Hendershot, 2013), whereas other proteins have to be proteolytically processed before they 
can engage the ERAD machinery. For example, proteins with charged residues in transmem-
brane domains and a Ub tag can be cleaved by the intramembranous protease rhomboid-
related protein 4 (RHBDL4/RHBDD1), initiating substrate dislocation into the cytoplasm and 
proteasomal degradation (Fleig et al., 2012; Knopf et al., 2020). Similarly, signal peptide pepti-
dase (SPP) is required for the cleavage and turnover of several tail-anchored proteins within 
the ER membrane (Boname et al., 2014) and for proteins regulating ER shape (Avci et al., 
2019). Although it was demonstrated that VCP is crucial for the solubility of extracted full-length 
clients with transmembrane domains in the cytoplasm, it remains questionable whether VCP 
alone would be able to remove proteins from a lipid bilayer (S. Neal et al., 2017). It should be 
noted that all these mechanisms are not mutually exclusive. In fact, some substrates use one 
of many parallel routes, probably in a context dependent manner, that allows to clear misfolded 
or aggregated proteins as well as stoichiometric misfits and regulatory targets. For example, 
the dislocation of TCRα can be triggered by RHBDL4/RHBDD1-dependent cleavage but its full-
length protein could also be found in the cytoplasm (Fleig et al., 2012) and in the ER (Feige & 
Hendershot, 2013). 
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2.3.2.5   Targeting to the proteasome and degradation of ERAD substrates 
ERAD substrates have to be delivered to the 26 S proteasome for degradation after successful 
retrotranslocation or dislocation. In eukaryotic cells, direct interaction between VCP and the 
proteasome can only be observed under extreme stress conditions (Isakov & Stanhill, 2011), 
implicating that shuttling factors are required to mediate substrate ‘handoff’. It was proposed 
that the subsequent binding of different factors might depend on the length of the provided Ub 
chain on the substrates (Richly et al., 2005). In the yeast cytoplasm, Ufd2 (human UBE4A/B) 
modifies Ub chains on substrates and thus allows their interaction with Rad23 (human 
RAD23A/B) or Dsk2 (human UBQLN, Medicherla et al., 2004; Richly et al., 2005). In mammals, 
UBQLN1 and VCP are recruited to the ER membrane by UBXN4, and UBQLN1 then recruits 
proteasomes, possibly binding to the substrate’s poly-Ub chains and the proteasome simulta-
neously (P. J. Lim et al., 2009). UBQLN2 was shown to interact with FAF2 (Xia et al., 2014) and 
several members of the UBQLN family interact with HERPUD, an ER membrane resident pro-
tein involved in the HRD1 complex (T.-Y. Kim et al., 2008). The delivery of dislocated ERAD 
substrates with hydrophobic transmembrane domains to the proteasome is especially difficult 
as these domains could potentially aggregate in the cytoplasm and harm the cell. BCL2-asso-
ciated athanogene 6 (BAG6) can bind such proteins in their unfolded state and chaperones 
them to the proteasome, together with its interaction partners transmembrane domain recog-
nition complex 35 kDa subunit (TRC35/GET4) and Ub-protein ligase 4A (UPL4A, Christianson 
& Ye, 2014; Q. Wang et al., 2011). Additionally, BAG6 and UBQLN are important chaperones 
for so called ‘orphans’, proteins which do not localise to their appropriate compartments after 
translation, and they help to recognise and deliver them to the proteasome (Juszkiewicz & 
Hegde, 2018). 
Bulky oligosaccharyl chains on a substrate could potentially hinder its degradation 
within the narrow proteasome pore. Therefore, these modifications are often cleaved off, for 
example by peptide:N-glycanase (NGLY1), which interacts with VCP and hands the deglyco-
sylated substrates over to RAD23A/B, a direct interaction partner of the proteasome (Hirsch et 
al., 2009; Katiyar et al., 2004; McNeill et al., 2004). Furthermore, (poly)ubiquitin modifications 
are cleaved and recycled by various proteasome-associated DUBs before degradation (Clague 
et al., 2019). 
2.3.3   Protein quantity control by regulatory ERAD 
Protein degradation by the UPS does not only affect misfolded proteins but it is also an im-
portant regulatory step and responds to cellular needs in many cellular signalling cascades. A 
well-described example is the degradation of β-catenin, which is both a component of cell 
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adhesion complexes at the cell surface and an important effector of the WNT/β-catenin path-
way in the cytoplasm and the nucleus. In the absence of active WNT signalling, β-catenin is 
continuously synthesised, ubiquitinated and degraded by the proteasome (Aberle et al., 1997). 
The binding of canonical WNT ligands to receptors at the cellular surface inhibits this degra-
dation and accumulated β-catenin translocates into the nucleus, where it activates downstream 
transcriptional programmes (see also 2.1.4, and Figure 9). Similar regulatory protein quantity 
control mechanisms also affect proteins in the ER, which are consequently clients of ERAD. 
Recently, it was shown that this ‘regulatory ERAD’ targets the conserved WNT ligand cargo 
protein EVI/WLS. When no WNT ligands are present, EVI/WLS is modified with Ub with the help 
of the E2 Ub conjugating enzyme UBE2J2 and the E3 Ub ligase CGRRF1, followed by its ex-
traction from the ER membrane with the help of VCP and subsequent proteasomal degradation 
(Glaeser et al., 2018). 
It is assumed that the regulatory ERAD pathway essentially relies on the same basic 
machinery as ERAD of misfolded proteins but differs in substrate recognition, which must be 
exquisitely specific (Hegde & Ploegh, 2010). Several mechanisms have been reported to initi-
ate regulatory ERAD: (i) binding of adaptor proteins, (ii) binding of ligands, and (iii) recognition 
of specific amino acid sequences or protein folding (Z. Sun & Brodsky, 2019). They are illus-
trated with two examples in the following. 
Probably the most extensively studied substrate of regulatory ERAD is HMG-CoA re-
ductase, an important enzyme in sterol synthesis (Hegde & Ploegh, 2010). In mammals, its 
ubiquitination by AMFR/GP78 and TRC8, dislocation, and proteasomal degradation are initiated 
by binding to sterols in the ER membrane and a sterol-induced interaction with insulin-induced 
gene 1 protein 1 and 2 (INSIG1/2), which in turn recruit E3 ligases (Jo, Lee, et al., 2011; Sever 
et al., 2003; Song et al., 2005). In addition to INSIG1/2, transmembrane and UBL domain-
Figure 9. Several components of the WNT signal-
ling pathways are degraded by the ubiquitin-pro-
teasome system (UPS) in the absence of WNT lig-
and production 
WNT ligands produced in the WNT secreting cell in-
teract with the WNT cargo protein EVI/WLS and pro-
tect it from being degraded by the UPS. EVI/WLS 
helps WNT ligands to leave the WNT secreting cell 
and is itself recycled back to the endoplasmic retic-
ulum (ER). The binding of WNT ligands to receptors 
on the surface of WNT target cells leads to the inhi-
bition of the destruction complex and the stabilisa-
tion of β-catenin, which then translocates into the nu-
cleus, where it leads to the activation of downstream 
target genes. In the absence of WNTs, β-catenin pro-
teins are constantly phosphorylated by the destruc-
tion complex and subsequently subjected to degra-
dation by the UPS. See main text or 6.4.1 for protein 
name abbreviations and further details. 
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containing protein 1 (TMUB1) and ERLIN2 are also important for AMFR/GP78-mediated deg-
radation of HMG-CoA reductase (Jo, Sguigna, et al., 2011). In yeast, the degradation of HMG-
CoA reductase depends on Hrd1 and possibly a conformational change which is recognised 
as degradation signal (Gardner et al., 2001; Garza et al., 2009; Hampton et al., 1996). 
Binding of the second messenger IP3 to its receptor (IP3R) on the ER membrane re-
leases Ca2+ from the ER stores and regulates various cellular functions (Berridge, 2016). IP3R 
is an important signalling hub due to its many interaction partners and is rapidly ubiquitinated 
and degraded by RING finger protein (RNF) 170 after activation by IP3 (Lu et al., 2011). The 
adaptor between IP3R and RNF170 is the ERLIN complex consisting of ERLIN1 and ERLIN2. 
This complex associates with IP3R immediately after ligand engagement and links the receptor 
to various components of the ERAD machinery (Pearce et al., 2007, 2009; Y. Wang et al., 2009). 
Only about 20 to 30 endogenous substrates of mammalian regulatory ERAD have been 
reported so far and it remains unclear in many cases how they are recognised and linked to 
the ERAD machinery, which interaction partners they have, or even by which E2/E3 proteins 
they are ubiquitinated (Bhattacharya & Qi, 2019; Printsev et al., 2017). Most of these data was 
generated in-vitro in yeast or mammalian cell lines, but animal studies were included only 
rarely, although these would help to determine the physiological impact of regulatory ERAD 
and possible roles in diseases (Bhattacharya & Qi, 2019). For instance, it was recently shown 
that the knock-out of AXIN interactor, dorsalization-associated protein (AIDA) led to obesity in 
mice through the stabilisation of enzymes important for fat synthesis (Luo et al., 2018). More-
over, deregulated quantity control of receptor tyrosine-protein kinases (ERBB, e.g. human ep-
idermal growth factor receptor 2, HER2, or EGFR) were implicated in cancer (Carraway, 2010) 
and the antidiabetic drug metformin induced regulatory ERAD of programmed cell death ligand 
1 (PD-L1) via HRD1/SEL1L and thus enhanced the activity of cytotoxic T lymphocytes against 
breast cancer cells (Cha et al., 2018). 
Taken together, these studies argue against a common or canonical route for recogni-
tion and degradation of regulatory ERAD substrates. By contrast, it can be assumed that many 
more substrates and other interaction partners will be discovered in the future. Nevertheless, 
the understanding of regulatory ERAD and its related proteins has advanced greatly in recent 
years and the best described endogenous ERAD substrates depend on SYVN1/HRD1 or 
AMFR/GP78 in mammals (Bhattacharya & Qi, 2019; Printsev et al., 2017; Z. Sun & Brodsky, 
2019). 
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2.3.4   Autophagy and lysosomal degradation 
Autophagy is the general term for several cellular pathways that deliver cytosolic cargo to ly-
sosomes for degradation in order to provide nutrients during fasting or degrade and recycle 
various cellular structures, and thus they are part of the cellular cytoprotective system (Pohl & 
Dikic, 2019). The best-studied form of autophagy is macroautophagy, a process in which cel-
lular material is engulfed by the autophagosome, a double-membrane structure. This is often 
initiated by the modification of unc-51-like kinase 1 (ULK1) with K63-linked Ub-chains by tu-
mour necrosis factor (TNF) receptor-associated factor 6 (TRAF6), followed by a tightly regu-
lated enzymatic cascade involving mammalian homologs of the yeast autophagy related genes 
(ATG) proteins (R.-H. Chen et al., 2019; Dikic & Elazar, 2018). In the end, kinesins use micro-
tubules to transport mature autophagosomes to the lysosomes, with which they fuse using 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) and homotypic 
fusion and protein sorting (HOPS) complexes. The cargo is then hydrolysed in the acidic, pro-
teolytic milieu of the resulting autolysosomes (Dikic & Elazar, 2018). 
Lysosomes were discovered in the 1950s (de Duve et al., 1955) and for a long time 
degradation via this lytic compartment was considered to be an unselective recycling route. 
However, bulk degradation of macromolecules happens preferentially as a response to nutrient 
or growth factor deprivation, while autophagy can also selectively target intra-cellular stressors 
such as protein aggregates, faulty organelles, or invading bacteria (Pohl & Dikic, 2019). In part, 
this selective autophagy relies on monoubiquitination or K63-linked Ub chains as molecular 
‘eat-me’-signals. Importantly, Ub can initiate and accelerate autophagy but core autophagy 
proteins can also be targeted to proteasomal degradation if tagged with K48- or K11-linked Ub, 
thus inhibiting autophagy (R.-H. Chen et al., 2019; Pohl & Dikic, 2019). 
2.3.5   Endocytosis and ubiquitination 
Internalisation of integral membrane proteins and their interaction partners from the cell sur-
face by endocytosis can lead to their lysosomal degradation or re-distribution within the cell. 
In this process, ubiquitination has a major role in substrate localisation and fate decision. Typ-
ical cargos are transmembrane proteins bound to their extracellular ligands, examples include 
the well-studied EGFR or the WNT cargo protein EVI/WLS (Cullen & Steinberg, 2018). While 
both EGFR and EVI/WLS can undergo clathrin-dependent endocytosis, it should be noted that 
there are also clathrin-independent mechanisms. For EGFR, the dosage of EGF ligand signal 
decides which of these mechanisms is activated and high EGF leads to clathrin-dependent 
internalisation (Sigismund et al., 2013) with the help of the adaptor protein growth factor re-
ceptor-bound protein 2 (GRB2) and the E3 casitas B-lineage lymphoma proto-oncogene (CBL, 
 
   2   Introduction 
31 
 
Huang et al., 2007). However, contrary to previous assumptions, the K63-linked and mono-
ubiquitination of EGFR is not important for its EGF-induced internalisation (Huang et al., 2007), 
but functions as sorting signal for its recognition by the multiprotein ESCRT complexes (Cullen 
& Steinberg, 2018). This modular protein machinery assembles at the surface of early endo-
somes and sorts proteins with Ub modifications into specialised compartments with degrada-
tive fate. These are then internalised and form intraluminal vesicles (ILVs), while the Ub mole-
cules are cleaved off by DUBs. Biogenesis of cargo-enriched ILVs and maturation of the early 
endosome lead to its transformation into the late endosome which is also known as multivesic-
ular body (MVB). The late endosome’s fusion with lysosomes results in the degradation of ILVs 
and their cargo (Cullen & Steinberg, 2018; Komander & Rape, 2012), whereas its fusion with 
the plasma membrane leads to the release of ILVs as exosomes (Edgar, 2016). 
Sorting signals are also commonly used by the coat complex retromer (and a similar 
protein complex called retriever), to retrieve and recycle cargos with the help of membrane 
remodelling and by sorting them in tubule-vesicular transport carriers, following the central 
dogma of intracellular membrane trafficking (Cullen & Steinberg, 2018). In the absence of mo-
tif-dependent recycling, the default route of many endocytosed cargos, such as EVI/WLS, 
seems to be lysosomal degradation (Cullen & Steinberg, 2018; Franch-Marro et al., 2008; 
McGough et al., 2018; P.-T. Yang et al., 2008). 
It is important to note that ubiquitination of proteins at the plasma membrane can indeed 
initiate their endocytosis, as shown for G protein coupled receptors (Burton & Grimsey, 2019; 
Terrell et al., 1998). If and how Ub modifications also help to navigate EVI/WLS through the 
endocytotic network is currently only rudimentary understood (Zhang et al., 2018). 
2.4   Aim of this thesis 
The WNT signalling pathways shape tissue development and are associated with various dis-
eases, such as cancer. It was recently shown that EVI/WLS is ubiquitinated by UBE2J2 and 
CGRRF1 and subjected to ERAD in a WNT ligand dependent manner. However, this Ub signal 
is presumably too weak to recruit the ERAD machinery. ERAD can affect cellular signalling and 
cell physiology by degrading mature proteins within the secretory routes, but this type of post-
translational regulation is not well studied in mammals. Furthermore, the reciprocal interaction 
of EVI/WLS with WNT ligands and the availability of EVI/WLS protein are important determi-
nants of the malignancy of various cancers, such as melanoma, but the underlying pathomech-
anisms are incompletely understood. Therefore, I wanted to gain insights into the regulation of 
EVI/WLS as an endogenous substrate of regulatory ERAD by analysing its ubiquitination and 
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interaction with ERAD-associated proteins in cells with or without active WNT ligand secretion. 
Using melanoma cells as a model system with high WNT ligand production, I further wanted to 
examine the functional impact of EVI/WLS abundance on cellular invasiveness. Elucidating the 
correlation of EVI/WLS protein levels and disease progression will also help to develop novel 




3 Material & Methods 
3.1 Material 
3.1.1 Antibodies 
Table 1. Primary antibodies 
Specificity Host Clonality 
(reference) 
Reference Supplier Dilution  
(application) 
β-ACTIN ms mono (AC-15) ab6276 Abcam 
1/10 000 
(WB) 
β-ACTIN rb poly #4967 
Cell Signaling 
Technology 1/1 000 (WB) 
β-CATENIN ms mono (14) 610154 
BD Biosci-
ences 1/1 000 (WB) 
CORTACTIN/p80/85 ms mono (4F11) 05-180 
Merck Milli-
pore 1/1 000 (IF) 
ERLIN2/SPFH2 gt poly EB06896 VWR 1/1 000 (WB) 




EVI/WLS rb poly PA5-42570 
Thermo 
Fisher Scien-
tific 1/100 (IF) 
FAF2/ETEA/UBXD8 gt poly GTX14759 GeneTex 1/1 000 (WB) 
FLAG-Tag ms mono (M2) F1804 Sigma-Aldrich 1/1 000 (WB) 
FLAG-Tag rb poly F7425 Sigma-Aldrich 1/8 000 (WB) 
HA-Tag ms Mono (6E2) #2367 
Cell Signaling 
Technology 1/1 000 (WB) 
HSC70 ms mono (B-6) sc-7298 
Santa Cruz 
Biotechnology 1/2 000 (WB) 
K48-linkage Spe-










Technology 1/1 000 (WB) 
SEL1L rb poly ab78298 Abcam 1/1 000 (WB) 
α-TUBULIN rb poly #2144 
Cell Signaling 
Technology 1/3 000 (WB) 
UBE2K/E2-25K ms 
mono 
(701316) MAB6609 R&D Systems 1/1 000 (WB) 
Continued on the next page 
 
3   Material & Methods 
34 
 
Specificity Host Clonality 
(reference) 
Reference Supplier Dilution  
(application) 
UBE2N rb mono (D2A1) #6999 
Cell Signaling 
Technology 1/1 000 (WB) 
Ubiquitin ms Mono (P4D1) #3936 
Cell Signaling 
Technology 1/3 000 (WB) 














Technology 1/1 000 (WB) 
WNT11 rb poly GTX105971 GeneTex 1/1 000 (WB) 
gt: goat; ms: mouse; rb: rabbit; mono: monoclonal; poly: polyclonal; IF: immunofluorescence; WB: Western blot 
 
Table 2. Fluorescence-protein coupled antibodies and labelling substances 
Name Conjugate Reference Supplier Dilution (ap-
plication) 


























Alexa Fluor® 633 W21404 Thermo Fisher 
Scientific 
1/1 000 (IF) 
IgG (H+L): Gamma Immunoglobins heavy and light chains; IF: immunofluorescence; NA: not applicable 
 
Table 3. Horse-radish peroxidase (HRP)-coupled antibodies 
Specificity Host Clonality Reference Supplier Dilution (ap-
plication) 
β-ACTIN ms mono (C4) SC47778 HRP Santa Cruz Bio-
technology 
1/5 000 (WB) 
Anti-Goat IgG rb poly 6160-05 SouthernBiotech 1/5 000 (WB) 
Anti-Mouse 
IgG (H+L) 





gt poly AB_2313567 Jackson Immu-
noResearch 
1/10 000 (WB) 
gt: goa;, ms: mouse; rb: rabbit; mono: monoclonal; poly: polyclonal; WB: Western blot 
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Table 4. Reagents for protein purifications and controls  
Name Specificity Conjugate/beads Reference Supplier 
TUBE Control Control Agarose beads UM400 LifeSensors 
TUBE1 Pan-ubiquitin Magnetic beads UM401M LifeSensors 
TUBE2 Pan-ubiquitin Agarose beads UM402 LifeSensors 
K63-TUBE K63-linked ubiquitin FLAG-tag UM604 LifeSensors 
M2 AFFINITY GEL Anti-FLAG Agarose beads A2220 Sigma-Aldrich  
Monoclonal Anti-
HA-Agarose 
Anti-HA Agarose beads A2095 Sigma-Aldrich 
Dynabeads Pro-
tein G  
Immunoglobulin 
Fc-region 
Magnetic beads 10004D Thermo Fisher 
Scientific 
BLUE SE-









3.1.2 Buffers and solutions 
Table 5. Buffers and solutions 
Name Purpose Composition 
Blocking solution (IF 
staining) 
Prevention of unspe-
cific antibody binding  
1 % goat serum, 3 % FCS, 0.1 % Triton X-




cific binding and for 
antibody dilution 
5 % skim milk/TBST (mass fraction) 
Blue Sepharose 
washing buffer 
Washing of Blue Se-
pharose resin 
50 mM Tris-HCl, pH 7.5; 150 mM KCl; vol-
ume fraction of 1 % Triton X-100 in ddH2O 
Eukaryotic lysis 
buffer 
Cell lysis buffer used 
for immunoprecipita-
tion and TUBE assays 
20 mM Tris-HCl, pH 7.4; 130 mM NaCl; 
2 mM EDTA; glycerol at a volume fraction 
of 10 %; supplemented before use with a 
volume fraction of 1 % of Triton X-100, 
5 mM NEM/ethanol, 2 mM oPA/ethanol, 
and 1 cOmplete™, mini Protease Inhibitor 
Cocktail tablet per 10 ml buffer 
Fixation solution Fixation of cells before 
IF staining 
4 % PFA/PBS (mass fraction) 
HRP inactivation so-
lution  
Inactivation of HRP af-
ter Western blot de-
veloping 
5 % acetic acid/H2O (volume fraction) 
Laemmli buffer (5×) Reducing sample 
loading buffer for 
Western blot 
312.5 mM Tris-HCl, pH 6.8; 0.5 M DTT; 
mass fraction of 10 % SDS, and 0.1 % 
bromphenol blue; volume fraction of 10 % 
TCEP, and 50 % glycerol 
Continued on the next page  
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Name Purpose Composition 
LB medium liquid Plasmid preparation 1 % Tryptone, 1 % NaCl, 0.5 % yeast ex-
tract in ddH2O (all mass fraction), pH 7.0 
LB medium solid (for 
agar plates) 
Plasmid preparation 1 l LB medium liquid, 15 g Agar, antibiotics 
as needed 
MOPS SDS running 
buffer (20×) 
Buffer for SDS-PAGE 1 M MOPS, 1 M Tris-Base, 20 mM EDTA, 
69.3 mM SDS in ddH2O 
NuPAGE transfer 
buffer (20×) 
Buffer for Western 
blot transfer 
500 mM Bicine, 500 mM Bis-Tris, 20 mM 
EDTA (supplement with 10 % volume frac-
tion methanol before use) 
PBS (1×) Various 1.0588236 mM KH2PO4, 155.17241 mM 
NaCl, 2.966418 mM Na2HPO4-7H2O 
(Thermo Fisher Scientific, 10010056) 
Peptide dissolve 
buffer 
Dissolving of 3×FLAG 
or HA peptide 
0.5 M Tris-HCl, pH 7.5, 1 M NaCl in ddH2O 
TBS Dilution of 3×FLAG 
or HA peptide 
50 mM Tris-HCl, pH 7.4 and 150 mM NaCl 
in ddH2O 
TBST (10×) Various  1,37 M NaCl, 200 mM Tris-HCl, pH 7.6, and 
1 % Tween-20 (volume fraction) 
Urea buffer General cell lysis 8 M urea, PBS 
DTT: Dithiothreitol; EDTA: Ethylenediaminetetraacetic acid; FCS: fetal calf serum; HRP: horse radish peroxidase; IF: immunoflu-
orescence; LB: lysogeny broth; MOPS: 3-(N-morpholino)propanesulfonic acid; NEM: N-ethylmaleimide; oPA: 1,10-phenanthroline; 
PBS: phosphate buffered saline; PFA: paraformaldehyde; SDS-PAGE: sodium dodecyl sulfate–polyacrylamide gel electrophoresis; 
TBS: Tris-buffered saline; TBST: TBS with Tween-20; TCEP: Tris-(2-carboxyethyl)-phosphin; TUBE: tandem ubiquitin binding entity 
 
3.1.3 Cell lines and culture media 
Table 6. Human cell lines and their culture media 
Cell line Specification Source Culture medium 
A375 Malignant melanoma ATCC® CRL-1619™ DMEM, 10 % FBS 
A375 sgEVI2_4  EVI/WLS KO in-house DMEM, 10 % FBS 
HEK293T Embryonic kidney ATCC® CRL-11268™ DMEM, 10 % FBS 
HEK293T KO2.9 EVI/WLS KO in-house DMEM, 10 % FBS 
RPMI7951 Malignant melanoma ATCC® HTB-66™ DMEM, 10 % FBS 
WM793 Malignant melanoma Meenhard Herlyn (Wistar In-
stitute, Philadelphia, USA) 
DMEM, 10 % FBS 
ATCC®: American Type Culture Collection; KO: knock-out; DMEM: Dulbecco’s Modified Eagle’s Medium;  
FBS: Fetal bovine serum, added as volume fraction 
  
 




Table 7. Consumables 
Name Reference Supplier 
Amersham Hyperfilm ECL 28906836 Cytiva/GE Healthcare 
Amersham Protran 0.45 nitrocellulose 
membranes 
10600002 Cytiva/GE Healthcare 
Autoklavierband Rolle 27005 neoLab Migge GmbH 
Bad Stabil® 16095 neoLab Migge GmbH 
Beschriftungsklebeband Rainbow-Pack 817-0027 VWR™ 
Bolt 4-12 % Bis-Tris plus gels, 10-well NW04120BOX Thermo Fisher Scientific 
Bolt 4-12 % Bis-Tris plus gels, 12-well NW04122BOX Thermo Fisher Scientific 
Bolt 4-12 % Bis-Tris plus gels, 15-well NW04125BOX Thermo Fisher Scientific 
Cell Culture Multiwell Plate, 12 Well,  
CELLSTAR® 
665180 Greiner Bio-One  
International GmbH 
Cell Culture Multiwell Plate, 24 Well,  
CELLSTAR® 
662160 Greiner Bio-One  
International GmbH 
Cell Culture Multiwell Plate, 6 Well,  
CELLSTAR® 
657160 Greiner Bio-One  
International GmbH 
Cell scraper 99002 TPP® 
Cover slip, round, 12 mm 9161064 Gerhard Menzel 
Disposable scalpel 200140021 Feather® 
Falcon® 100 mm TC-treated Cell Culture 
Dish 
353003 Corning, Inc. 
Falcon® 14 ml Round-Bottom Tube  352059 Corning, Inc. 
Falcon® 25cm² Rectangular Canted Neck 
Cell Culture Flask with Vented Cap 
353108 Corning, Inc. 
Falcon® 75cm² Rectangular Canted Neck 
Cell Culture Flask with Vented Cap 
353136 Corning, Inc. 
Falcon® 96-well Clear Flat Bottom TC-
treated Culture Microplate, with Lid 
353072 Corning, Inc. 
Falcon® Serological Pipet 1 ml  357521 Corning, Inc. 
Falcon® Serological Pipet 10 ml  357551 Corning, Inc. 
Falcon® Serological Pipet 2 ml  357507 Corning, Inc. 
Falcon® Serological Pipet 25 ml  357525 Corning, Inc. 
Falcon® Serological Pipet 5 ml  357543 Corning, Inc. 
Falcon® Serological Pipet 50 ml  357550 Corning, Inc. 
Filter tip PP, premium surface, 0.1-10 μl 07-612-8300 nerbe plus GmbH & Co. KG 
Filter tip PP, premium surface, 0-20 μl 07-622-8300 nerbe plus GmbH & Co. KG 
Filter tip PP, premium surface, 0-200 μl 07-662-8300 nerbe plus GmbH & Co. KG 
Filter tip PP, premium surface, 100-1000 μl 07-693-8300 nerbe plus GmbH & Co. KG 
Finntip™ pipette tips 613-2597 VWR™ 
Folded Filters 4.303.090 MUNKTELL & FILTRAK 
GmbH 
Gel Saver II Tip 1-200µl  
(protein gel loading tip) 
I1022-0600 STARLAB International 
GmbH 
Grade 3MM Chr Cellulose  
Chromatography Papers 
3030-917 Cytiva/GE Healthcare 
Continued on the next page 
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Name Reference Supplier 
Hand towel zigzag fold 66424 Essity Hygiene and Health 
Incidin™ Foam 30 460 10 ECOLAB Healthcare 
Injekt-F Tuberculin (1 ml) 9166017V BRAUN Melsungen AG 
LEITZ 4020, flush fold, Sichthüllen 1079554 Lyreco 
Lid for microplate, low profile 656191 Greiner Bio-One  
International GmbH 
LightCycler® 480 Sealing Foil 4729757001 Roche 
Medoject 25Gx1" CH25100 Chirana T. Injecta, a.s. 
Microplate, 96 well, clear, F-bottom 655101 Greiner Bio-One  
International GmbH 
Millex-GP Syringe Filter Unit, 0.22 µm SLGP033RS Merck Millipore 
Müllbeutel Blau 100 L 400.350 DKFZ Lager 
Nalgene™ General Long-Term Storage 
Cryogenic Tubes, 1.2 ml 
11740573 Thermo Fisher Scientific 
PARAFILM® M PM996 Merck Millipore 
PCR 384-Well TW-MT-Plate, white, for RT-
qPCR 
712456X Biozym Scientific GmbH 
PCR tubes 12er SoftStrips 711068 Biozym Scientific GmbH 
Petri dish, 94 x 16nmm, without vent 632180 Greiner Bio-One  
International GmbH 
profix® Allzweck- und Kosmetiktücher  
 
TEMCA 
Safe-Lock microcentrifuge tubes 1.5 ml 0030 120.086 Eppendorf AG 
Safe-Lock microcentrifuge tubes 2 ml 0030 120.094 Eppendorf AG 
Spezial Vernichtungsbeutel/ disposal bags 646201 Greiner Bio-One  
International GmbH 
SuperFrost Plus™ Adhesion slides J1800AMNZ Thermo Fisher Scientific 
Syringe, 20 ml, with BD Luer-Lok™ Tip BDAM302830 VWR™ 
TipOne® Tip, 10 µl Graduated, Refill  
(non-sterile) 
S1111-3700 STARLAB International 
GmbH 
TipOne® Tips, 1000 µl Blue Graduated, 
Refill (non-sterile) 
S1111-6701 STARLAB International 
GmbH 
TipOne® Tips, 200 µl Yellow, Refill  
(non-sterile) 
S1111-0706 STARLAB International 
GmbH 
TUBE, 15 ML, Centrifuge Tube,  
CELLSTAR® 
188271 Greiner Bio-One  
International GmbH 
TUBE, 50 ML, Centrifuge Tube, 
CELLSTAR® 
227261 Greiner Bio-One  
International GmbH 
Vernichtungsbeutel, 200X300;  
autoclavable bags 
09-302-0020 nerbe plus GmbH & Co. KG 
XCEED® Nitrile Gloves, S XC-INT-S STARLAB International 
GmbH 
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3.1.5 Enzymes, reagents, chemicals, and drugs 
Table 8. Molecular biology reagents, chemicals, enzymes, and drugs 
Name Reference Supplier 
1,10-Phenanthroline monohydrate (oPA) P9375-1G Sigma-Aldrich 
3× FLAG peptide F4799-4MG Sigma-Aldrich 
3-Morpholinopropanesulfonic acid (MOPS) A1076 AppliChem GmbH 
5× siRNA Buffer B-002000-UB-
100 
Horizon Discovery 
Acetic acid 15642900 Thermo Fisher Scientific 
Agar A0949,0500 AppliChem GmbH 
Agarose A9539 Sigma-Aldrich 
Bicine sc-216087A Santa Cruz Biotechnology 
BIS-Tris sc-216088A Santa Cruz Biotechnology 
Bond-Breaker TCEP Solution 77720 Thermo Fisher Scientific 
Bromophenol Blue sodium salt B5525-25G Sigma-Aldrich 
BSA Fraction V 1501,05 GERBU Biotechnik GmbH 
Carbenicillin; dinatriumsalz A1491,0010 AppliChem GmbH 
cOmplete™, Mini Protease Inhibitor Cocktail 11836153001 Sigma-Aldrich 
Cycloheximide solution C4859-1ML Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) D8418-50ML Sigma-Aldrich 
DTT BioChemica A2948,0005 AppliChem GmbH 
EDTA, Tetrasodium Tetrahydrate Salt  sc-204735 Santa Cruz Biotechnology 
Ethanol absolute 20.821.330 VWR™ 
Fetal bovine serum (FBS), Lot: CBX9154 F7524-500ml  Merck Millipore/Sigma 
Fixation reagent for histology (PFA 4 %) 12004 Morphisto 
FuGENE HD Transfection Reagent, 1ml E2311 Promega Corporation 
GelPilot® Loading Dye, 5× 1037650 QIAGEN 
GeneRuler 100 bp DNA ladder SM0243 Thermo Fisher Scientific 
Gibco™ DMEM, high glucose 41965062 Thermo Fisher Scientific 
Gibco™ PBS, pH 7.4 10010056 Thermo Fisher Scientific 
Gibco™ RPMI-1640, without l-glutamine 31870074 Thermo Fisher Scientific 
Gibco™ Trypsin-EDTA (0.25 %), Phenolred 25200056 Thermo Fisher Scientific 
Glycerol G5516  Sigma-Aldrich 
HA Peptide HY-P0239 Hölzel Diagnostika 
Hydrochloric acid (HCl) H/1200/PC15 Fisher Chemical 
Immobilon Western Chemiluminescent HRP 
Substrate 
WBKLS0100 Merck Millipore 
Kanamycinsulfat BioChemica A1493,0010 AppliChem GmbH 
LGK974 Custom Wuxi AppTec (Tianjin) 
Lipofectamine RNAiMAX 13778075 Thermo Fisher Scientific 
Methanol 32213 Sigma-Aldrich 
MG-132 in solution (1mg) 474791-1MG Sigma-Aldrich 
N-Ethylmaleimide (NEM) E3876-5G Sigma-Aldrich 
Nitric acid, min 65 % 30709-1L Sigma-Aldrich 
Normal Goat Serum 5425S Cell Signaling Technology 
Continued on the next page 
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Name Reference Supplier 
One Shot TOP10 Chemically Competent 
Escherichia coli  
C404006 Thermo Fisher Scientific 
PageRuler plus prestained protein ladder, 
10 to 250 kDa 
26619 Thermo Fisher Scientific 
Paraformaldehyde (PFA) BioChemica A3813,1000 AppliChem GmbH 
PHYSIODERM ® CREME PZN 4632286 Physioderm 
Pierce™ Western Blot Signal Enhancer 21050 Thermo Fisher Scientific 
Poly D-lysine A-003-E Millipore 
Ponceau S solution P7170-1L Sigma-Aldrich 
Potassium chloride (KCl) P-9541 Sigma-Aldrich 
ProLong™ Diamond Antifade Mountant with 
DAPI 
P36962 Thermo Fisher Scientific 
Propan-2-ol 33539 Honeywell Research Che-
micals 
Restore™ Plus Western Blot Stripping-
Buffer 
46430 Thermo Fisher Scientific 
S.O.C. Medium 15544034 Thermo Fisher Scientific 
Seraman® sensitive 30 393 80 ECOLAB Healthcare 
Shine last & go! gel nail polish NA Essence Cosmetics 
Skim Milk Powder 70166-500G Sigma-Aldrich 
Sodium chloride (NaCl) 31434-M Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) 75746-250G Sigma-Aldrich 
Sodium hydroxide (NaOH) UN1824 VWR™ 
Spitacid™ 30 953 70 ECOLAB Healthcare 
SuperSignal West Femto Maximum  
Sensitivity Substrate 
34095 Thermo Fisher Scientific 
TransIT-LT1 transfection reagent, 10 ml 731-0029 VWR™ 
Triton™ X-100 T8787-250ml Sigma-Aldrich 
Trizma® base (Tris) T1503-1KG Sigma-Aldrich 
Tryptone  8952 Carl Roth GmbH + Co. KG 
TWEEN® 20 P9416 Sigma-Aldrich 
Urea Molecular biology grade A1049,1000 AppliChem GmbH 
Yeast extract 1133 GERBU Biotechnik GmbH 
DMEM: Dulbecco’s Modified Eagle’s Medium; DTT: Dithiothreitol; EDTA: Ethylenediaminetetraacetic acid; PBS: phosphate buffe-








Table 9. Commercially available kits and master mixes 
Name Reference Supplier 
Gateway™ LR Clonase II Enzym-Mix 11791020 Thermo Fisher Scientific 
LightCycler® 480 Probes Master 4887301001 Roche 
NucleoSpin Gel and polymerase chain reac-
tion (PCR) Clean-up Kit 
740609 Macherey-Nagel 
Pierce™ BCA™ Protein-Assay 23227 Thermo Fisher Scientific 
Q5® Site-Directed Mutagenesis Kit E0554S New England BioLabs 
QCM™ Gelatin Invadopodia Assay (Green) ECM670 Merck Millipore 
QIAGEN Plasmid Maxi Kit 12165 QIAGEN 
QIAGEN Plasmid mini Kit 12125 QIAGEN 
RevertAid H minus First Strand cDNA Synthe-
sis Kit 
K1632 Thermo Fisher Scientific 
RNase-Free DNase Set 79254 QIAGEN 
RNeasy mini Kit 74106 QIAGEN 
 
3.1.7 Oligonucleotides and antisense oligonucleotides 
 Primers for reverse-transcription quantitative PCR (RT-qPCR) 
Table 10. Primer sequences used for RT-qPCR with the Universal ProbeLibrary (Roche) 
Target mRNA Forward primer sequence (5' - 3') Re-
verse primer sequence (5’ - 3’)   










ERLIN2/SPFH2 GGAAGAAGGCGCTCATTG  
TGAAATCTTCTCAGTCTCCTTC 
#29 4687612001 
EVI/WLS TCATGGTATTTCAGGTGTTTCG  
GCATGAGGAACTTGAACCTAAAA 
#38 4687965001 
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Target mRNA Forward primer sequence (5' - 3') Re-
verse primer sequence (5’ - 3’)   








































 Small interfering ribonucleic acids (siRNAs) 
Table 11. Control siRNA sequences 
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Table 12. siRNA sequences  
Target gene Supplier Reference No Sequence (5' - 3') 
EVI/WLS Ambion™ s36745  1 GGACAUUGCCUUCAAGCUA  
  s36747  3 GGAUUUCCAUGACCUUUAU  
AMFR/GP78 Dharmacon™ D-006522-01  1 GCAAGGAUCGAUUUGAAUA  
  D-006522-02 2 GGAGCUGGCUGUCAACAAU  
  D-006522-03 3 GAGGACUGCUCAUGUGAUU  
  D-006522-04 4 CGAGCUGGCUGCCGAGUUU 
ATXN3 Dharmacon™ D-012013-01 1 GUACAAAUCUUACUUCAGA 
  D-012013-02 2 GCUCAGGAAUGUUAGACGA 
  D-012013-03 3 GCAGGGCUAUUCAGCUAAG 
  D-012013-04 4 ACGAGAAGCCUACUUUGAA 
BAG6 Dharmacon™ D-005062-01 1 GGACAAACCUGGAAUUCU 
  D-005062-02 2 CAGAAUGGGUCCCUAUUAU 
  D-005062-03 3 CAGCAGCUCCGGUCUGAUA 
  D-005062-04 4 UGAGCUGGCUGACCACUAU 
CGRRF1 Dharmacon™ D-006933-01  1 GAAGAUAGCCUCCUUACAU  
  D-006933-02 2 GACCUUAGCUGAUGAGGAU  
  D-006933-03 3 UAUGAAUACUCGCCGCUUU  
  D-006933-04 4 CUACAUCGCGGUGGUCUUU  
CTNNB1 Ambion™ 4390824/s438 CUGUUGGAUUGAUUCGAA 
DERL1 Dharmacon™ D-010733-02  2 GAACAGAGACAUGAUUGUA  
  D-010733-03 3 GAUAUGCAGUUGCUGAUGA  
  D-010733-04 4 GGCCAGGGCUUUCGACUUG 
  D-010733-18 18 CAAUUAUGUUGCACGUACA  
DERL2 Dharmacon™ D-010576-01 1 GAAGAUGUAUUUCCCAAUC 
  D-010576-02 2 CAAUAAUGCUCGUCUAUGU 
  D-010576-03 3 CAGCAGACUUUGUAUUUAU 
  D-010576-04 4 GGAGAUUAAUCACCAACUU 
DERL3 Dharmacon™ D-032237-04 4 GGAUUGCGGUGGGCCAUAU 
  D-032237-05 5 GGAUUCAGCUUCUUCUUCA 
  D-032237-06 6 UCUGGAGGCUCGUCACCAA 
  D-032237-07 7 CUUGGGCGCUCAUGGGUU 
ERLIN1/SPFH1 Dharmacon™ D-015639-02 2 CGAAUAGAAGUGGUUAAUA 
  D-015639-18 18 GAUUAUGACAAGACCUUAA 
  D-015639-19 19 AGAGUUAACCUGUGGCAUU 
  D-015639-20 20 GGCCCGAGAGAAAGCGAAA 
ERLIN2/SPFH2 Dharmacon™ D-017943-02 2 GAACGCAGUGUAUGAUAUA 
  D-017943-03 3 GAUAGAAGAGGGACAUAUU 
  D-017943-04 4 GAAUGUACCUUGUGGGACU 
  D-017943-05 5 CAACAAGAUCCACCACGAA 
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Target gene Supplier Reference No Sequence (5' - 3') 
FAF2/ETEA/UBXD8 Dharmacon™ D-010649-01 1 GGACCUAACUGACGAAUGA 
  D-010649-03 3 AGACUUACCUGGUGUCAGA 
  D-010649-04 4 CUACAGCUAUGUUGUCUCA 
  D-010649-17 17 CCUAAUGAUUCUCGAGUAG 
HERPUD1/HERP Dharmacon™ D-020918-01 1 GACCAGAGGUUAAUUUAUU 
  D-020918-02 2 GGGCCACCGUUGUUAUGUA 
  D-020918-03 3 CAACAAUAACUUACAGGAA 
  D-020918-04 4 CGACAGUACUACAUGCAAU 
HM13/SPP Dharmacon™ D-005896-4 4 AAAUAUUCUCCCAGGAGUA  
  D-005896-5 5 CAAGAAUGCUUCAGACAUG 
  D-005896-6 6 GCCCUCAGCGAUCCGCAUA 
  D-005896-19  19 AUUUCUUCGUGCUGGGAAU  
MARCH4 Dharmacon™ D-023172-02  2 CAUCACCACUGUGCUUAUA  
  D-023172-03 3 GAGCUGGUCAUGAGAGUCA  
  D-023172-05 5 GUACUGCUAUGGAUUGUGU  
  D-023172-06 6 GAGGAUCGCUACUCACUGG  
MARCH6 Dharmacon™ D-006925-01  1 GAAGACAUAUGUAGAGUGU  
  D-006925-02 2 UCAUAGAUCUCGUCGCUUA 
  D-006925-03 3 GAAUUGGAAUGCUUUAGAA 
  D-006925-04 4 GAGCUUACAUGGGAAAGAA 
MITF Dharmacon™ D-008674-01 1 GAACGAAGAAGAAGAUUUA 
  D-008674-02 2 GCAGAUGGAUGAUGUAAUC 
  D-008674-03 3 GACCUAACCUGUACAACAA 
  D-008674-04 4 AGACGGAGCACACUUGUUA 
NGLY/PNG1 Dharmacon™ D-016457-01 1 GAGGAGCUGUUGAAUGUUU 
  D-016457-02 2 AGACAAAGCUUAAAUGACC 
  D-016457-03 3 GCGAGUGGGCCAAUUGUUU 
  D-016457-04 4 GAAAUUGCGAUCUGAUACA 
NPLOC4/NPL4 Dharmacon™ D-020796-02 2 AAUAAUGGCUUCUCGGUUU 
  D-020796-03 3 GGACACCUAUUUCCUAAGU 
  D-020796-04 4 GACAAUAUCAUGUUUGAGA 
  D-020796-17 17 AGGAAAAGCAUUGGCGAUU 
PORCN Dharmacon™ D-009613-01 1 GAUCUUCUACCGUCUCAUA 
  D-009613-02 2 UCACUUACGUGGAGCAUGU 
  D-009613-03 3 GGUGCGAGCCUUAAACUUG 
  D-009613-04 4 GGUCAAUGGUGGAAGUUGU 
RAD23B Dharmacon™ D-011759-01 1 GCAGAUAGGUCGAGAGAAU 
  D-011759-02 2 GUACAUCGGGUGAUUCUUC 
  D-011759-03 3 GAACGAGAGCAAGUAAUUG 
  D-011759-04 4 GGGUCAGUCUUACGAGAAU 
Continued on the next page 
  
 
   3   Material & Methods 
45 
 
Target gene Supplier Reference No Sequence (5' - 3') 
RHBDD1/RHBDL4 Dharmacon™ D-019378-01  1 CGGCAAUACUACUUUAAUA  
  D-019378-02 2 GUACACAGCAGGACUGAGU  
  D-019378-03 3 GGGAUAAAUACUGGACUUA 
  D-019378-04 4 UGUACUUACUGGAGUGGUA  
RNF128 Dharmacon™ D-007061-01  1 GAAUUGAGGUGGAUGUUGA  
  D-007061-04 4 CAAAGAGGCAUACAAGUGA  
  D-007061-17 17 GGUCAUUGAUCUUCGUUCA  
  D-007061-18 18 GAGACUGCUGUUCGAGAAA  
RNF139/TRC8 Dharmacon™ D-006942-01  1 GGGAAAAGCUUGACGAUUA  
  D-006942-02 2 GAACUGUGCUUAAAAGUAA  
  D-006942-04 4 GCACAUGUAUCGAAUUUAC 
  D-006942-17 17 AUAAUUAGUGGGUGCGAUU  
RNF170 Dharmacon™ D-007078-01  1 GAAACUGGAUGAUGAUUCA  
  D-007078-02 2 GGGCAACCCAGAUCUAUUA  
  D-007078-03 3 GGCCAAAUAUCAAGGUGAA  
  D-007078-04 4 GAGAUUGCAUCAGGAUAUU  
RNF5 Dharmacon™ D-006558-01  1 CGGCAAGAGUGUCCAGUAU 
  D-006558-02 2 GCUGGGAUCAGCAGAGAGA  
  D-006558-03 3 GCAAGAGUGUCCAGUAUGU  
  D-006558-18 18 CCGAAGGGCCAAAUCGCGA  
SEL1L Dharmacon™ D-004885-02 2 UAAGAAAGCUGCUGACAUG 
  D-004885-03 3 GAAUUAAGCUCGGAGACUA 
  D-004885-04 4 GGAGAGGAGUUCAAGUUAA 
  D-004885-05 5 GAGAGGAGUUCAAGUUAAU 
SH3PXD2A/TKS5 Dharmacon™ D-006657-02 2 CGCGGAAGCUCAAGUAUGA 
  D-006657-03 3 CCAGCCACCUCGUACAUGA 
  D-006657-05 5 GAAGGCUGGUGGUAUAUCA 
  D-006657-06 6 CAUCAUACAUCGAUAAGCG 
SYFN/HRD1 Dharmacon™ D-007090-01  1 CAACAAGGCUGUGUACAUG  
  D-007090-02 2 UGUCUGGCCUUCACCGUUU  
  D-007090-03 3 GGAGAUGCCUGAGGAUGGA  
  D-007090-04 4 CCAAGAGACUGCCCUGCAA  
TMUB2 Dharmacon™ D-014307-01 1 GCAAAUACUUCCCUGGACA 
  D-014307-03 3 UGGGAUGUAUGGACGAUAA 
  D-014307-04 4 GGUACUUCCGAAUCAAUUA 
  D-014307-18 18 UCUCUGAACAUUACCGACA 
UBAC2 Dharmacon™ D-107914-01 1 GAACCCAUCUUCUCUUCUU 
  D-107914-02 2 GGAAUGAUCAAUUGGAAUC 
  D-107914-03 3 GCACAAGGGAGGCGACAGA 
  D-107914-04 4 UGAGAUGUUUCAAGUGG 
Continued on the next page 
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Target gene Supplier Reference No Sequence (5' - 3') 
UBE2G1 Dharmacon™ D-010154-01 1 GCGAAAGAAUGGAGGGAAG 
  D-010154-02 2 GCACCCAAAUGUUGAUAAA 
  D-010154-04 4 GUGGAAACCAUCAUGAUUA 
  D-010154-05 5 CGAUGGGAAGUCCUUAUUA 
UBE2G2 Dharmacon™ D-009095-01 1 UCUAUAAGAUUGCCAAGCA  
  D-009095-02 2 GAUGGGAGAGUCUGCAUUU  
  D-009095-03 3 CCACUUGAUUACCCGUUAA  
  D-009095-05  5 GAGCUAACGUGGAUGCGUC  
UBE2J1 Dharmacon™ D-007266-01 1 GAAAGAAGCGGCAGAAUUG  
  D-007266-03 3 GAAUAUAUCUGGCAAACGA 
  D-007266-19 19 GGAAGUAUAUGUAAGGUUA  
  D-007266-20 20 GGCUAAUGGUCGAUUUGAA  
UBE2J2 Dharmacon™ D-008614-01  1 GAAGGUGGCUAUUAUCAUG  
  D-008614-02 2 GCACAAGACGAACUCAGUA  
  D-008614-04 4 GUAUAGAGACGUCGGACUU  
  D-008614-18 18 CCCAGUAUCUAUAUGAUCA 
UBE2K Dharmacon™ D-009431-17  17 GGGUAUUUGUCUUGAGAAU  
  D-009431-18 18 GAAUCAAGCGGGAGUUCA  
  D-009431-19 19 UGUUGAGGCUGCUUAAUAA  
  D-009431-20 20 GGGCUAUUUGUUUGGAUAU  
UBE2N Dharmacon™ D-003920-01 1 GCACAGUUCUGCUAUCGAU 
  D-003920-02 2 GAGCAUGGACUAGGCUAUA 
  D-003920-04 4 CAGAUGAUCCAUUAGCAAA 
  D-003920-05 5 GCGGAGCAGUGGAAGACCA 
UBE2U Dharmacon™ D-008998-01  1 GAAGUGGAAUACAAACUAU  
  D-008998-02 2 GAAUACUGGUUAAAGAUGA  
  D-008998-03 3 GUGAAGAUAUGAUGGAAUG  
  D-008998-04 4 CAACCUCAUUUAGUGAUUA  
UBE2V1 Dharmacon™ D-010064-02 2 GGACAGUGUUACAGCAAUU 
  D-010064-21 21 GUGGAUGCAUACCGAAAUA 
  D-010064-22 22 GCCGAAGCAUAGAUUGUAA 
  D-010064-23 23 UGAGAUUGGCCUUCGGUGA 
UBE2V2 Dharmacon™ D-008823-01 1 GCUAAGACGUCUAAUGAUG 
  D-008823-02 2 GGACAGGCAUGAUUAUUGG 
  D-008823-03 3 GAGUUAAAGUUCCUCGUAA 
  D-008823-04 4 GCAUACCAGUGUUAGCAAA 
UBE4A Dharmacon™ D-007200-01 1 CCUCUUCGCUCGCUUAUUA 
  D-007200-02 2 GGAAUAUGAUUAUGGCUUU 
  D-007200-03 3 GAGUAUCUCCUGCUUAUUA 
  D-007200-04 4 GAUAAUAGCGUGUCAGAGA 
Continued on the next page 
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Target gene Supplier Reference No Sequence (5' - 3') 
UBXN4/ERASIN/ 
UBXD2 
Dharmacon™ D-014184-03 3 CUACACAGAUGGCUGCAAG 
 D-014184-04 4 GCGGAGACAUUUGGACCUU 
  D-014184-17 17 GAAAGUAGCUGGCGAGGUU 
  D-014184-18 18 UAGAGUGGACAUACGGAAA 
UBXN6/UBXD1 Dharmacon™ D-008785-01  1 CCAAGUACCUGGACAACAU 
  D-008785-02 2 GAAACCAGGUGAGAAAGGA 
  D-008785-03 3 UCAUGAAGAUCUACACGUU 
  D-008785-04 4 ACGAGAACCUGGCCUUGAA 
UFD1L/UFD1 Dharmacon™ D-017918-02  2 AAUCAAGCCUGGAGAUAUU 
  D-017918-03 3 GACCAAACCCGACAAGGCA 
  D-017918-04 4 GAGCGUCAACCUUCAAGUG 
  D-017918-17 17 GAGGCAGAUUCGUCGCUUU 
USP13 Dharmacon™ D-006064-01 1 GAAGAUGGGUGAUUUACAA 
  D-006064-02 2 GCACUGGAUUGGAUCUUUA 
  D-006064-03 3 GCACGAAACUGAAGCCAAU 
  D-006064-04 4 UGAUUGAGAUGGAGAAUAA 
USP19 Dharmacon™ D-006068-03 3 GAUGAGGAAUGACUCUUUC 
  D-006068-04 4 GAGGACACCACUAGUAAGA 
  D-006068-05 5 UGGCGGAGGUAAUUAAGAA 
  D-006068-06 6 UCAAGAAUGACUCGUAUGA 
USP25 Dharmacon™ D-006074-02 2 GCAGAUGGAUGAAGUACAA 
  D-006074-03 3 UGAAAGGUGUCACAACAUA 
  D-006074-04 4 GAGCUGAGGUAUCUAUUUG 
  D-006074-05 5 CAAUUAAGUUGGAAUAUGC 
USP50 Dharmacon™ D-031837-2 2 UAUGAUACCCUUCCAGUUA  
  D-031837-3 3 GAGAACGGAUAUUCAUUAC  
  D-031837-4 4 GGUUUGACAUUCAGGGUAC  
  D-031837-17  17 CAACACAUGCUGCGUGAAU  
VCP Dharmacon™ D-008727-05  5 GUAAUCUCUUCGAGGUAUA  
  D-008727-06 6 AAACAGAUCCUAGCCCUUA  
  D-008727-07 7 GAGAGCAACCUUCGUAAAG  
  D-008727-08 8 GCACAGGUGGCAGUGUAUA  
VCPIP1 Dharmacon™ D-019137-01 1 GAGAAGCUCUGGUGAUUAU 
  D-019137-02 2 GACAGAAGUUUGCAAGAUA 
  D-019137-03 3 GGGACAGACUUUAGUAAUA 
  D-019137-04 4 CAGAAGGACUGGAGUGAUA 
WNT5A Ambion™ s14871 1 UAUCAAUUCCGACAUCGAA 
  s14872 2 AGAUGUCAGAAGUAUAUAU 
  s14873 3 GGUGGUCGCUAGGUAUGAA 
Continued on the next page 
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Target gene Supplier Reference No Sequence (5' - 3') 
WNT11 Dharmacon™ D-009474-02 2 CAGGAUCCCAAGCCAAUAA 
  D-009474-03 3 CGACAGCUGCGACCUUAUG 
  D-009474-04 4 GUCGAGCGGUGCCACUGUA 
  D-009474-05 5 GGACUCGGAACUCGUCUAU 
YOD1 Dharmacon™ D-027369-01 1 CGAUUGAGAUUGAGUAUUA 
  D-027369-02 2 GAAUGAGGGUUGAAGCCUA 
  D-027369-03 3 GAUCCAGACUUCUAUAGUG 
  D-027369-04 4 GCAAUAGAGAUAUCGAUUU 
 
Table 13. siRNA sequences from Dharmacon Genomewide 96 well plates MTP 
Target gene Supplier Reference Sequence (5' - 3') 




























Continued on the next page 
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Target gene Supplier Reference Sequence (5' - 3') 


















Table 14. Plasmids 
Name Description Reference 
pRK5-HA-Ubiq-
uitin wt 
Mammalian expression of HA-tagged ubiquitin Addgene #17608  
(K. L. Lim et al., 2005) 
pRK5-HA-Ubiq-
uitin K11 
Mammalian expression of HA-tagged ubiquitin 
with only K11, other K mutated to R 
Addgene #22901  




Mammalian expression of HA-tagged ubiquitin 
with only K48, other K mutated to R 
Addgene #17605 
(K. L. Lim et al., 2005) 
pRK5-HA-Ubiq-
uitin K63 
Mammalian expression of HA-tagged ubiquitin 
with only K63, other K mutated to R 
Addgene #17606 
(K. L. Lim et al., 2005) 
pcDNA Wnt3 Mammalian expression of WNT3 Addgene #35909  
(Najdi et al., 2012) 
pcDNA-Wnt5A Mammalian expression of WNT5A Addgene #35911 
(Najdi et al., 2012) 
pcDNA-Wnt11 Mammalian expression of WNT11 Addgene #35922 
(Najdi et al., 2012) 
pcDNA-V5-hWls 
(EVI/WLS-V5) 
Mammalian expression of V5-tagged EVI/WLS 
(N-terminal V5-tag at AA166 of EVI/WLS) 




Mammalian expression of V5-tagged EVI/WLS, 
K410 and K419 mutated to R 
In-house (Kathrin 
Glaeser), unpublished 
Continued on the next page 
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FLAG-tagged Porcupine Origene (#RC223764) 
ERLIN1-FLAG Mammalian expression of FLAG-tagged ER-
LIN1 (C-terminal); Gateway cloning with 
pENTR #187225731 (open, backbone 
pENTR221; 1081 bp) and pDEST-FLAG C-ter-
minal, CMV promotor 
this study 
ERLIN2-FLAG Mammalian expression of FLAG-tagged ER-
LIN2 (C-terminal); Gateway cloning with 
pENTR #127630018 (open, backbone 
pENTR201; 1059bp) and pDEST-FLAG C-ter-
minal, CMV promotor 
this study 
FAF2-FLAG Mammalian expression of FLAG-tagged FAF2 
(C-terminal); Gateway cloning with pENTR 
#191683255 (open, backbone pENTR221; 
1294 bp) and pDEST-FLAG C-terminal, CMV 
promotor 
this study 
UBXN4-FLAG Mammalian expression of FLAG-tagged 
UBXN4 (C-terminal); Gateway cloning with 
pENTR #178534864 (open, backbone 
pENTR221; 1567 bp) and pDEST-FLAG C-ter-




Mammalian expression of FLAG-tagged UBE2K 
(N-terminal) STOP codon re-introduced by 
site-directed mutagenesis; Gateway cloning 
with pENTR #123919860 (open, backbone 
pENTR221; 643 bp) and pDEST-FLAG N-termi-
nal, CMV promotor 
this study 
Bp: base pairs; wt: wild type 
  
 




Table 15. Online and offline software 
Software Version Source/Reference 
Fiji/ImageJ-win64 1.51n Wayne Rasband, National Institutes of 
Health (Schindelin et al., 2012) 
GeneCards  
– the human gene database 
v5.0.0 
Build 318 
Weizmann Institute of Science (2020), 
(Stelzer et al., 2016) 
GlycoProtDB 2016-12-05 National Institute of Advanced Industrial 
Science and Technology (AIST) 
IncuCyte™ Basic Software & 
Scratch Wound Cell Migration 
Software Module 
2013B Rev1 Essen BioScience Inc. 
Inkscape 0.92.2 Inkscape-project (2020) 
LightCycler® 480 Software 1.5.1.62 
SP3 
Roche 
Microsoft® Excel Office 2019 Microsoft Corporation 
Microsoft® PowerPoint Office 2019 Microsoft Corporation 
Microsoft® Word  Office 2019 Microsoft Corporation 
MikroWin 2010  
(Mithras LB 940 reader) 
5.23 Labsis Laborsysteme GmbH 
NanoDrop 1000 3.8.1 Thermo Scientific 
NEBaseChanger 1.3.0 New England BioLabs (2020) 
PhosphoSitePlus® v.6.5.9.3 Cell Signaling Technology (2020),  
Hornbeck et al., 2015 
Primer3web tool 4.1.0 Kõressaar et al., 2018; Koressaar & 
Remm, 2007; Untergasser et al., 2012 
PyMOL 2.3 Schrödinger 
R 3.6.1 R Core Team (2019) 
RStudio 1.2.1335 RStudio Team (2020) 
Sequencing Primer Design Tool / Eurofins Genomics (2020) 
SerialCloner 2.6.1 Serial Basics Softwares 
TCGA / TCGA Research Network, National Insti-
tutes of Health (2019) 
UniProt / UniProt Consortium (2020) 
Universal ProbeLibrary Assay 
Design Center 
/ Roche (2019) 
ZEN (blue edition) 2.3 Carl Zeiss Microscopy GmbH 
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3.1.10   Technical equipment 
Table 16. Technical equipment 
Name Reference Supplier 
AccuBlock™ Digital dry bath 51602070 Labnet 
Agarose gel documentation station E-Box VX2 PeqLab Biotechnologie 
GmbH 
Carrousel Pipette Stand F161401 Gilson 
Centrifuge 5804 Eppendorf AG 
Centrifuge 5804 R Eppendorf AG 
Centrifuge 5415 D Eppendorf AG 
Centrifuge 5810 R Eppendorf AG 
Centrifuge  5424 Eppendorf AG 
Centrifuge  5424 R Eppendorf AG 
COMPACT 2 X-Ray Film Processor 1190-1 PROTEC GmbH & Co. KG 
Cryo-Safe™ Cooler (Mr. Frosty) F18844-0000 Bel-Art Products 
CryoStorage Systems (liquid nitrogen) 562004JJ4 Taylor Wharton 10K 
DynaMag™-2 12321D Thermo Fisher Scientific 
Electrophoresis cell SUB-CELL® GT 710 BR 04827 Bio-Rad 
Finnpipette® 50-300 µl 4510 Thermo Scientific 
Finnpipette® 5-50 µl 4510 Thermo Scientific 
Fluorescence microscope 'Cell observer' Axio Observer Z1 Zeiss 
Freezer -20 °C G5216 Liebherr 
Freezer -20 °C TGS 5200 Liebherr 
Freezer -20 °C Comfort 77 552 
404.86 
Liebherr 
Fridge 4 °C Lkexv 3910 Liebherr 
Fridge 4 °C KT-1740 Liebherr 
Fridge 4 °C FKEX 5000 Liebherr 
GenPure water purifier 50131323 Thermo Fisher Scientific 
HERAfreeze basic HFU320 BV Thermo Fisher Scientific 
Hypercassette™ RPN11642 Amersham Biosciences 
Ice machine FM-150KE-50 Hoshizaki 
Incubator (37 °C) BD 53 Binder 
Incubator (60 °C) ED 53 Binder 
Incubator, with CO2 sensor CB210 & CB220 Binder 
Incubator, with CO2 sensor NU-4750E IBS Integra Biosciences 
IncuCyte® WoundMaker (96-pin 
woundmaking tool) 
4493 Essen BioScience Inc. 
IncuCyte® Zoom 40239 Essen BioScience Inc. 
Label Manager® 280 DYMO 
Laminar flow hood/biosafety cabinet HERA safe KS18 Kendro 
Laminar flow hood/biosafety cabinet MaxiSafe 2030i Thermo Fisher Scientific 
LightCycler® 480 1220, 5447 Roche 
Magnetic hotplate stirrer MR 3001 Heidolph 
Magnetic hotplate stirrer MR Hei-Standard Heidolph 
Megafuge 1.0R 40618926 Heraeus 
Continued on the next page 
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Name Reference Supplier 
Microscope Axiovert 25 CFL 3810669840 Zeiss 
Microscope EVOS FL G2616-155G-
0348 
Thermo Fisher Scientific 
Microwave NA BOSCH 
Mini Blot Module B1000 Thermo Fisher Scientific 
Mini Gel Tank A25977 Thermo Fisher Scientific 
Mithras microplate reader LB 940 Berthold Technologies 
NanoDrop ND-1000 spectrophotometer C957 PeqLab Biotechnologie 
GmbH 
Neubauer Hemocytometer 718605 Brand GmbH 
Peltier Thermal Cycler PTC-200 MJ Research 
PEQPower 300 81119172 PeqLab Biotechnologie 
GmbH 
pH-meter-basic PB-11 Sartorius 
Pinzette Dumont 5 INOX K342.1 Carl Roth GmbH 
Pipetboy accu-jet® pro BRAND 
PIPETMAN L Multichannel P12x200L,  
20-200 µL  
FA10012 Gilson 
PIPETMAN Neo P1000N, 100-1000 μl F144566 Gilson 
PIPETMAN Neo P10G, 1-10 μl F144055M Gilson 
PIPETMAN Neo P200G, 20-200 μl F144565 Gilson 
PIPETMAN Neo P20G, 2-20 μl F144056M Gilson 
PIPETMAN Neo P2N, 0.2-2 µl F144561 Gilson 
PowerPac™ 200 JB 892 LC Bio-Rad 
PowerPac™ Basic 1645050 Bio-Rad 
PowerPac™ Universal 04 BR 05104 Bio-Rad 
Precision balance BJ 2100D Precisa 
Precision balance CP124S Sartorius 
PROMIX A40 Automatic Mixer 1180-1-0000 PROTEC GmbH & Co. KG 
Research pro 5-100 µl P6985  Eppendorf AG 
Shaker/mixer Polymax 1040 Heidolph 
Shaker/mixer Duomax 1030 Heidolph 
Shaking incubator AJ 112 Infors AG 
Soda Lime Glass Balls; 4mm  Z265934-1EA Sigma-Aldrich 
Spectrafuge Mini C1301 Labnet 
Sprout™ HSD43769 Biozym 
Thermocycler Tadvanced 3812230 analytik jena 
Thermomixer - Mixer HC S8012-0000 STARLAB International 
GmbH 
Thermomixer comfort 5355 Eppendorf AG 
Tube rotator (1.5 ml or 2 ml) 444-0500 VWR™ 
Tube rotator (15 ml or 50 ml) RM 10 W CAT 
Tube rotator (15 ml or 50 ml) RM 10  CAT 
Vacusafe comfort 80877 IBS Integra Biosciences 
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3.2.1 Cell biological methods 
 Cell lines, culture media, and cell handling 
The human melanoma cell lines A375 (American Type Culture Collection, ATCC, CRL-1619) 
and RPMI7951 (ATCC HTB-66), as well as the human embryonic kidney cells HEK293T (ATCC 
CRL-11268) were purchased from ATCC. The human melanoma cell line WM793 was a gen-
erous gift by Meenhard Herlyn (The Wistar Institute Melanoma Research Center, Philadelphia, 
USA). HEK293T KO2.9 and A375 sgEVI2_4 EVI/WLS knock-out cell lines were generated in-
house using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 and 
single cell clonal expansion by Oksana Voloshanenko or Iris Augustin, respectively. Cells were 
regularly authenticated and confirmed to be mycoplasma negative. Cell counting was per-
formed with a hemocytometer. 
All cells were cultured as monolayers in Dulbecco´s modified Eagle´s medium (DMEM) 
with 4.5 g/l (high) glucose and L-glutamine supplemented with 10 % fetal bovine serum (FBS, 
volume fraction) without antibiotics at 37 °C and 5 % CO2 in a humidified atmosphere. When 
they reached 80 % to 90 % confluence, cells were washed once with phosphate buffered saline 
(PBS) and then passaged after trypsinisation with 0.25 % trypsin/ethylenediaminetetraacetic 
acid (EDTA) for 2 min to 5 min. Typically, cells were re-seeded at 1/10 or 1/20 of initial conflu-
ence. No cells with a higher passage number than 25 were used for experiments (for HEK293T 
cells not higher than 20). It should be noted that RPMI7951 cells with higher passage numbers 
regularly have multiple nuclei and divide considerably slower than cells with lower passage 
numbers. 
To cryopreserve cells, a minimum of 1 × 106 cells in 1 ml FBS with 10 % dimethyl sul-
foxide (DMSO, volume fraction) was frozen at -80 °C in cryotubes with the help of Mr. Frosty 
Freezing Containers. For long term storage, cells were kept in the liquid nitrogen tank. Defrost-
ing was done by heating the cryotubes to 37 °C for 2 min, followed by resuspension of cells in 
culture medium. The DMSO was removed by centrifugation at 200 × g for 5 min and one wash 
with PBS before cells were taken into culture. 
 Plasmid transfection 
Plasmid transfection for overexpression of genes was either done using TransIT-LT1 Transfec-
tion Reagent for HEK293T and A375 cells or FuGENE HD Transfection Reagent for RPMI7951 
cells. Cell numbers for seeding and reagent volumes are indicated in Table 17. Cells were 
seeded 24 h prior to plasmid transfection. The next day, the culture medium was replaced after 
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one wash with PBS. All reagents were brought to room temperature before use. Plasmid DNA 
was diluted in serum-free RPMI-1640 medium before adding the transfection reagent and the 
tube was gently mixed by flipping. TransIT-LT1 reactions were incubated for 15 min at room 
temperature before being added dropwise to the cells. FuGENE HD reactions were added di-
rectly dropwise to the cells. Cells were harvested 48 h after plasmid transfection for immuno-
precipitation and/or Western blot assays and fixed after 24 h for immunofluorescence analysis. 
Table 17. Volumes for plasmid transfection 













Cell number 3 × 104 1.5 × 105 7 × 104 5 × 105 2 × 105 3.5 × 106 
Culture medium (ml) 0.5 2 2 10 2 10 
Plasmid DNA (µg) 0.375 1.5 1 1.5 0.25 - 1 1.5 
Transfection reagent (µl) 1.5 6 6 12 3 - 5 12 
RPMI-1640 medium (µl) 25 100 250 500 250 500 
 
 siRNA transfection 
Lipofectamine RNAiMAX Transfection Reagent was used to transfect melanoma cells with 
siRNA 24 h after seeding, whereas HEK293T cells were transfected in parallel to being seeded 
(reverse transfection). Cell numbers for seeding and reagent volumes are indicated in Table 
18. siRNAs purchased from Ambion (Thermo Fisher Scientific) were diluted to a working con-
centration of 5 µM with ddH2O and siRNAs from Dharmacon (Horizon Discovery) were diluted 
to 20 µM using 1× siRNA Buffer from Dharmacon. All further experimental steps were done 
with the same volumes for both siRNA suppliers. siRNAs were kept on ice as much as possible, 
all other reagents were brought to room temperature before use. 
For the transfection of melanoma cells, reagent mix A and B were prepared as indicated 
in Table 18, incubated at room temperature for 2 min and then combined. In the meantime, the 
cells were washed once with PBS and the culture medium was changed. After incubating the 
mix for 5 min at room temperature, it was added dropwise to the cells. The culture medium was 
changed again 24 h before harvest or further processing of the cells, with a total siRNA incu-
bation time of 72 h to 96 h.  
For the transfection of HEK293T cells, siRNA working solutions were diluted 1/40 with 
ddH2O, resulting in concentrations of 500 nM for Dharmacon and 125 nM for Ambion, and 
100 µl of this solution was distributed dropwise to the bottom of wells or dishes. Lipofectamine 
RNAiMAX was diluted with half of the volume of serum-free RPMI-1640 medium indicated in 
Table 18 and incubated at room temperature for 10 min, before being further diluted with the 
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remainder. This mix was then added to the siRNAs in the wells and further incubated for 30 min 
at room temperature. In the meantime, cells were prepared and seeded in culture medium on 
top of the siRNA/RNAiMAX mix. Gentle shaking ensured equal distribution of siRNA and cells. 
Cells were typically harvested 72 h after siRNA transfection.   
Table 18. Volumes for siRNA transfections 
 Melanoma cells HEK293T 
 6-well 10 cm dish 12-well 6-well 10 cm dish 






6 × 104 3 × 105 3,5 × 106 
Culture medium (ml) 2 10 0.3 1.4 8 
siRNA (µl) 3 (Mix A) 20 (Mix A) 20 100 400 
RNAiMAX (µl) 6 (Mix B) 40 (Mix B) 0.8 4 8 
RPMI-1640 medium 
(µl) 
125 (Mix A) +  
125 (Mix B) 
625 (Mix A) + 
 625 (Mix B) 







 Inhibitor treatments 
LGK974 is an inhibitor of PORCN and was used at 10 µM for 96 h with daily medium changes 
and PBS washes (stock solution: 50 mM in DMSO). MG132 is an inhibitor of the proteasome 
and was used at 1 µM for 24 h (stock solution: 10 mM in DMSO). Cycloheximide is an inhibitor 
of translocation at the ribosomes and thus an inhibitor of protein synthesis (stock solution: 
100 mg/ml in DMSO). It was used at 20 µM for the indicated time frames. For all inhibitors, 
equivalent volumes of DMSO were used as control. 
 Gelatin degradation assay 
The gelatin degradation assay was used to assess the invasive potential of melanoma cells in-
vitro. To this end, gelatin coated cover glasses (diameter 12 mm) were prepared using the 
QCM Gelatin Invadopodia Assay (Green) following the manufacturer’s instructions in 24-well 
plates, but with only half the suggested volumes (except for washing, disinfection, and blocking 
steps). Before coating, cover glasses were incubated in 20 % nitric acid for 30 min and then 
washed in ddH2O for 2 h with multiple changes of ddH2O. After drying in a chemical hood, they 
were autoclaved and stored until needed. 
It proofed to be very helpful to mark the uncoated side of the glass slides with a ‘7’ using 
an ethanol-resistant marker before starting the coating – this way, it was easy to tell whether 
the slide is upside down or not (looks like ‘7’ means uncoated side up; looks like ‘4’ means 
coated side up). Additionally, it was of upmost importance to avoid contaminating the cells with 
ethanol by transferring the glass slides to new wells after both the disinfection step with 70 % 
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ethanol and after the subsequent washing step before the addition of culture medium. Coated 
slides could be stored in culture medium overnight in the cell culture incubator or up to one 
week in PBS at 4 °C. Care was taken to keep the coated cover glasses protected from light as 
much as possible. 
As described above, melanoma cells were pre-treated with LGK974 for 96 h or siRNAs 
or plasmids for 72 h in 6-well plates. The culture medium was changed 24 h before seeding on 
gelatin slides. For seeding on the gelatin, the culture medium was removed (and collected for 
further analyses, if necessary), cells were washed once with PBS and dissociated using 0.5 ml 
of 0.25 % trypsin/EDTA for as short as possible (note that prolonged incubation with trypsin 
can negatively influence the cells’ gelatin degradation potential). After stopping the trypsinisa-
tion with 4.5 ml of culture medium, the cells were counted and seeded on gelatin coated cover 
glasses in 24-well plates (ca. 30 000 cells in 0.5 ml culture medium). To prevent the cover 
glasses from floating, they were gently pushed down using a pipette tip. Plates were then in-
cubated at 37 °C and 5 % CO2 in a humidified atmosphere for 24 h and then fixed using 4 % 
paraformaledehyde (PFA, pre-warmed to 37 °C) for 10 min at room temperature followed by 
three 5 min washes with PBS. Fixed cells could be stored in PBS at 4 °C before the immuno-
fluorescence staining (see 3.2.4.1). 
3.2.2 Molecular biological methods 
 Molecular cloning and sequencing 
 Gateway cloning to generate FLAG-tagged constructs 
Plasmids encoding FLAG-tagged constructs of ERLIN1, ERLIN2, FAF2, UBE2K, or UBXN4 with 
a Cytomegalovirus (CMV) promoter were generated using the Gateway Technology according 
to the manufacturer’s instructions. Therefore, respective ‘entry clones’ (Kanamycin resistance, 
10 µg/ml) carrying full open reading frames (ORF) for each gene were integrated in the desti-
nation vectors (pDEST, Ampicillin resistance, 100 µg/ml) ‘pDEST-FLAG C-terminal’ and 
‘pDEST-FLAG N-terminal’ (UBE2K ORF only). Entry clones and pDEST were provided by the 
Genomics and Proteomics Core Facility (GPCF) at the German Cancer Research Center 
(DKFZ). In brief, 1 µl to 7 µl of entry clones (50 ng to 150 ng) and 1 µl of pDEST (150 ng/µl) 
were mixed and filled to 8 µl with ddH2O. Then, 2 µl of LR Clonase II Enzyme Mix were added 
to each reaction and samples were incubated at 25 °C for 1 h. To stop the reaction, 1 µl of 
Proteinase K solution was added to each sample followed by 10 min incubation at 37 °C. 1 µl 
of each LR reaction was used to transform One Shot TOP10 Chemically Competent Esche-
richia coli (E. coli).  
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 Site-directed mutagenesis 
The Q5 Site-Directed Mutagenesis Kit was used according to the manufacturer’s instructions 
to introduce a STOP codon (TAG) at the 3’ end of the UBE2K ORF in the UBE2K-N-FLAG 
plasmid. Primers were generated using the NEBaseChanger (5’-3’, forward: 
TGATTGGACCCAGCTTTCTTG, reverse: GTTACTCAGAAGCAATTCTG). In brief, PCR was 
performed with the settings shown in Table 19 using 12.5 µl Q5 Hot Start High-Fidelity 2× Mas-
ter Mix, 1.25 µl of both forward and reverse primers (10 µM), 1 µl plasmid (1 ng/µl to 25 ng/µl), 
and 9 µl ddH2O. Afterwards, 1 µl of the PCR product together with 3 µl ddH2O were treated with 
5 µl 2× KLD reaction buffer and 1 µl of 10× KLD enzyme mix for 5 min at room temperature. 
5 µl of each reaction were used to transform One Shot TOP10 Chemically Competent E. coli. 
Table 19. Thermocycler conditions used for site-directed mutagenesis. 
Temp (°C) Time (s)  Step 
98 30  Denaturation and activation 
98 10  Denaturation 
60 30 25 cycles Annealing 
72 210  extension 
72 120  Final extension 
4 ∞  pause 
 
 Plasmid DNA amplification and sequencing 
Plasmid DNA was amplified after Gateway cloning (see 3.2.2.1.1), site-directed mutagenesis 
(see 3.2.2.1.2), or retro-transformation using 30 µl - 50 µl of One Shot TOP10 Chemically Com-
petent E. coli. For the transformation, bacteria were defrosted on ice and carefully mixed with 
plasmid DNA. After 30 min further incubation on ice, a heat-shock was performed by incubation 
cells at 42 °C for 30 s. Then, 250 µl of pre-warmed (37 °C) Super Optimal broth with Catabolite 
repression (S.O.C.) medium were added to cells and samples incubated for 1 h at 37 °C with 
shaking (300 rpm). This pre-culture was plated in full or in parts on selective LB agar plates 
using glass beads and incubated at 37 °C overnight. The next day, single bacteria colonies 
were picked to start small liquid cultures in selective LB medium (5 ml - 7 ml, ‘Mini-Prep’). After 
8 h incubation at 37 °C, these could also be used as starting cultures for large liquid cultures 
(ca. 250 ml, ‘Maxi-Prep’). 
Plasmid preparations from overnight liquid bacteria culture were performed using the 
QIAGEN Plasmid Mini and Maxi Kits according to the manufacturer’s instructions (Version: 
March 2016). Plasmid DNA was eluted in ddH2O and concentration and purity were measured 
using a NanoDrop ND-1 000 spectrophotometer. DNA was stored at -20 °C. 
} 
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DNA sequencing was outsourced to Eurofins Genomics using SupremeRun Tube 
Sanger Sequencing (previously GATC). Primers for sequencing were either provided directly 
by Eurofins Genomics or generated in silico using SerialCloner, the Primer3web tool or the 
Sequencing Primer Design Tool. Obtained sequences were analysed using SerialCloner. 
 Isolation of total RNA and synthesis of complementary DNA (cDNA) 
RNA was isolated from cells using the QIAGEN RNeasy Mini Kit with on-column DNase diges-
tion with the QIAGEN RNase-Free DNase Set to reduce contamination of DNA, both according 
to the manufacturer’s instructions (quick start protocol version: March 2016, including optional 
centrifugation step at full speed). The DNase digest was especially important for the analysis 
of genes for which no intron-spanning primers for RT-qPCR could be designed. Before RNA 
isolation, culture medium was removed and cells were washed twice with PBS. After complete 
removal of PBS with a pump, cells were lysed directly in the wells with 350 µl RLT buffer, 
scraped off using a cell scraper and transferred to a 1.5 ml tube. Samples could be stored at 
this stage at -20 °C or processed further. In the end, RNA was eluted in 30 µl RNase-free ddH2O 
and concentration and purity were measured using a NanoDrop ND-1 000 spectrophotometer. 
RNA was stored at -20 °C and kept on ice as much as possible.  
cDNA synthesis was performed in 1.5 ml tubes using the RevertAid H minus First 
Strand cDNA Synthesis Kit with 1 µg to 5 µg of total RNA input and oligo (dT)18 primers. For 
easier handling, a master mix was prepared with all reagents except for RNA and the respective 
amount of RNase-free ddH2O. A non-reverse transcribed control without enzyme was included 
to check for specificity. The samples with a total volume of 20 µl were incubated at 42 °C for 
60 min and then at 75 °C for 5 min to terminate the reaction. Afterwards, the samples were 
diluted with ddH2O to a cDNA concentration of 5 ng/ µl to 10 ng/µl. cDNA was stored at -20 °C. 
 RT-qPCR 
mRNA expression was quantified using RT-qPCR performed in 384-well plates on a Roche 
LightCycler 480 Instrument II with dual hybridisation probes from The Universal ProbeLibrary 
and primers were designed using The Universal Probe Library Assay Design Center. Primers 
and respective probes are listed in Table 10. All reactions were performed in technical tripli-
cates. Per reaction, 6 µl of primer-enzyme mix (5.5 µl LightCycler 480 Probes Master, 2× con-
centrated, 0.17 µl dual hybridisation probe, 0.11 µl of both forward and reverse primer, 20 µM, 
and 0.17 µl ddH2O) was added to 5 µl of diluted cDNA (see 3.2.2.2). The PCR was run with the 
settings depicted in Table 20. Threshold or quantification cycles (Cq) were calculated using the 
LightCycler 480 software. 
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Table 20. Thermocycler conditions for RT-qPCR 
Temp (°C) Time (s)  Step 
95 600  Denaturation 
95 10  Denaturation 
55 20 45 cycles Annealing 
72 1  extension 
40 10  Cooling 
 
RT-qPCRs were performed in accordance with the Minimum Information for Publication 
of Quantitative Real-Time PCR Experiments (MIQE) guidelines (Bustin et al., 2009), using at 
least two reference genes per experiment (GAPDH, SDHA, G6PD, or ACTB). PCR amplification 
efficiencies were determined for each primer pair and cell line from a calibration curve resulting 
from performing a RT-qPCR with the following cDNA concentrations: 10 ng/µl, 2 ng/µl, 
0.4 ng/µl, 0.08 ng/µl, 0.0016 ng/µl. The log10 values of these concentrations were plotted on the 
x-axis and the resulting Cq values on the y-axis. Then, a linear regression curve was fitted, and 
its slope was used to calculate the efficiency E with the equation: E = 10(-1/slope). 
Calculations of relative mRNA expression levels were performed using the Pfaffl 
method (Pfaffl, 2001), which includes PCR amplification efficiencies, using the following for-
mula: 
Relative mRNA expression = (Etarget gene)ΔCq, target gene (calibrator – sample)/ (Eref. gene)ΔCq, ref. gene (calibrator – sample) 
 Expression levels were calculated relative to GAPDH as reference gene and siControl, 
siLuciferase, or DMSO treatment were used as calibrators. Data analysis was done using Mi-
crosoft Excel and R. 
3.2.3 Protein biochemical methods 
 Cell lysis and determination of protein concentration 
In order to analyse cellular protein content and protein-protein interactions, total protein lysates 
were isolated from cells using eukaryotic lysis buffer (20 mM Tris-HCl, pH 7.4; 130 mM NaCl; 
2 mM EDTA; glycerol at a volume fraction of 10 %; used for immunoprecipitation and TUBE 
assays) or 8 M urea/PBS (all other assays).  
Eukaryotic lysis buffer was supplemented before use with 1 % Triton X-100 (volume 
fraction), 5 mM N-ethylmaleimide/ethanol (NEM), 2 mM 1,10-phenanthroline/ethanol (oPA), 
and 1 cOmplete, mini Protease Inhibitor Cocktail tablet per 10 ml buffer. Buffer with inhibitors 
could be stored for one week at 4 °C. Triton X-100 was used to break up cell membranes, 
cOmplete contains several protease inhibitors, NEM is an inhibitor of cysteine peptidases, and 
oPA inhibits metalloproteases. NEM and oPA are important to include when analysing 
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ubiquitination of proteins, since this type of modification can be cleaved off rapidly by DUBs. 
Lysis buffer, PBS and reaction tubes were pre-cooled to 4 °C. The cells’ medium was removed 
and cells washed twice with ice cold PBS – after the last wash, cell culture dishes were put in 
an upright position and remaining PBS was removed as completely as possible with a cell 
culture pump. Then, 200 µl to 750 µl of ice-cold eukaryotic lysis buffer were added to each dish 
and the cells collected using a cell scraper. Lysates were transferred to pre-cooled reaction 
tubes and further homogenised by pipetting up and down 3 to 5 times. 
Cells in 6-well format were lysed in ca. 100 µl to 200 µl 8 M urea/PBS buffer (without 
supplements) after two washes with PBS, then scraped off and transferred to reaction tubes.  
After harvesting, cell lysates from both methods were incubated in a tube rotator at 4 °C 
for at least 20 min and, subsequently, clarified by centrifugation in a pre-cooled table-top cen-
trifuge (4 °C) at maximum speed for 20 min. Pellets containing cell debris were discarded. At 
this point, protein lysates could be frozen and stored at -20 °C. 
To determine protein concentrations for downstream applications, the Pierce bicin-
chonic acid (BCA) Protein Assay Kit was used according to the manufacturer’s instructions. 
4 µl of samples were measured in duplicates together with bovine serum albumin (BSA) stand-
ards for the standard curve (included in each plate: 2 000 µg/ml, 1 000 µg/ml, 500 µg/ml, 
250 µg/ml, 125 µg/ml, and 0 µg/ml) in transparent flat bottom 96-well plates. After a 30 min in-
cubation at 37 °C, a Mithras LB 940 Multimode Microplate Reader was used to measure the 
absorbance at 562 nm. Protein concentrations of each sample were then calculated according 
the standard curve using Microsoft Excel. 
For protein lysates prepared with 8 M urea/PBS, the respective volumes for 40 µg to 
60 µg protein were transferred to a new reaction tube, filled up to 80 µl with ddH2O and then 
incubated together with 20 µl 5× Laemmli buffer (312.5 mM Tris-HCl, pH 6.8; 0.5 M Dithio-
threitol, DTT; mass fraction of 10 % sodium dodecyl sulphate, SDS, and 0.1 % bromphenol 
blue; volume fractions of 10 % Tris-(2-carboxyethyl)-phosphin, TCEP, and 50 % glycerol) at 
95 °C for 5 min. Samples were immediately cooled down on ice and either used for SDS poly-
acrylamide gel electrophoresis (SDS-PAGE, 40 µl per sample) or frozen at -20 °C. 
 Isolation of secreted WNTs from supernatant 
Secreted WNTs were enriched from cell culture supernatants using the affinity chromatog-
raphy resin Blue Sepharose 6 Fast Flow and analysed by Western blotting (Glaeser et al., 
2016). All steps were carried out at room temperature unless indicated otherwise. Medium was 
collected from 6-well plates except for endogenous WNT11 studies that were performed in 
10 cm dishes with 10 ml of culture medium. 
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Cell culture medium was changed 24 h before harvesting to accurately compare differ-
ent treatment conditions at a specific time point. Note that differences in seeding density or 
viability also influence WNT secretion levels. The next day, 2 ml culture medium from one well 
of a 6-well plate was transferred to a 2 ml reaction tube and centrifuged at room temperature 
for 10 min at 8 000 × g. 1,8 ml of the supernatant were then transferred to a new 2 ml tube and 
the pellet discarded. Samples could be stored at this point at -20 °C. Next, Triton X-100 was 
added to a final volume fraction of 1 %. Per sample, 30 µl of Blue Sepharose 6 Fast Flow resin 
was washed twice in washing buffer (50 mM Tris-HCl, pH 7.5; 150 mM KCl; volume fraction of 
1 % Triton X-100 in ddH2O) by centrifugation and decanting of supernatant (3 min, 2 800 × g). 
Then, resin was distributed equally to all samples and incubated over night at 4 °C in a tube 
rotator. The following day, resin was washed 2 to 3 times as above, until the wash buffer was 
clear. After the last wash, ca 100 µl wash buffer were left in the tube together with the resin 
and 100 µl of 2× Laemmli buffer (see 3.2.3.1) were added. The samples were boiled at 95 °C 
for 5 min, then cooled on ice and either used for SDS-PAGE (40 µl loading per gel) or frozen at 
-20 °C.  
 Tandem Ub Binding Entity (TUBE) Assays 
TUBEs are stretches of tandem Ub binding domains that bind poly-ubiquitinated proteins and 
protect them from being degraded but also facilitate their enrichment and their analyses 
(Hjerpe et al., 2009).  
 
Figure 10. Tandem Ubiquitin Binding Entities (TUBEs) are used to examine the ubiquitination of substrate proteins 
A, B. RNAi mediated knock-down of proteins involved in the recognition, ubiquitination, dislocation, targeting to, or degradation 
by, the proteasome can lead to the accumulation of their substrates with or without ubiquitin modifications, depending on whether 
the cascade is interrupted before or after substrate ubiquitination. TUBEs are used to stabilise and enrich poly-ubiquitinated pro-
teins from cell lysates. These poly-ubiquitinated substrates will appear as high-molecular bands on a Western blot, because each 
ubiquitin adds to the protein’s molecular mass. Depending on the treatment, protein samples before (‘Input’) and after (‘TUBE’) 
pull-down show characteristic patterns on the Western blot stained for the substrate. ER = endoplasmic reticulum, Ub = poly-
ubiquitin  
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Pull-downs with TUBEs can be used to analyse the ubiquitination of substrates, due to 
the characteristic ‘ladder’ patterns poly-ubiquitinated substrates show on Western blots as 
every ubiquitin adds about 8.5 kDa to the substrate’s molecular mass. These patterns can also 
appear as high molecular ‘smear’ if the substrate is differentially modified and therefore not all 
molecules run at the same heights. The observed pattern might change depending on sample 
treatment (Figure 10). 
Four different kinds of TUBEs were used: TUBE1 magnetic and TUBE2 agarose beads 
bind to both K48- and K63-linked Ub chains, whereas FLAG K48 and K63 TUBEs specifically 
bind K48- or K63-linked poly-Ub, respectively. All steps were carried out at 4 °C unless stated 
otherwise.  
TUBE1 (magnetic) or TUBE2 (agarose) pull-downs were performed from one 10-cm 
dish per condition. After cell harvest in 200 µl eukaryotic lysis buffer and protein quantification 
(see 3.2.3.1), all pull-down samples were adjusted to contain the same amount of protein in 
1 ml lysis buffer (between 0.5 mg and 1 mg in total). Per pull-down sample, 15 µl TUBE1 mag-
netic or control beads or 30 µl TUBE2 agarose or Control Agarose Beads were washed twice 
with 1 ml Tris-buffered saline with Tween-20 (TBST; 10× TBST contained 1,37 M NaCl, 200 mM 
Tris-HCl, pH 7.6, and 1 % Tween-20, volume fraction) by centrifugation (3 000 × g, 3 min) at 
room temperature and added to the diluted protein lysates. After overnight rotation at 4 °C in 
a tube rotator, samples were washed 4x with 800 µl TBST or eukaryotic lysis buffer without 
Triton X-100 (pre-cooled to 4 °C, including NEM and oPA) after collecting the beads with cen-
trifugation (4 °C, 3 000 × g, 5 min) or a magnetic rack and 5 min rotation at 4 °C in a tube rotator 
after each buffer change. After the last wash, buffer was removed completely, beads taken up 
in 100 µl 1× Laemmli buffer and boiled at 95 °C for 5 min.  
FLA K48 or K63 TUBE pull-downs were performed from one 10-cm dish per condition. 
After cell harvest in 200 µl eukaryotic lysis buffer plus 250 nM FLAG TUBEs and protein quan-
tification (see 3.2.3.1), the same amount of protein for each sample was transferred to a new 
2 ml reaction tube (between 0.5 mg and 1 mg in total) and diluted by adding 1.8 ml of eukaryotic 
lysis buffer without Triton X-100 (but with all other inhibitors), then, the concentration of FLAG 
TUBEs was restored to 250 nM. Samples were incubated at 4 °C in a tube rotator for 1 h to 2 h 
to allow for binding of TUBEs to poly-Ub chains. Afterwards, 15 µl of ANTI-FLAG M2 Affinity 
Gel or 15 µl Control Agarose Beads (negative control) per sample were washed twice in lysis 
buffer, added to the respective samples and incubated over night at 4 °C in a tube rotator. The 
next day, samples were transferred to 1.5 ml reaction tubes for easier handling and washed 4× 
with 800 µl eukaryotic lysis buffer without Triton X-100 (pre-cooled to 4 °C, including NEM and 
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oPA) by centrifugation (4 °C, 3 000 × g, 5 min) and 5 min rotation at 4 °C in a tube rotator after 
each buffer change. After the last wash, remaining buffer was removed completely, and beads 
taken up in 100 µl 3× FLAG Peptide elution solution (see 3.2.3.4) for elution of poly-ubiqui-
tinated proteins from M2 Affinity Gel. The incubation for 30 min at 4 °C in a tube rotator was 
followed by centrifugation as above and transfer of 100 µl of the supernatant to a new reaction 
tube. Samples were mixed with 25 µl 5× Laemmli buffer and boiled for 5 min at 95 °C, then 
cooled on ice. 
40 µg of protein from the original clarified lysates were taken as ‘input controls’ and 
diluted to 200 µl with ddH2O to reflect protein content before pull-down experiment. After ad-
dition of 50 µl of 5× Laemmli buffer to the ‘Input’ samples, they were boiled for 5 min at 95 °C 
and then cooled on ice. 40 µl of ‘input’ and ‘pull-down’ were loaded to do SDS-PAGE or sam-
ples were frozen at -20 °C. 
 Immunoprecipitation (IP) 
To investigate protein interactions within the ERAD pathway, FLAG-tagged proteins were over-
expressed in HEK393T wild type and EVI/WLS KO cells in 10-cm dishes (see 3.2.1.2 and 
3.2.2.1.1). Similarly, pRK5-HA-Ubiquitin constructs were overexpressed in A375 cells to deter-
mine the ubiquitination status of EVI/WLS. 48 h after transfection, cells were harvested in 600 µl 
eukaryotic lysis buffer and protein content was quantified using a BCA assay (see 3.2.3.1). 
Tubes with equal amount of proteins were prepared (0.5 mg to 3.5 mg). Per sample, 40 µl 
ANTI-FLAG M2 Affinity Gel, Monoclonal Anti-HA-Agarose or Control Agarose Beads (negative 
control) were washed twice in 750 µl lysis buffer (centrifuge for 30 s at 5 000 × g), then blocked 
for 1 h with 2.5 % BSA/TBST (mass fraction) at 4 °C in a tube rotator and washed again twice 
as previously. The resin was then equally distributed to the respective samples and incubated 
over night at 4 °C in a tube rotator. The next day, resin was washed five to seven times as 
previously, and proteins were eluted using 3× FLAG Peptide or HA Peptide. To do so, 3× FLAG 
Peptide or HA Peptide was dissolved in peptide dissolve buffer (0.5 M Tris-HCl, pH 7.5 and 1 M 
NaCl in ddH2O) to obtain a concentration of 0.25 µg/µl and was then further diluted with ddH2O 
to a stock solution of 5 µg/µl. The final elution solution of 150 ng/µl was obtained by further 
diluting 3 µl of the stock solution in 100 µl Tris-buffered saline (TBS, 50 mM Tris-HCl, pH 7.4 
and 150 mM NaCl in ddH2O). After complete removal of wash buffer after the last washing step, 
100 µl of elution solution were added to each sample and incubated for 30 min at 4 °C in a tube 
rotator. Then, samples were centrifuged as previously and 100 µl of the supernatant transferred 
to a new tube. Samples were mixed with 25 µl 5× Laemmli buffer and boiled for 5 min at 95 °C, 
then cooled on ice. 
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100 µg (FLAG) or 40 µg (HA) of protein from the original clarified lysates were taken as 
‘input controls’ and diluted to 240 µl with ddH2O to reflect protein content before pull-down 
experiment. After addition of 60 µl 5× Laemmli buffer to ‘input’ samples, they were boiled for 
5 min at 95 °C and then cooled on ice. 40 µl of ‘input’ and 40 µl of ‘pull-down’ samples were 
loaded to do SDS-PAGE or samples were frozen at -20 °C. 
 SDS-PAGE and Western blotting 
All steps were carried out at room temperature unless stated otherwise. Samples containing 
denatured proteins in 1× Laemmli buffer (see 3.2.3.1, 3.2.3.2, 3.2.3.3, and 3.2.3.4) were boiled 
for 5 min at 95 °C before being loaded on Bolt 4-12% Bis-Tris Plus Gels (10, 12, or 15 wells) in 
1× running buffer with 3-(N-morpholino)propanesulfonic acid (MOPS; 20× running buffer: 1 M 
MOPS, 1 M Tris-Base, 20 mM EDTA, 69.3 mM SDS in ddH2O). The SDS-PAGE separated pro-
teins and the PageRuler Prestained Protein Ladder by size and was run for 15 min at 80 V and 
then for 45 min at 180 V or until the blue loading dye left the gel. Then, proteins were trans-
ferred to nitrocellulose membranes by wet blotting in 1× NuPage transfer buffer (20× transfer 
buffer: 500 mM Bicine, 500 mM Bis-Tris, 20 mM EDTA) with 10 % methanol for 75 min at 20 V. 
Successful and bubble-free transfer was confirmed by Ponceau Red staining. After complete 
de-staining of the membranes in TBST, they were blocked in 5 % skim milk/TBST (mass frac-
tion) for 30 min at room temperature and then incubated with primary antibody over night at 
4 °C or for 1 h at room temperature (see Table 1, typically 3 ml total volume in 50 ml Falcon 
tube) on a Roller Falcon Tube Mixer. Afterwards, membranes were washed three times for 
7 min in TBST on a shaker and incubated with horseradish peroxidase (HRP)-coupled second-
ary antibody for 1h at room temperature (see Table 3) and then again washed as before. All 
antibodies were diluted in 5 % skim milk/TBST (mass fraction). Then, membranes were incu-
bated with enhanced chemiluminescence (ECL) substrates and the HRP induced light signals 
were captured using Amersham Hyperfilm ECL and made visible using the COMPACT 2 X-Ray 
Film Processor. Immobilon Western HRP Substrate was used for standard application and Su-
perSignal West Femto Maximum Sensitivity Substrate was used if stronger signal amplification 
was necessary. 
Western blot quantification using Fiji (Fiji is just ImageJ) was performed to analyse the 
cycloheximide chase assay. To this end, signal intensities were measured in equally sized re-
gions of interest of EVI/WLS staining, HSC70 staining, and areas without signal (background). 
The background signal was deduced from the EVI/WLS or HSC70 values and their ratio was 
calculated to account for potential differences in loading. In a last step, each ratio was then 
normalised to timepoint 0 h. 
 




 Immunofluorescence staining, imaging, and image analysis 
Immunofluorescence staining was performed to examine the intracellular localisation of 
EVI/WLS and to analyse gelatin degradation assays (see 3.2.1.5). All steps were carried out at 
room temperature, unless stated otherwise. Gelatin experiments were protected from light as 
much as possible, all others were protected from light after addition of fluorescent dyes. 
All cells were fixed directly after removal of culture medium (without PBS wash) using 
4 % PFA/PBS (preheated to 37 °C, volume fraction) for 10 min at room temperature, followed 
by three washes with PBS for 5 min. Afterwards, cells could be stored in PBS at 4 °C. 
To facilitate the entry of staining agents into the cells, plasma membranes were perme-
abilised using 0.2 % Triton X-100/PBS (volume fraction) for 10 min. Then, blocking solution 
(1 % goat serum, 3 % FCS, 0.1 % Triton X-100, all volume fraction in PBS) was added for at 
least 30 min to reduce unspecific binding of antibodies. Afterwards, primary antibodies diluted 
in 200 µl PBS (for 24 well plate well) were added for 1 h at room temperature or overnight at 
4 °C (for dilutions refer to Table 1), followed by three 5 min washes with PBS, 0.05 % Tween-
20/PBS (volume fraction), and again PBS on a shaker at high speed. Secondary antibodies and 
other fluorescent stains were diluted according to Table 2 and added for 1 h, followed by three 
washes as above. Ultimately, cover glasses were inverted and mounted on microscope slides 
using ProLong Diamond Antifade Mountant with 4′,6-diamidino-2-phenylindole (DAPI). Once 
the mounting medium had hardened, cover glasses were additionally fixed with nail polish. 
Stained specimens were stored at -20 °C. 
Images were acquired in the .czi format using a Zeiss motorized inverted Axio Ob-
server.Z1 microscope (‘Cell Observer’) with the ZEISS ZEN (blue edition) software provided 
by the DKFZ Light Microscopy Facility (excitation sources: mercury arc burner HXP 120 and 
LED module Colibri; detector: gray scale CCD camera AxioCam; filter sets: 49(DAPI), 38 HE 
(eGFP), 43 HE (Cy3), 50 (Cy5); objectives: 20× / 0.8 Pln Apo DICII and 63× / 1.4 Oil Pln Apo 
DICIII). 
For gelatin degradation assays, images of 8 to 10 different fields of view (20× objective) 
with at least 100 cells per replicate of each experiment were taken and analysed. All image 
analysis was done using Fiji and is described in more detail in 4.7. In brief, cells were counted 
based on their phalloidin (F-actin) and DAPI signal using the ‘Cell Counter Plugin’ and the area 
of gelatin degradation was assessed after setting a threshold to capture real degradation 
events and to exclude any background. This was usually done by automatically adjusting 
‘brightness/contrast’ so that the ‘maximum displayed pixel value’ equalled the largest detected 
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value according to each image’s histogram of value intensity distributions, but without adjusting 
the respective minimum value. Then, the images were converted to the RGB colour system 
and the ‘Colour Threshold’ was adjusted to capture brightness values ranging from 0 to 70 
using the default thresholding method and no ‘dark background’ selection. The total area of 
the selection was measured by selecting ‘Analyze Particles’ with ‘size’ settings ranging from 0 
to infinity and ‘circularity’ from 0 to 1. The obtained values were copied to a Microsoft Excel file 
to calculate the ratio of total thresholded area to cell number and to normalise them to the 
respective control condition. The normalised values were log10 transformed so that the controls 
equalled 0, a negative fold change in treatment conditions indicated decreased degradation 
compared to the control, and a positive fold change indicated increased degradation. The non-
parametric one-sample Wilcoxon signed rank test was used in R (mu = 0, alternative = “two-
sided”) to assess statistical significance. 
 Migration and proliferation live cell imaging assays 
Time-lapse live cell imaging to assess migration and proliferation capacities of melanoma cells 
were performed using an IncuCyte ZOOM system together with the IncuCyte Basic Software 
and the IncuCyte Scratch Wound Cell Migration Software Module. In detail, melanoma cells 
(Proliferation: 3 000 cells, Migration: 50 000 cells) were seeded in 300 µl of culture medium in 
transparent, flat bottom 96-well plates with 4 to 5 technical replicates and imaged every 2 h 
using a 10× objective. For proliferation analysis, confluence of cells was quantified from 4 im-
ages per well. For migration analysis, a confluent monolayer of cells was scratched one day 
after seeding using the 96-well WoundMaker according to the manufacturer’s instructions and 




















4.1 RNAi screen identified novel candidates involved in the 
ERAD of EVI/WLS 
Various proteins are involved in the recognition and retrotranslocation or dislocation of ERAD 
substrates, but additional regulators of EVI/WLS remain elusive. To address this in a systematic 
manner, I performed a siRNA and Western blot-based screen in HEK293T cells to investigate 
candidates chosen from literature. Figures 11B, 11C, S1, and Supplementary Table 1 show the 
read-out and the summarised results: in total, 52 ERAD- or Ub-associated candidates were 
tested, including those previously investigated by Glaeser et al., 2018. 
 
Figure 11. siRNA-based mini-screen identifies novel candidates involved in the degradation of EVI/WLS 
A. Schematic illustration of the principle underlying RNAi screening. EVI/WLS protein accumulates if the siRNA targets a mRNA 
encoding a protein important for EVI/WLS degradation. ER = endoplasmic reticulum, Ub = poly-ubiquitin chain 
B. EVI/WLS protein levels were analysed after siRNA mediated knock-down of target genes. Increased EVI/WLS protein levels 
compared to siControl treatment indicated the candidate’s possible involvement in EVI/WLS’s ERAD process. HEK293T wild type 
cells were treated with the indicated siRNAs for 72 h. Then, total cell lysates were analysed by SDS-PAGE and Western blotting 
for the specified proteins. β-ACTIN served as loading control. Non-targeting siRNA (siControl) was used as negative control and 
siEVI/WLS was used as on-target control for knock-down efficiency. siVCP was used as positive control as it had been shown 
previously to increase EVI/WLS protein levels (Glaeser et al., 2018). Western blots are representative of three independent exper-
iments. kDa = kilodalton 
C. Results of the siRNA-based screen represented as heat-map. Candidates without effect are marked in grey, candidates with 
low/variable effects in blue and candidates with strong and consistent upregulation of EVI/WLS in yellow. Asterisks indicate genes 
that were previously tested by Glaeser et al., 2018. A detailed table including gene accession numbers and phenotypes in HEK293T 
and A375 cells can be found in Supplementary Table S1, the Western blots underlying this analysis are shown in Figure S1.  
 
4   Results 
70 
 
Of the 52 candidates, 20 were either E2 Ub conjugating enzymes or E3 Ub ligases and 
7 were DUBs. Furthermore, I included 5 proteins important for substrate recognition within the 
ER and 8 proteins involved in delivery of the substrate to the proteasome in the cytoplasm. The 
last group of candidates consisted of 12 proteins associated with substrate retrotranslocation 
or dislocation by either forming a channel, cleaving the substrate, or by recruiting or interacting 
with VCP. 
Each candidate was targeted with a pool of four siRNAs, and I searched for genes 
whose knock-down resulted in increased EVI/WLS protein levels after transfection, thus indi-
cating impaired degradation (Figure 11A). siEVI/WLS served as a control for assay specificity 
and siVCP was used as a positive control as it had been previously shown that the knock-down 
of VCP increased endogenous EVI/WLS protein levels without an effect on EVI/WLS mRNA 
expression (Glaeser et al., 2018). As expected, silencing of protein expression by siEVI/WLS 
and siVCP was efficient and VCP downregulation induced upregulation of EVI/WLS protein 
levels (Figures 11B,S1). 15 candidates (DERL3, ERLIN2, FAF2, NGLY1, NPLOC4, RAD23B, 
SEL1L, TMUB2, UBAC2, UBE2K, UBE2N, UBXN4, UBXN6, UFD1, and USP50) showed pre-
dominantly consistent upregulation of EVI/WLS protein levels across three independent repli-
cates and were chosen for further validation experiments (Figures 11C,S1). 
In these validation experiments, I tested the effects of the respective four single siRNAs 
that constitute the siRNA pool on EVI/WLS protein level and, in selected cases, on mRNA level. 
RT-qPCR was used to analyse on-target knock-down efficiencies and to exclude regulation of 
EVI/WLS gene expression, thus ensuring real post-translational effects. To the greatest extent, 
the tested siRNAs induced mRNA knock-downs between 5 % and 25 % of initial activity with 
minimal effects on EVI/WLS mRNA expression (Figures 12,16,18,S3). Especially silencing of 
EVI/WLS or VCP was very efficient on mRNA and protein level (Figures S1,S2,S3). However, 
the results of some Western blots were not reproducible and varied between biological repli-
cates and single siRNAs, maybe due to non-target effects of the siRNAs (Figures S2,S3). These 
10 genes (DERL3, NGLY1, NPLOC4, RAD23B, SEL1L, TMUB2, UBAC2, UBXN6, UFD1, and 
USP50) and their protein product were not chosen for further in-depth analysis, but they might 
be interesting candidates for future investigations in different cellular systems or with other 
methods, e.g. CRISPR/Cas9 induced knock-out. Nevertheless, five genes (FAF2, ERLIN2, and 
UBXN4, as well as the E2 Ub conjugating enzymes UBE2K and UBE2N) were selected for 
further experiments because they showed both reproducible on-target gene silencing without 
regulation of EVI/WLS and consistent up-regulation of EVI/WLS protein levels by all four siRNAs 
and the pool (Figure 12,16,18). The siRNAs targeting UBXN4 were less efficient in on-target 
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silencing and the siRNAs #4 and #17 additionally reduced the expression of VCP. However, 
this effect on VCP was not visible on the respective Western blots and no antibody was availa-
ble to test the effect of these siRNAs on UBXN4 protein expression (Figure 12H,I). 
 
Figure 12. ERLIN2, FAF2, and UBXN4 regulate endogenous EVI/WLS on protein level (see next page for figure legend) 
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◄ previous page | Figure 12. ERLIN2, FAF2, and UBXN4 regulate endogenous EVI/WLS on protein level 
A, D, G. Schematic representations of the proteins ERLIN2, FAF2, and UBXN4 according to UniProt IDs: O94905 (entry version 
165), Q96CS3 (entry version 163) and Wang & Lee, 2012, and Q92575 (entry version 162) respectively. Numbers indicate amino 
acid positions. TM = transmembrane domain, IM = intramembrane domain, UBA = ubiquitin associated domain important for 
binding to ubiquitin, UBX = ubiquitin regulatory X domain important for binding to VCP, ER = endoplasmic reticulum 
B, C, E, F, H, I. Knock-down of ERLIN2, FAF2, or UBXN4 increased EVI/WLS protein levels but had no effect on EVI/WLS mRNA 
expression. HEK293T wild type cells were treated with the indicated siRNAs for 72 h. siRNAs targeting ERLIN2, FAF2, or UBXN4 
were used as either single siRNAs or an equimolecular mix of all four respective siRNAs (pool). Samples treated with transfection 
reagent only (mock), non-targeting siRNA (siControl), or siLuciferase were used as negative control, siVCP as positive control. B, 
E, H, total cell lysates were analysed by SDS-PAGE and Western blotting for the specified proteins. VINCULIN or β-ACTIN served 
as loading control. Western blots are representative of three independent experiments. kDa = kilodalton. C, F, I, total cellular RNA 
was transcribed to cDNA and used for mRNA expression analyses by RT-qPCR. Target gene expression was normalised to siCon-
trol treatment and GAPDH served as reference gene. Individual data points from three or four independent experiments are shown.  
The experiments shown in B, C, H, and I were performed by Julie Haenlin, the experiments shown in E & F were performed by 
Annika Lambert. 
4.2   ERLIN2, FAF2, and UBXN4 regulate EVI/WLS 
The results from the RNAi-based screen indicated the involvement of ERLIN2, FAF2, UBXN4, 
UBE2K, and UBE2N in the regulation of EVI/WLS protein levels. However, this could be due to 
indirect effects and does not necessarily imply that the candidates are involved in the ERAD of 
EVI/WLS. Therefore, I wanted to characterise their role in EVI/WLS degradation further by an-
alysing interaction between EVI/WLS and the selected candidates, but the available antibodies 
did not allow co-immunoprecipitation experiments of endogenous proteins. Hence, overex-
pression constructs of ERLIN2, FAF2, UBXN4, and UBE2K with a FLAG-tag were generated 
using Gateway cloning to check their interaction with endogenous EVI/WLS and VCP. PORCN-
FLAG was used as a positive control since it is a known interaction partner of both EVI/WLS 
and VCP (Glaeser et al., 2018). FAF2 and UBXN4 were described previously to interact with 
VCP via their UBX domain (Figure 12D,G, Schuberth & Buchberger, 2008). 
4.2.1 EVI/WLS and VCP interact with ERLIN2-FLAG, FAF2-FLAG, and 
UBXN4-FLAG 
ERLIN2-FLAG, FAF2-FLAG, UBXN4-FLAG, and PORCN-FLAG were overexpressed in 
HEK293T cells in the absence of WNT ligands. Under these conditions, EVI/WLS is constantly 
ubiquitinated and degraded by the proteasome (Glaeser et al., 2018) and interactions between 
EVI/WLS and possible mediators of this degradation should be detectable. Indeed, co-immuno-
precipitation experiments demonstrated that endogenous EVI/WLS interacted with ERLIN2-
FLAG, FAF2-FLAG, UBXN4-FLAG, and PORCN-FLAG (Figure 13A,C,D). All four proteins also 
interacted with endogenous VCP. HEK293T EVI/WLS knock-out cells were used to confirm the 
specificity of the EVI/WLS antibody and showed that the interaction of VCP with FAF2-FLAG, 
UBXN4-FLAG, and PORCN-FLAG was EVI/WLS independent. However, the binding between 
ERLIN2-FLAG and VCP was reduced in the absence of EVI/WLS, suggesting that a substrate 
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is necessary to bridge the two proteins (Figure 13A). The expression of the plasmids was quite 
different, although the same amount of DNA had been transfected. This indicates that the over-
expressed proteins themselves were also regulated extensively. In summary, these results 
strongly suggest that ERLIN2, FAF2, and UBXN4 are novel interaction partners of EVI/WLS. 
 
Figure 13. ERLIN2-FLAG, FAF2-FLAG, and UBXN4-FLAG interact with endogenous EVI/WLS 
Immunoprecipitation (IP) experiments confirmed interaction between endogenous EVI/WLS and ERLIN2-FLAG (A), FAF2-FLAG 
(C), and UBXN4-FLAG (D) but not ERLIN1-FLAG (B). HEK293T wild type and EVI/WLS knock-out (EVI/WLSKO) cells were trans-
fected with ERLIN1-FLAG, ERLIN2-FLAG, FAF2-FLAG, UBXN4-FLAG, or PORCN-FLAG overexpression plasmids. After 48 h, total 
cell lysates were harvested for input control or used for FLAG IP to precipitate FLAG-tagged proteins and their interaction partners. 
Proteins were eluted using competition with 3× FLAG Peptide. Eluates and input control were analysed by SDS-PAGE and Western 
blotting for the specified proteins. FLAG non-binding Control Agarose Beads showed level of unspecific binding during FLAG IP 
and EVI/WLSKO cells confirmed specificity and independent effects of EVI/WLS. HSC70 or β-actin served as loading control. As-
terisks indicate background bands. Western blots are representative of three independent experiments. The experiments shown 
here were performed by Annika Lambert. kDa = kilodalton 
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It had previously been described that the function of ERLIN2 can depend on the for-
mation of a complex with ERLIN1. Surprisingly, ERLIN1 was not identified as a candidate in the 
screen, in contrast to ERLIN2 (Figures 11C, S1). I included ERLIN1 in the pull-down experi-
ments as a control and did not detect interaction with either EVI/WLS or VCP (Figure 13B). 
However, I detected its interaction with endogenous ERLIN2, confirming that the overexpres-
sion construct worked (Figures 14). This suggests an ERLIN1-independent role of ERLIN2 in 
the degradation of EVI/WLS. 
In addition to their interaction with EVI/WLS and VCP, I also investigated interactions 
between the novel candidates on endogenous level in the presence or absence of EVI/WLS. 
Such interactions would suggest the existence of pre-formed complexes which might be im-
portant for the ERAD of other proteins as well. Indeed, endogenous ERLIN2 and FAF2 were 
immunoprecipitated with PORCN-FLAG independent of EVI/WLS (Figure 14). I also validated 
known interactions within the ERAD machinery, such as between FAF2 and ERLIN2 (Figure 14, 
Christianson et al., 2012). However, no interaction was found between FAF2 and UBXN4, de-
spite both being interaction partners of VCP (Figure 14A). This suggests that the interaction of 
FAF2, ERLIN2, and PORCN might have a more general role in ERAD beyond EVI/WLS or that 
ERLIN2 and FAF2 are involved in the degradation of PORCN. 
 
Figure 14. Interactions between novel candidates in the presence and absence of EVI/WLS 
IP experiments confirmed endogenous FAF2 and ERLIN2 interacted with PORCN-FLAG and each other. Furthermore, endoge-
nous ERLIN2 interacted with ERLIN1-FLAG. HEK293T wild type and EVI/WLS knock-out (EVI/WLSKO) cells were transfected with 
UBXN4-FLAG, ERLIN1-FLAG, ERLIN2-FLAG, FAF2-FLAG, or PORCN-FLAG overexpression plasmids. After 48 h, total cell lysates 
were harvested for input control or used for FLAG IP to precipitate FLAG-tagged proteins and their interaction partners. Proteins 
were eluted using competition with 3× FLAG Peptide. Eluates and input control were analysed by SDS-PAGE and Western blotting 
for the specified proteins. FLAG non-binding Control Agarose Beads showed level of unspecific binding during FLAG IP and 
EVI/WLSKO cells confirmed EVI/WLS independent effects. HSC70 served as loading control. Asterisks mark signal from previous 
stainings. Representative of three independent experiments. The experiments shown here were performed by Annika Lambert.  
kDa = kilodalton 
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4.2.2   FAF2 knock-down impedes EVI/WLS turn-over 
My previous results showed interaction between endogenous EVI/WLS and ERLIN2-FLAG, 
FAF2-FLAG, and UBXN4-FLAG. However, it remained unclear if these candidates are involved 
in the turn-over of EVI/WLS. Protein homeostasis is the result of balanced translation and deg-
radation. If translation is perturbed, cellular protein levels will decrease according to their in-
trinsic half-life, unless their degradation is inhibited as well. Analysing the development of 
EVI/WLS protein levels over time after target gene knock-down can therefore help to clarify the 
target gene’s role in EVI/WLS degradation. Hence, I hypothesised that the knock-down of FAF2 
should result in a slower turn-over of EVI/WLS compared to the control if FAF2 is important for 
its homeostasis. 
 
Figure 15. EVI/WLS turnover is decreased after FAF2 knock-down 
Cycloheximide (CHX) decay assays demonstrated decreased EVI/WLS turnover dynamics after knock-down of FAF2. HEK293T 
wild type cells were transfected with pooled siRNAs against FAF2 or Luciferase as control and were challenged with CHX for the 
indicated times 72 h later. 8 h of DMSO treatment were used as solvent control. A, total cell lysates were analysed by SDS-PAGE 
and Western blotting for the specified proteins. HSC70 served as loading control. B, quantification of EVI/WLS signal relative to 
HSC70 loading control and normalised to timepoint 0 h of CHX treatment of the blot shown in A. The experiments shown here 
were performed by Annika Lambert. Western blots represent an example of three independent experiments. kDa = kilodalton  
Cycloheximide (CHX) as a general inhibitor of translation was used to study the effects 
of siFAF2 on the dynamics of EVI/WLS protein level (Figure 15). Staining for FAF2 confirmed 
that the knock-down of FAF2 by siRNA was very efficient and EVI/WLS was more abundant in 
the siFAF2 condition compared to siLuciferase, as expected from previous experiments (see 
Figure 12). To nevertheless be able to compare the two conditions, the detected bands had to 
be normalised to the loading control and to timepoint 0 h. In the siLuciferase control, EVI/WLS 
protein levels declined over time after CHX treatment. In the depicted example, they fell below 
50 % of the starting value after 8 h of CHX treatment. Similarly, EVI/WLS protein levels also 
declined after siFAF2 and CHX treatment. However, the overall decrease was less than in the 
control condition, indicating that EVI/WLS was more stable after knock-down of FAF2 and 
strongly suggesting that FAF2 indeed played a role in EVI/WLS turn-over (Figure 15). However, 
degradation was not completely inhibited, indicating that EVI/WLS is most likely subjected to 
several parallel degradation mechanism, not all of which are FAF2-dependent. Unexpectedly, 
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8 h of DMSO treatment also increased EVI/WLS protein levels compared to 0 h of treatment. 
While the underlying effects should be investigated in more detail in the future, it shows that 
the regulation of EVI/WLS is multi-layered and complex. 
4.3   EVI/WLS is modified with Ub by multiple E2 enzymes 
Apart from ERLIN2, FAF2, and UBXN4, two cytosolic E2 Ub conjugating enzymes were identi-
fied as potential regulators of EVI/WLS in the RNAi-mediated screen: UBE2K and UBE2N (Fig-
ures 11,S1). Both were validated in subsequent analyses by upregulating EVI/WLS protein lev-
els proportional to single siRNA efficiency but without affecting EVI/WLS transcription (Figures 
16B,C, 18A,B). This raised the possibility that EVI/WLS might be regulated and ubiquitinated 
by multiple E2 enzymes, beside the previously described UBE2J2 (Glaeser et al., 2018). It 
should be noted that the single siRNAs targeting UBE2K had quite different efficiencies, in so 
far as #17 and #19 decreased UBE2K transcription only to about 60 % of the siControl value, 
while #18, #20, and the siRNA pool reached up to 30 % of the control. The effect on EVI/WLS 
protein was correspondingly: #18, #20, and the siRNA pool increased its protein level dramat-
ically, while transfection of #18 and #20 resulted in EVI/WLS protein levels similar to the control 
treatment (Figure 16B,C). Likewise, siRNAs #2 and #4 targeting UBE2N where less efficient 
than the siRNA pool, #1, and #5 in downregulating UBE2N and had no effect on EVI/WLS pro-
tein levels (Figure 18A). 
While UBE2N has predominantly proteasome-independent functions through K63-
linked ubiquitination, UBE2K is an important mediator of protein degradation and was previ-
ously implicated in ERAD (Mehrtash & Hochstrasser, 2019; Swatek & Komander, 2016). To 
investigate whether it is directly involved in the degradation of EVI/WLS, I first examined if 
UBE2K interacted with EVI/WLS in HEK293T cells after overexpression of FLAG-UBE2K con-
structs, as described above (see 4.2). Overexpression of a UBE2K construct with a FLAG-tag 
close to its UBA domain at the C-terminus did not show interaction with EVI/WLS (data not 
shown), maybe because the tag interfered with the domain’s function and thus prevented in-
teraction with its substrates. However, also N-terminally tagged constructs with a re-introduced 
STOP codon, which was absent from the UBE2K Gateway ORF clone, showed no interaction 
(Figure 16D). While this could indicate that the effect on EVI/WLS protein stabilisation is indi-
rect, e.g. via the ubiquitination of other proteins involved in its degradation, it is also possible 
that the interaction was not detected because of its transient nature and the stringent pull-
down conditions.  
 




Figure 16. UBE2K regulates EVI/WLS on protein level 
A. Schematic representation of the UBE2K protein according to UniProt ID: P61086, entry version 178. Numbers indicate amino 
acid (AA) positions. UBA = UBA domain important for binding to ubiquitin 
B, C. Knock-down of UBE2K increased EVI/WLS protein levels but had no effect on EVI/WLS mRNA expression. HEK293T wild 
type cells were treated with the indicated siRNAs for 72 h. siRNAs targeting UBE2K were used as either single siRNAs or an 
equimolecular mix of all four respective siRNAs (pool). Samples treated with transfection reagent only (mock) or non-targeting 
siRNA (siControl) were used as negative control, siVCP as positive control. A, total cell lysates were analysed by SDS-PAGE and 
Western blotting for the specified proteins. VINCULIN served as loading control. B, total cellular RNA was transcribed to cDNA 
and used for mRNA expression analyses by RT-qPCR. Target gene expression was normalised to siControl treatment and GAPDH 
served as reference gene. Individual data points from four independent experiments are shown. Western blots are representative 
of three independent experiments. 
D. No interaction between EVI/WLS and FLAG-UBE2K was observed by immunoprecipitation (IP). HEK293T wild type and EVI/WLS 
knock-out (EVI/WLSKO) cells were transfected with UBE2K FLAG (N-terminal) or PORCN-FLAG overexpression plasmids. After 48 
h, total cell lysates were sampled for input control or used for FLAG IP to precipitate FLAG-tagged proteins and their interaction 
partners. Proteins were eluted using competition with 3× FLAG Peptide and eluates or input control were analysed by SDS-PAGE 
and Western blotting for the specified proteins. FLAG non-binding Control Agarose Beads showed level of unspecific binding 
during FLAG IP and EVI/WLSKO cells confirmed specificity and independent effects of EVI/WLS. HSC70 served as loading control. 
Asterisks indicate background bands. The experiment shown in D is a representative of two independent experiments.  
The experiments shown here were performed by Annika Lambert. kDa = kilodalton 
4.3.1   EVI/WLS is ubiquitinated at several positions 
Beside the involvement of additional E2 Ub conjugating enzymes, it was also unclear at which 
positions EVI/WLS is ubiquitinated. According to publicly available mass spectrometry data 
(PhosphoSitePlus, Hornbeck et al., 2015) and the presumed structural orientation of EVI/WLS 
in the ER membrane, the two lysines K410/419 in the third cytosolic loop close to the AEGL 
endocytosis motif are the most likely primary ubiquitination sites of EVI/WLS (see Figure 2). 
However, some E2 enzymes, such as UBE2J2, can ubiquitinate non-lysine residues, for 
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example serines or threonines (X. Wang et al., 2009). To address the question if EVI/WLS is 
initially ubiquitinated at K410/419, I used V5 tagged EVI/WLS constructs that encoded the wild 
type protein or a mutant in which the lysines at the positions 410/419 were replaced by arginine 
(K410/419R), thus inhibiting their modification. Expression of these constructs in EVI/WLS 
knock-out HEK293T cells in combination with the siRNA mediated knock-down of VCP, 
CGRRF1, UBE2J2, or UBE2K allowed me to determine the relevance of these sites for the 
degradation of EVI/WLS (Figure 17A). The removal of K410/419 should inhibit the proteasomal 
degradation of EVI/WLS if these positions were primarily important for its ubiquitination. 
 
Figure 17. EVI/WLS is ubiquitinated by more than one E2 enzyme  
A. Substrates can be targeted for proteasomal degradation after being ubiquitinated by multiple enzymes and at multiple positions. 
Mutations of single amino acids can abolish ubiquitination at a specific site (e.g. replacing a lysine with an arginine). Combinations 
of siRNA treatment with such mutated proteins can help to identify site- and enzyme-specific modifications by Western blot.  
B. Knock-down of UBE2J2 led to the accumulation of EVI/WLS-V5 K410/419R but not wild type EVI/WLS-V5. HEK293T EVI/WLS 
knock-out (EVI/WLSKO) cells were treated with the indicated siRNAs. 24 h after siRNA transfection, cells were additionally trans-
fected with 250 ng (per 6-well) of EVI/WLS-V5 plasmids as indicated. Again 48 h later, total cell lysates were analysed by SDS-
PAGE and Western blotting for the specified proteins. Non-targeting siRNA (siControl) was used as negative control, siVCP as 
positive control. VINCULIN served as loading control. Western blots are representative of four independent experiments.   
kDa = kilodalton 
The effect of siVCP on EVI/WLS protein level was the strongest of the observed phe-
notypes. Nevertheless, siVCP, siCGRRF1, and siUBE2K had similar effects on EVI/WLS protein 
levels of both wild type and mutant constructs, while siUBE2J2 specifically stabilised mutant 
K410/419R EVI/WLS (Figure 17B). The conclusion from this complicated experiment is that the 
lysines at the positions 410 and 419 are used to target EVI/WLS for degradation but are not 
the only sites of ubiquitination. It is conceivable that UBE2J2 ubiquitinates serines and 
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threonines next to K410/419 and that at least one other E2 enzyme is involved in ubiquitinating 
lysines, potentially UBE2K (Figure 17A). The K410/419R construct is less efficiently degraded 
in the absence of UBE2J2, as neither serines or threonines, nor the arginines at the lysine-
positions can be ubiquitinated. 
4.3.2   K63-linked Ub chains regulate WNT secretion 
Beside UBE2K, UBE2N (Ubc13) was also identified in the RNAi screen as a putative novel Ub 
conjugating enzyme important for EVI/WLS regulation. The K63-linkage preference of this en-
zyme made it an exciting candidate, as K63-linked Ub chains are important for protein locali-
sation and endosomal trafficking (Akutsu et al., 2016; Erpapazoglou et al., 2014; Swatek & 
Komander, 2016), processes which are also essential for the function of EVI/WLS. UBE2N ubiq-
uitinates different sets of substrates after forming heterodimers with its catalytically inactive 
interaction partners UBE2V1 or UBE2V2 (Figure 18F), it is therefore also interesting to investi-
gate which of these proteins is important for EVI/WLS (Andersen et al., 2005; McKenna et al., 
2001). I hypothesised that if UBE2N was involved in the recycling of EVI/WLS, as well as in the 
availability of EVI/WLS protein, its knock-down would influence EVI/WLS functionality and thus 
WNT ligand secretion. Hence, I wanted to examine the role of UBE2N and its partners on WNT 
secretion, after initial experiments had confirmed the post-translational regulation of EVI/WLS 
by UBE2N using single siRNAs (18A,B, see paragraph 4.3). 
Therefore, I overexpressed WNT3 in HEK293T cells in combination with the transfec-
tion of siRNAs against UBE2N, UBE2V1, or UBE2V2 (Figure 18C). siEVI/WLS served as target 
specific control and siVCP was used as a positive control, as its knock-down had increased 
EVI/WLS protein abundance and WNT5A and WNT3A secretion in previous experiments (Glae-
ser et al., 2018). As expected, siEVI/WLS abolished WNT3 secretion completely. Importantly, 
knock-down of UBE2N and its interaction partners not only increased EVI/WLS protein levels, 
but also the secretion of WNT ligands, implying a possible modulatory effect on Wnt signalling 
in general. However, in my experimental settings, the knock-down of VCP increased both in-
tracellular EVI/WLS and WNT3 protein levels, indicating that WNT3 is also affected by VCP-
dependent degradation, but did not increase WNT3 secretion. It should also be noted that 
siVCP and siUBE2N affect cell viability, which could cause Ub-independent effects as well. 
WNT3 seems to be expressed a little less in the siControl condition, although the same 
amount of DNA was transfected in all samples. This makes the interpretation of the blot more 
difficult and should be addressed in follow-up experiments. The effects of UBE2V1 knock-down 
were variable between replicates, and its involvement in the ubiquitination of EVI/WLS cannot 
be conclusively confirmed or rejected at this point. However, this variability was not due to 
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insufficient siRNA efficiency, which was comparably good for all three gene targets. Further-
more, gene expression analyses confirmed that EVI/WLS and VCP were not regulated by siR-
NAs targeting either UBE2N, UBE2V1, or UBE2V2 (Figure 18B,D,E). 
 
Figure 18. UBE2N and UBE2V1/UBE2V2 regulate EVI/WLS protein levels and WNT secretion 
A. Knock-down of UBE2N increased EVI/WLS protein levels. HEK293T wild type cells were treated with the indicated siRNAs for 
72 h. siRNAs targeting UBE2N were used as either single siRNAs or an equimolecular mix of all four respective siRNAs (pool). 
Samples treated with transfection reagent only (mock) or siLuciferase were used as negative control, siVCP as positive control. 
Total cell lysates were analysed by SDS-PAGE and Western blotting for the specified proteins. HSC70 served as loading control.  
B, D, E. mRNA expression analyses showed specific gene silencing without cross-regulating other investigated mRNAs. HEK293T 
wild type cells were treated with the indicated siRNAs for 72 h. Each gene’s mRNA was targeted by either single siRNAs or an 
equimolecular mix of all four respective siRNAs (pool) to analyse their effect on mRNA expression. Samples treated with trans fec-
tion reagent only (mock) or siLuciferase were used as negative control, siVCP as positive control. Total cellular RNA was tran-
scribed to cDNA and used for mRNA expression analyses by RT-qPCR. Target gene expression was normalised to siLuciferase 
treatment and GAPDH served as reference gene. Individual data points from three independent experiments are shown. 
C. Knock-down of UBE2N, UBE2V1, and UBE2V2 increased EVI/WLS protein levels and WNT3 secretion compared to control 
treatment. HEK293T wild type cells were treated with the indicated siRNAs. 24 h after siRNA transfection, cells were additionally 
transfected with a pcDNA WNT3 plasmid. Again 48 h later, secreted proteins were precipitated from the supernatant using Blue 
Sepharose. Eluates and total cell lysates were analysed by SDS-PAGE and Western blotting for the specified proteins. siRNAs 
without specific target (siControl) and siVCP were used as controls, VINCULIN or HSC70 served as loading control.  
F. Schematic representation of the formation of active complexes by UBE2N and UBE2V1 or UBE2V2 to modify target substrates 
with K63-linked ubiquitin. 
Western blots are representative of three independent experiments. kDa = kilodalton 
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4.4    EVI/WLS is ubiquitinated and degraded in cells with 
endogenous WNT ligands 
Up to this point, my results were generated in HEK293T cells. This cell line is a commonly used 
cellular model to analyse WNT signalling due to their low endogenous WNT secretion. The 
striking observation that ubiquitination of EVI/WLS might have an influence on WNT ligand se-
cretion, and thus might regulate WNT signalling itself, opened the question of whether EVI/WLS 
is also regulated by ubiquitination and ERAD in cells with high endogenous levels of WNT sig-
nalling. To investigate this further, I chose melanoma cell lines as a model system as many of 
them express high amounts of WNT proteins, most notably WNT5A (P.-T. Yang et al., 2012). 
 
Figure 19. Knock-down of VCP increases endogenous EVI/WLS protein levels in melanoma cells 
Immunofluorescence (IF) staining showed elevated endogenous EVI/WLS levels after siVCP treatment. RPMI7951 melanoma cells 
were transfected with the indicated siRNAs and fixed 72 h later with 4 % paraformaldehyde/PBS. Non-targeting siRNA (siControl) 
was used as negative control. Cells were stained for EVI/WLS with antibodies from two different providers (cyan) and for VCP 
(red). Wheat germ agglutinin (WGA) Alexa Fluor 633 Conjugate was used to image cellular membranes (grey). Cover glasses 
were mounted using ProLong Diamond Antifade Mountant with DAPI, to visualise DNA (blue). Images were acquired using a Zeiss 
motorised inverted Observer.Z1 microscope with the ZEISS ZEN (blue edition) software and processed with Fiji (Fiji is just ImageJ). 
Image quality was optimised by adjusting brightness and contrast. Preliminary.  
As an initial experiment, I wanted to test whether EVI/WLS was also regulated by VCP 
in melanoma cells. Therefore, I stained endogenous EVI/WLS with two different antibodies after 
transfection of siVCP, siEVI/WLS, or siControl in RPMI7951 melanoma cells, which have large, 
flat cell bodies and are easy to visualise. Cytoplasmic EVI/WLS signal increased after transfec-
tion of siVCP and decreased after transfection of siEVI/WLS, indicating that the endogenous 
staining was specific, and that EVI/WLS is regulated by VCP, and thus potentially by ERAD, in 
cells with endogenous WNT ligand production. However, some EVI/WLS signal remained after 
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transfection of siEVI/WLS, either due to insufficient siRNA-mediated knock-down or back-
ground signal of the antibodies (Figure 19). 
Although RPMI7951 cells are suitable for imaging, they are difficult to transfect with 
plasmid DNA. Hence, I selected the commonly used melanoma cell line A375 for the next ex-
periments since it is easy to transfect and proliferates fast. Glaeser et al. showed that the over-
expression of various WNT ligands led to the stabilisation of EVI/WLS protein in HEK293T cells 
(Glaeser et al., 2018). Following up on this, I wanted to investigate whether the effect can be 
reversed in A375 cells by preventing WNT ligands from being lipid-modified by treatment with 
LGK974, an inhibitor of the acyl-transferase PORCN. The absence of the lipid-modification pre-
vents EVI/WLS-WNT interaction and I hypothesised that this seeming ‘absence of WNT ligands’ 
would induce the degradation of EVI/WLS (Figure 20A). 
LGK974 treatment did not change intracellular WNT5A ligand abundance but abolished 
the secretion of WNT5A, as expected (Figure 20B). Indeed, EVI/WLS protein levels were re-
duced in cell lysates treated with LGK974 compared to DMSO. At the same time, mRNA ex-
pression of EVI/WLS or PORCN was not decreased but rather slightly elevated upon LGK974 
treatment compared to the control, suggesting true post-translational regulation of EVI/WLS 
protein levels. These findings also indicated that the detected WNT ligands that remained in 
the cell lysates after LGK974 treatment were not functional. AXIN2 expression as a read-out 
for canonical/β-catenin dependent WNT signalling was decreased after LGK974 treatment, in-
dicating overall reduced WNT target gene transcription (Figure 20B,C).  
This post-translational regulation of EVI/WLS in A375 cells suggests that EVI/WLS is 
ubiquitinated and degraded by the proteasome in these cells upon LGK974-induced inhibition 
of WNT ligand lipidation. To directly test this hypothesis, I used TUBEs to enrich A375 protein 
lysates for ubiquitinated proteins. By doing so, I expected to see the accumulation of ubiqui-
tinated EVI/WLS after LGK974 treatment and inhibition of the proteasome by MG132. Surpris-
ingly, however, proteasome inhibition induced high-molecular EVI/WLS bands after both 
LGK974 and control DMSO treatment, indicating ubiquitinated EVI/WLS in the absence and 
presence of endogenous lipid-modified WNTs (Figure 20D). In general, the K48-Ub signal in-
creased in samples treated with MG132 compared to DMSO, indicating the overall accumula-
tion of ubiquitinated proteins and the ubiquitination of β-catenin was detected in all except for 
the control beads sample, suggesting continuous turn-over of this protein (Figure 20D). 
In conclusion, these results show that EVI/WLS protein levels depend on the availability 
of mature WNT ligands in cells with high endogenous WNT signalling, but a part of the EVI/WLS 
protein pool is ubiquitinated and targeted for degradation even in the presence of WNT ligands. 
 




Figure 20. EVI/WLS is ubiquitinated in cells with and without endogenous WNT ligands 
A. Schematic illustration of LGK974’s mode of action. LGK974 prevents WNT ligands from being lipid -modified in the endoplasmic 
reticulum (ER) by inhibiting the acyl-transferase PORCN. Un-lipidated WNTs cannot associate with EVI/WLS and are not secreted 
from the WNT producing cell. 
B, C. LGK974 treatment reduced intracellular EVI/WLS levels and abolished the secretion of WNT5A/B ligands, without reducing 
EVI/WLS gene expression. A375 melanoma cells were treated with LGK974 (10 µM) or equivalent volumes of DMSO as solvent 
control for 96 h with daily medium changes. B, secreted proteins were precipitated from the supernatant 24 h after the last medium 
change using Blue Sepharose and eluates and total cell lysates were analysed by SDS-PAGE and Western blotting for the specified 
proteins. VINCULIN or HSC70 served as loading control. C, total cellular RNA was transcribed to cDNA and used for mRNA 
expression analyses by RT-qPCR. Target gene expression was normalised to DMSO treatment and GAPDH served as reference 
gene. Individual data points from three independent experiments are shown. 
D. Inhibition of the proteasome led to the accumulation of ubiquitinated EVI/WLS after both LGK974 and control treatment. A375 
melanoma wild type and EVI/WLS knock-out (EVI/WLSKO) cells were treated with LGK974 (10 µM) or equivalent volumes of DMSO 
as solvent control for 96 h with daily medium changes. 24 h before harvest, samples were treated with the proteasome inhibitor 
MG132 (1 µM) as indicated. Then, total cell lysates were harvested for input control or used for TUBE2 (agarose) pull -down to 
precipitate poly-ubiquitinated proteins. Eluates or input controls were analysed by SDS-PAGE and Western blotting for the speci-
fied proteins. Ubiquitin non-binding Control (Ctrl) Agarose Beads showed level of unspecific binding and EVI/WLSKO cells con-
firmed specificity for EVI/WLS. β-ACTIN served as loading control. TUBE = tandem ubiquitin binding entity 
Western blots are representative of three independent experiments. Note that the WNT5 antibody used in these studies recognises 
both WNT5A and WNT5B. kDa = kilodalton 
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I then asked which proteins influence the degradation of EVI/WLS in A375 cells. Hence, 
I combined LGK974 and transfection of siRNA to analyse which knock-downs of ERAD-associ-
ated genes would interfere with the degradation of EVI/WLS. Of the tested genes, only the 
knock-down of UBE2J2, CGRRF1, and VCP consistently elevated EVI/WLS protein levels, in 
line with the previously obtained results in HEK293T cells (Figure S4, Glaeser et al., 2018). 
These results suggest that the underlying mechanisms of EVI/WLS turn-over are conserved 
between different human cell types. 
4.5   EVI/WLS is modified with K11-, K48-, and K63-linked Ub 
I decided to study the ubiquitination of EVI/WLS further in A375 cells, as the concurrent pres-
ence of a stabilised and a degraded pool of EVI/WLS allowed me to detect both accumulation 
and depletion of high-molecular EVI/WLS signals. It should also be considered that different 
Ub modifications might be present at different cycling/recycling stages of EVI/WLS and thus 
might not be observed in HEK293T cells due to their low endogenous WNT ligand secretion.  
As the E2 Ub conjugating enzymes which had been associated with EVI/WLS, namely 
UBE2J2, UBE2K, and UBE2N, each have a preferential Ub-linkage specificity, I hypothesised 
that different Ub-linkage types would also be present on EVI/WLS. The TUBE assay presented 
in Figure 20D showed several high-molecular EVI/WLS bands, indicating poly-Ub chains or 
several mono Ubs attached to EVI/WLS, but as the TUBEs used here were non-selective, they 
did not allow to distinguish between different Ub linkage types. Hence, I expressed different 
mutant Ub constructs with HA-tags to test the presence of Ub linkages via K11, K48, or K63 
(Clague et al., 2015; Tsuchiya et al., 2018; P. Xu et al., 2009) on endogenous EVI/WLS. Each 
of these Ub constructs allowed only one linkage type to form, because all other lysines were 
mutated to arginine. Thus, immunoprecipitation of the HA-tag captured all proteins modified 
with the respective Ub. 
I detected high-molecular EVI/WLS bands in pulldowns from samples with wild type, 
K11, K48, or K63 ubiquitin-HA overexpression after inhibition of the proteasome, indicating the 
presence of multiple linkage types on EVI/WLS (Figure 21A). Staining for the HA-tag in the 
input samples reflected how well the Ub-HA constructs modified substrate proteins. Not sur-
prisingly, the amount of detected wild type Ub-HA was much higher than any of the mutant 
forms, presumably because it can be used at any position (Figure 21A). That is probably also 
why it appears as if the Ub-HA constructs were expressed at varying levels, although the same 
amount of DNA had been transfected. It should be noted that the endogenous, unmodified Ub 
is still present in these samples and the detected Ub signal is probably a mixture of tagged and 
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un-tagged Ub. This is difficult to prevent, as the knock-out of Ub is lethal and it would require 
the combinatorial knock-down of Ub and overexpression of the Ub-HA constructs to perform 
these experiments without endogenous Ub. Nevertheless, using the present conditions, it is 
unclear how much endogenous and how much mutant Ub is used for substrate modification. 
While the overexpressed form is probably more abundant, endogenous Ub might be more 
stable. 
The two E2 Ub conjugating enzymes UBE2K and UBE2N were identified in my screen 
as post-translational regulators of EVI/WLS and have a specificity for K48- and K63-linkage, 
respectively (Z. Chen & Pickart, 1990; Middleton & Day, 2015). I therefore assumed that UBE2K 
and UBE2N mediate the K48- and K63 Ub-linkage I detected on EVI/WLS (Figure 21A). Pan-
Ub TUBEs did not show differences in ubiquitination after transfection of siUBE2K (data not 
shown). Possibly, the effect of siUBE2K was small and might have been masked by other poly- 
or mono-Ub modifications that are present at the same time on EVI/WLS. However, linkage-
type specific TUBEs can be used to specifically enrich proteins modified with either K48- or 
K63-linked Ub and thus might offer greater sensitivity. Hence, I used linkage-type specific 
TUBEs with a FLAG-tag to detect differences in high-molecular EVI/WLS bands after transfect-
ing siUBE2K or siUBE2N. Indeed, FLAG K48 TUBEs showed a reduction of high-molecular 
EVI/WLS bands after transfection of siUBE2K compared to siLuciferase control (Figure 21B). 
Likewise, siUBE2N markedly reduced the signal of endogenous high-molecular EVI/WLS 
bands after K63-specific FLAG-TUBE pull-down, as did the knock-down of UBE2V2 (Figure 
21C). This data strongly indicates the modification of EVI/WLS with K48-linked Ub by UBE2K 
and with K63-linked Ub by UBE2N together with UBE2V2 in human cells. 
► next page | Figure 21. EVI/WLS is modified with K11-, K48-, and K68-linked ubiquitin in A375 melanoma cells 
A. Endogenous EVI/WLS is modified with ubiquitin linked via K11, K48, and K63. A375 wild type (wt) and EVI/WLS knock-out 
(EVI/WLSKO) cells were transfected with pRK5-HA-Ubiquitin wt, K11, K48, or K63 overexpression plasmids or left untreated (ut). 
The K11, K48, and K63 ubiquitin constructs can only be elongated with further ubiquitins at the specified position, all others have 
been mutated to arginines. 24 h before harvest, samples were treated with the proteasome inhibitor MG132 (1 µM) or equivalent 
voume of DMSO as solvent control. After 72 h, total cell lysates were harvested for input control or used for HA immunoprecipita-
tion to analyse proteins modified with HA-tagged ubiquitin. Proteins were eluted using competition with HA Peptide. Eluates and 
input control were analysed by SDS-PAGE and Western blotting for the specified proteins. HA non-binding Control (Ctrl) Agarose 
Beads showed level of unspecific binding during HA IP and EVI/WLSKO cells confirmed specificity and independent effects of 
EVI/WLS. Tubulin served as loading control. 
B, C. FLAG K48 specific TUBE pull-down confirmed that EVI/WLS is modified with K48-linked ubiquitin chains by UBE2K and 
FLAG K63 specific TUBE pull-down confirmed that EVI/WLS is modified with K63-linked ubiquitin chains by UBE2N. A375 mela-
noma wild type and EVI/WLS knock-out (EVI/WLSKO) cells were treated with the indicated siRNAs for 72 h. 24 h before harvest, 
samples were treated with the proteasome inhibitor MG132 (1 µM) or equivalent volume of DMSO as solvent control. Total cell 
lysates were harvested for input control or used for FLAG TUBE pull-down to specifically precipitate proteins modified with K48- 
(B) or K63-linked (C) poly-ubiquitin. Proteins were eluted using competition with 3× FLAG Peptide and eluates or input controls 
were analysed by SDS-PAGE and Western blotting for the specified proteins. Ubiquitin non-binding Control (Ctrl) Agarose Beads 
showed level of unspecific binding and EVI/WLSKO cells confirmed specificity for EVI/WLS. β-ACTIN served as loading control.  
Asterisks indicate background/unspecific signals. Western blots are representative of three independent experiments. kDa = ki lo-
dalton, TUBE = tandem ubiquitin binding entity 
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(see previous page for figure legend) 
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In general, it should be noted that EVI/WLS protein staining was often visible in the 
control bead samples after immunoprecipitation (Figures 20D,22A,B,23A). This is probably due 
to insufficient washing and unspecific binding of proteins to the beads. Nevertheless, interpre-
tation of the data was still possible because of the absence of high-molecular EVI/WLS bands, 
even after inhibition of the proteasome, and intensity differences to the samples of interest. 
Along the same line, signals detected just above 50 kDa corresponded most likely to the 
gamma immunoglobin heavy chains (Figure 21). It is surprising that these bands were detected 
after sample elution using competition with either HA- or FLAG peptide. They probably indicate 
that a few antibodies dissociated from their beads over time and are visible after the long ex-
posure times necessary to detect endogenous EVI/WLS. 
4.6   ERLIN2 links EVI/WLS to the ubiquitination machinery 
The obtained results show that EVI/WLS can be both stabilised and degraded in cells with 
endogenous WNT signalling. Its degradation depends on Ub signals which are mediated by 
UBE2K and UBE2N, in addition to the previously reported UBE2J2 and CGRRF1 (Glaeser et al, 
2018). Furthermore, ERLIN2, FAF2, and UBXN4 are important for the regulation of EVI/WLS 
protein levels. However, it remains elusive how the latter three proteins influence the ubiquiti-
nation of EVI/WLS. This is important to examine, because it can indicate whether ERLIN2, 
FAF2, and UBXN4 interact with EVI/WLS before or after it is ubiquitinated. As ERLIN2 had been 
implicated in linking the regulatory ERAD substrates IP3R and HMG-CoA reductase to the ubiq-
uitination machinery (Jo, Sguigna, et al., 2011; Pearce et al., 2007), I hypothesised that the 
knock-down of ERLIN2 would reduce the ubiquitination of EVI/WLS. Conversely, FAF2 and 
UBXN4 are VCP-interacting proteins, and FAF2 additionally contains an Ub-interacting domain 
(Schuberth & Buchberger, 2008). Hence, a function in the ERAD of EVI/WLS after it has been 
ubiquitinated, but before it is removed from the ER-membrane by VCP, is conceivable and 
ubiquitinated EVI/WLS was expected to accumulate after the knock-down of FAF2 and UBXN4. 
Pan-ubiquitin specific TUBE1 magnetic beads were used to investigate the ubiquitina-
tion status of EVI/WLS in combination with RNAi mediated knock-down of ERLIN2, FAF2 or 
UBXN4. Indeed, I observed a strong reduction of high-molecular EVI/WLS bands after trans-
fection of siERLIN2 and the high-molecular EVI/WLS signal increased following knock-down of 
FAF2 and UBXN4 (Figure 22A). This confirmed the hypothesis that ERLIN2 functions as a linker 
and connects EVI/WLS to the ubiquitination machinery and that FAF2 and UBXN4 interact with 
EVI/WLS after it is ubiquitinated, but before it is delivered to the proteasome. siVCP was used 
as a positive control and it increased the signal of high-molecular EVI/WLS bands 
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pronouncedly, indicating that the knock-down of VCP prevented the degradation of ubiqui-
tinated EVI/WLS (Figure 22A). Indeed, this signal was much stronger than the one after knock-
down of FAF2 or UBXN4, suggesting that EVI/WLS is subject to several recruitment mecha-
nisms which all culminate in dislocation by VCP. Further analysis, e.g. by combinatorial knock-
down of ERLIN2 and VCP, should reveal more about the sequence of events. 
 
Figure 22. EVI/WLS is linked to the ubiquitination machinery via ERLIN2  
A. Knock-down of ERLIN2 reduced the ubiquitination of EVI/WLS, while knock-down of FAF2 and UBXN4 increased it. A375 wild 
type and EVI/WLS knock-out (KO) cells were treated with the indicated siRNAs for 72 h. Then, total cell lysates were harvested for 
input control or used for TUBE1 (magnetic beads) pull-down to precipitate poly-ubiquitinated proteins. Eluates or input controls 
were analysed by SDS-PAGE and Western blotting for the specified proteins. Ubiquitin non-binding control (Ctrl) magnetic beads 
showed level of unspecific binding and EVI/WLSKO cells confirmed specificity for EVI/WLS. α-TUBULIN served as loading control.  
B, C. Overexpression of FLAG-tagged UBXN4, ERLIN1, ERLIN2, FAF2, or UBE2K did not change endogenous EVI/WLS protein 
levels or WNT5A/B secretion. FLAG-tagged constructs were overproduced in wild-type A375 melanoma cells for 48 h. Then, 
secreted proteins were precipitated from the supernatant using Blue Sepharose. Eluates and total cell lysates were analysed by 
SDS-PAGE and Western blotting for the specified proteins. VINCULIN or HSC70 served as loading control.  
Asterisks indicate background/unspecific signals. Western blots are representative of three independent experiments. Note that 
the WNT5 antibody used in these studies recognises both WNT5A and WNT5B. kDa = kilodalton, TUBE = tandem ubiquitin binding 
entity 
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After having analysed the effect of ERLIN2, FAF2, and UBXN4 knock-down in A375 
cells, I next asked whether their overexpression would influence EVI/WLS protein levels as well. 
It was conceivable that an increase of ERLIN2, FAF2, or UBXN4 abundance would accelerate 
the degradation of EVI/WLS. However, expression of the FLAG-tagged constructs (see also 
4.2) in these cells did neither have an effect on intracellular EVI/WLS protein levels nor on the 
secretion of WNT5A/B (Figure 22B,C). It was again apparent that these constructs are not 
equally well expressed, or their protein products are differentially regulated, as was observed 
previously in HEK293T cells. Nevertheless, this suggested that while the proteins are present, 
their abundance is not rate limiting for the degradation of EVI/WLS. 
4.7    In-vitro gelatin degradation assay assesses the invasive 
capacity of melanoma cells 
My results show that EVI/WLS protein levels are regulated on various molecular levels. Next, I 
wanted to investigate how EVI/WLS abundance functionally affects cellular behaviour. I chose 
melanoma cells as a cellular model as it has been described previously that WNT signalling 
plays an important role in determining the switch between a more proliferate and a more inva-
sive phenotype and metastasis in this system (Webster et al., 2015). However, the role of WNT 
secretion and EVI/WLS in melanoma is still not very well characterised. 
Invasion and metastasis are exceedingly complex phenotypes and as such are difficult 
to recreate and analyse in-vitro, despite the possible advantage of having a less time-consum-
ing, less costly, and more flexible assay than in-vivo experiments (Kramer et al., 2013). Never-
theless, it is possible to investigate individual steps of these complex organismal processes 
and recapitulate them in-vitro. One example is the analysis of the degradation of gelatin in cell 
culture as a proxy for the remodelling of extracellular matrix. In-vivo, this would help tumour 
cells to infiltrate and migrate through their surrounding connective tissue (Iizuka et al., 2016; 
H. Lu et al., 2016; Paterson & Courtneidge, 2018). Therefore, I established the so called ‘gelatin 
degradation assay’ (also called ‘invadopodia assay’) in our laboratory and developed an anal-
ysis pipeline to allow the comparison between different conditions (Figure 23A). In brief, a 
specified number of cells is seeded on top of a thin layer of fluorescently labelled gelatin. After 
the cells attach, they start to form small, actin-based protrusions which secrete proteases and 
degrade both gelatin and fluorophores. This results in black patterns which can be visualised 
using fluorescence microscopy. These structures are referred to as invadopodia in cancer cells 
(Paterson & Courtneidge, 2018). According to cell line and treatment, these patterns can be 
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different in size and shape, ranging from small clusters of dots (e.g. WM793 melanoma cells, 
Figure 23C) to large patches (e.g. RPMI7951, Figures 24,25,26). 
 
Figure 23. The gelatin degradation assay is a versatile tool to analyse the invasive capacity of cells in-vitro 
A. Schematic illustration of the gelatin degradation assay and subsequent analysis pipeline.  
B. F-ACTIN and CORTACTIN colocalise with gelatin degradation foci. RPMI7951 melanoma cells were seeded on fluorescein-
gelatin (green) coated cover glasses and fixed 24 h later with 4 % paraformaldehyde/PBS. Immunofluorescence staining was used 
to visualise CORTACTIN (red) and ACTIN-filaments were stained using Phalloidin-TRITC (orange). 
C. Knock-down of SH3PXD2A or MITF influence the invasive capacity of melanoma cells. WM793 cells were treated with the 
indicated siRNAs for 72 h before being seeded on fluorescein-gelatin (green) coated cover glasses. Non-targeting siRNA (siCon-
trol) was used as negative control. 24 h after seeding, cells were fixed with 4 % paraformaldehyde/PBS and stained for ACTIN -
filaments using Phalloidin-TRITC (orange). 
Cover glasses were mounted using ProLong Diamond Antifade Mountant with DAPI, in order to visualise DNA (blue). Images were 
acquired using a Zeiss motorised inverted Observer.Z1 microscope with the ZEISS ZEN (blue edition) software and processed 
using Fiji (Fiji is just ImageJ). Image quality was optimised by adjusting brightness and contrast.  
Consequently, the most unbiased way of quantification is by measuring the size of the 
area of degradation after thresholding. To compare the invasive capacities between different 
treatments and replicates, I counted at least 100 cells per condition in each replicate. Then, I 
normalised the obtained values from thresholding to the number of cells in the respective im-
ages and calculated the ratio to the control condition. Thus, the invasive capacity was always 
1 in the control conditions, or 0 after log transformation. After log transforming the invasive 
capacity values of the treatment conditions, negative fold change indicated decreased degra-
dation of the cells compared to the control and a positive fold change indicated increased 
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degradation (Figure 23A). RPMI7951 and WM793 melanoma cells are adequate tools for this 
assay considering that they degrade gelatin even in an unperturbed state and deflection of 
their invasive capacity can be measured in both directions. Since the normalised values are 
not normally distributed, the non-parametric one-sample Wilcoxon signed rank test was used 
to assess statistical significance of treatments. 
Invadopodia are characterised by the co-localisation of actin and cortactin with areas 
of proteolytic activity (Paterson & Courtneidge, 2018) as shown in Figure 23B, thus confirming 
the presence of invadopodia formed by RPMI7951 melanoma cells in this assay. As a proof of 
concept, I also wanted to examine whether the area degraded by invadopodia would change 
upon perturbation of the cells with RNAi. As expected, knock-down of an essential scaffolding 
protein in invadopodia, SH3PXD2A/TKS5, abolished gelatin degradation by WM793 cells, while 
the knock-down of MITF, the transcription factor regulating melanocyte differentiation, resulted 
in more abundant degradation foci. This is in agreement with previous publications, which pre-
scribed MITF with an important role in the proliferative phenotype and its knock-down accord-
ingly shifts the cells towards a more invasive phenotype (Webster et al., 2015, Figure 23C). 
4.7.1   PORCN inhibition decreased the invasive capacity of melanoma cells 
WNT5A mediates melanoma cell invasiveness (Weeraratna et al., 2002). However, the knock-
down of EVI/WLS, and thus the abrogation of WNT5A secretion, led to more metastasis for-
mation in a melanoma xenograft mouse model (P.-T. Yang et al., 2012). This apparent contra-
diction might have important consequences for melanoma pathophysiology but has not been 
investigated in detail. 
To address this conundrum, I first examined the role of WNT ligand acylation and se-
cretion with the help of the PORCN inhibitor LGK974. I hypothesised that if the secretion of 
mature WNT ligands is important for melanoma cell invasiveness, this treatment should de-
crease the invasive capacity of RPMI7951 melanoma cells compared to the DMSO vehicle 
control. As expected, LGK974 treatment reduced gelatin degradation significantly compared 
to control treatment (Figure 24A,B), decreased intracellular EVI/WLS protein levels, and 
blocked the secretion of WNT5A/B (Figures 24C, see also Figure 20 for A375 cells). Surpris-
ingly, however, WNT11 was still secreted after LGK974 treatment, albeit in lower amounts com-
pared to DMSO (Figure 24C). 
The gelatin degradation assay does not allow to assess migration, as the readout is 
done from a static image of degraded gelatin after a specified period of time. Since it is im-
portant to analyse invasion and migration together, I used a scratch/wound healing assay to 
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examine the migration of treated cells over time and measured cell proliferation in parallel to 
exclude that an apparent quicker migration is due to underlying proliferation effects. LGK974 
treatment had no significant effect on either proliferation or migration compared to control, but 
it showed a small trend towards faster migration and slower proliferation (Figure 24D,E). 
In conclusion, these results suggest that PORCN activity and the secretion of lipidated 
WNT5A are important for the gelatin degradation capacity of melanoma cells. 
 
Figure 24. Inhibition of PORCN reduces invasive capacity of melanoma cells 
RPMI7951 melanoma cells were treated with LGK974 (10 µM) or equivalent volumes of DMSO as solvent control for 96 h with 
daily medium changes. 
A, B. Treatment with LGK974 reduced gelatin degradation by melanoma cells. After pre-treatment with LGK974 or DMSO, cells 
were seeded on fluorescein-gelatin (green) coated cover glasses. 24 h after seeding, cells were fixed with 4 % paraformalde-
hyde/PBS and stained for ACTIN-filaments using Phalloidin-TRITC (orange). Cover glasses were mounted using ProLong Diamond 
Antifade Mountant with DAPI, in order to visualise DNA (blue). A, Images were acquired using a Zeiss motorised inverted Ob-
server.Z1 microscope with the ZEISS ZEN (blue edition) software and processed using Fiji (Fiji is just ImageJ). Image quality was 
optimised by adjusting brightness and contrast. B, quantification of gelatin degradation relative to DMSO and normalised to cell 
number in six independent experiments with > 100 cells per condition. One-Sample Wilcoxon Signed Rank test, * p < 0.05 
C. LGK974 treatment reduced intracellular EVI/WLS levels and inhibited the secretion of WNT5A/B ligands, but not the secretion 
of WNT11. After pre-treatment with LGK974 or DMSO, secreted proteins were precipitated from the supernatant using Blue Se-
pharose 24 h after the last medium change. Eluates and total cell lysates were analysed by SDS-PAGE and Western blotting for 
the specified proteins. VINCULIN or HSC70 served as loading controls. Western blots are representative of three independent 
experiments. kDa = kilodalton 
D, E. Migration and Proliferation were similar between LGK974 and DMSO treated melanoma cells. After pre-treatment with 
LGK974 or DMSO, migration and proliferation were analysed by time-lapse live-cell imaging with the IncuCyte ZOOM system 
together with the IncuCyte Basic Software and the IncuCyte Scratch Wound Cell Migration Software Module. Plots are representa-
tive of three independent experiments. 
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4.7.2   WNT11 regulates the invasive capacity of melanoma cells 
LGK974 treatment revealed a possible PORCN-independent secretion of WNT11, but 
this compound treatment did not allow to deduce a possible mechanism of how this might be 
related to melanoma cell invasiveness. Hence, I used RNAi mediated knock-down of compo-
nents of the WNT transduction cascades to investigate how they specifically affect gelatin deg-
radation. Based on the literature, I expected that siWNT5A would reduce the cells’ invasive 
capacity (Weeraratna et al., 2002), while siEVI/WLS would increase it (P.-T. Yang et al., 2012). 
The role of WNT11 had not been investigated in detail in melanoma, but as WNT11 and WNT5A 
are both non-canonical WNT ligands, I assumed WNT11 would have a similar function as 
WNT5A. I also included siCTNNB1 in these experiments because the role of β-catenin in mel-
anoma is controversial and I wanted to investigate its contribution to gelatin degradation (Web-
ster & Weeraratna, 2013). 
Similar phenotypes were observed for the two melanoma cell lines RPMI7951 and 
WM793 upon transfection of siRNAs (Figure 25A,B;C). The knock-down of mRNA and protein 
levels by the siRNAs was good in both cell lines and predominantly reduced mRNA expression 
of all genes below 12 % of the control value (Figure S5). The knock-down of WNT5A reduced 
gelatin degradation significantly, as expected. Surprisingly, the cells’ invasive capacity in-
creased dramatically after both the knock-down of EVI/WLS or WNT11, indicating an important 
role of the non-canonical WNT11 for melanoma cells which differs from the well characterised 
WNT5A. At the same time, the results for siEVI/WLS are in line with the previously described 
increased invasiveness of melanoma cells after EVI/WLS knock-down (P.-T. Yang et al., 2012). 
The invasive capacity of siCTNNB1 transfected cells resembled the control, suggesting no ma-
jor influence of β-catenin on the invasive capacity of the tested melanoma cells in this assay. 
Migration was investigated in parallel to invasion, revealing that WM793 cells trans-
fected with siCTNNB1 migrated quicker and those transfected with siEVI/WLS migrated slower 
than all other conditions. Strikingly, both the knock-down of EVI/WLS and WNT11 had a strong 
negative impact on proliferation in these cells, suggesting that the signalling programmes that 
made the cells more invasive also slowed down proliferation (Figure 25D,E). 
 




Figure 25. Knock-down of EVI/WLS or WNT11 enhances invasive capacity of melanoma cells 
RPMI7951 or WM793 melanoma cells were treated with the indicated siRNAs for 72 h. Samples treated with transfection reagent 
only (mock) or non-targeting siRNA (siControl) were used as control.  
A, B, C. Silencing of EVI/WLS or WNT11 enhanced gelatin degradation by melanoma cells. After pre-treatment with siRNAs, 
RPMI7951 or WM793 cells were seeded on fluorescein-gelatin (green) coated cover glasses. 24 h after seeding, cells were fixed 
with 4 % paraformaldehyde/PBS and stained for ACTIN-filaments using Phalloidin-TRITC (orange). Cover glasses were mounted 
using ProLong Diamond Antifade Mountant with DAPI, in order to visualise DNA (blue). A, Images were acquired using a Zeiss 
motorised inverted Observer.Z1 microscope with the ZEISS ZEN (blue edition) software and processed using Fiji (Fiji is just Im-
ageJ). Image quality was optimised by adjusting brightness and contrast. B & C, quantification of gelatin degradation of respective 
siRNA (Target) relative to siControl (Ctrl) and normalised to cell number in at least six independent experiments with > 100 cells 
per condition. One-Sample Wilcoxon Signed Rank test, * p < 0.05, NS. = not significant  
D, E. Proliferation was reduced by knock-down of EVI/WLS or WNT11 in WM793 melanoma cells. After pre-treatment with siRNAs, 
migration or proliferation were analysed by time-lapse live-cell imaging with the IncuCyte ZOOM system together with the IncuCyte 
Basic Software and the IncuCyte Scratch Wound Cell Migration Software Module. Plots are representative of three independent 
experiments. 
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The role of WNT11 has not yet been investigated in depth in the context of melanoma. 
After I observed the striking upregulation of invasive capacity upon its knock-down, I next asked 
if this effect could be reversed by overexpression of WNT11. In parallel, I overexpressed WNT3 
and WNT5A, expecting to see a decrease and an increase in gelatin degradation, respectively. 
Indeed, the overexpression of WNT11 diminished gelatin degradation significantly, in some 
replicates even nearly completely, thus strengthening the link between WNT11 and melanoma 
invasiveness. Unexpectedly, overexpression of both WNT3 and WNT5A did not change the 
invasive capacity of RPMI7951 cells compared to the control. This indicates that the signalling 
induced by WNT5A is already at its maximum capacity and cannot be increased by further 
WNT5A secretion. Furthermore, these melanoma cells seem to be committed towards an in-
vasive phenotype beyond the control by canonical WNT ligands, such as WNT3 (Figure 26). 
 
Figure 26. Overexpression of WNT11 reduces invasive capacity of melanoma cells 
Overexpression of WNT11 reduced gelatin degradation by melanoma cells. RPMI7951 melanoma cells were transfected with the 
indicated overexpression constructs and seeded on fluorescein-gelatin (green) coated cover glasses 48 h later. Successful over-
expression was confirmed in the remaining cells and their supernatant by Western blotting performed by Oksana Voloshanenko 
(data not shown). 24 h after seeding, cells were fixed with 4 % paraformaldehyde/PBS and stained for ACTIN-filaments using 
Phalloidin-TRITC (orange). Cover glasses were mounted using ProLong Diamond Antifade Mountant with DAPI, in order to visu-
alise DNA (blue). A, Images were acquired using a Zeiss motorised inverted Observer.Z1 microscope with the ZEISS ZEN (blue 
edition) software and processed using Fiji (Fiji is just ImageJ). Image quality was optimised by adjusting brightness and contrast. 
B, quantification of gelatin degradation by indicated overexpression constructs relative to an empty pcDNA control plasmid (Ctrl) 
and normalised to cell number in at least six independent experiments with > 100 cells per condition.  One-Sample Wilcoxon 
Signed Rank test, * p < 0.05, NS. = not significant 
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In summary, I demonstrated that EVI/WLS and WNT11 have an impact on melanoma 
cell invasiveness in-vitro. Moreover, the abundance of EVI/WLS protein in melanoma and 
HEK293T cells is regulated by ubiquitination in the presence and absence of lipid-modified 
WNT ligands. Different Ub linkage types mediated by multiple E2 Ub conjugating enzymes im-
plicate a possible role for EVI/WLS trafficking and its WNT cargo function. Un-needed or mis-
folded EVI/WLS is removed from the ER by ERAD and then degraded by the proteasome. My 
results show that ERLIN2 links EVI/WLS to the ERAD machinery before it is ubiquitinated and 
that FAF2 and UBXN4 interact with EVI/WLS and VCP, presumably to ultimately remove it from 


























Cellular signalling frequently regulates and is regulated by protein stability. A prominent exam-
ple is the canonical WNT signalling pathway: its major effector, β-catenin, is constantly trans-
lated and degraded in the absence of pathway activators (T. Zhan et al., 2017). The two most 
important cellular protein degradation machineries are autophagy and the Ub-proteasome sys-
tem (Pohl & Dikic, 2019), which can be triggered by post-translational substrate modification 
with Ub. Substrates within the secretory routes or ER-(membrane)-resident proteins are de-
graded by ERAD and the proteasome if they fail quality control checkpoints (Christianson & 
Ye, 2014; Z. Sun & Brodsky, 2019). However, ERAD can also influence cellular signalling by 
controlling the quantity of proteins through selective degradation of functional proteins. The 
underlying mechanisms are incompletely understood and only few endogenous substrates of 
regulatory ERAD have been identified in mammals (Bhattacharya & Qi, 2019; Printsev et al., 
2017). One of these substrates is the conserved transmembrane protein EVI/WLS (Glaeser et 
al., 2018). EVI/WLS is essential for the secretion of WNT ligands and thus has important func-
tions throughout embryogenesis, as well as for tissue homeostasis and diseases, such as can-
cer (Zhan et al., 2017). This dependency requires a tight regulation of the availability of 
EVI/WLS itself and it was shown previously that EVI/WLS is ubiquitinated by UBE2J2 and 
CGRRF1 before it is removed from the ER with the help of VCP and proteasomal degradation 
(Glaeser et al., 2018). Glaeser et al. showed that EVI/WLS is apparently not ubiquitinated by 
SYVN1/HRD1 (Glaeser et al., 2018). This makes analysing the degradation of EVI/WLS espe-
cially interesting, as SYVN1/HRD1 was reported to be involved with most other known sub-
strates of regulatory ERAD (Bhattacharya & Qi, 2019; Printsev et al., 2017). Nevertheless, many 
open questions regarding the ubiquitination of EVI/WLS and its link to the proteasome re-
mained. The stability and availability of EVI/WLS influences WNT ligand secretion, but so far it 
was unknown whether ubiquitination might mediate the retrograde transport of EVI/WLS by 
different Ub linkage-types. Beside the regulation of EVI/WLS abundance, it is also crucial to 
define phenotypic or functional consequences of EVI/WLS stability. In melanoma, WNT5A over-
expression and EVI/WLS deficiency, and thus reduced WNT5A secretion, are associated with 
invasiveness and metastasis formation (Webster et al., 2015; P.-T. Yang et al., 2012). The un-
derlying mechanisms are not well understood, and only consistent methodologies and assays 
can help to resolve this apparent conundrum. 
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To gain insight into the regulation of EVI/WLS protein abundance in physiology and 
pathophysiology, I analysed its ‘Ub code’, novel ERAD-associated interaction partners, and 
how its relation to melanoma cell invasiveness. The presented results demonstrate that 
EVI/WLS is modified with K11-, K48-, and K63-linked Ub by different E2 enzymes and at multi-
ple positions, which impacts on its degradation and function. I show that ERLIN2 is an important 
link between EVI/WLS and the Ub machinery and FAF2 and UBXN4 interact with both EVI/WLS 
and VCP, possibly to help with the dislocation of EVI/WLS from the ER. EVI/WLS is ubiquitinated 
and degraded in cells irrespective of the availability of lipid-modified WNT ligands, indicating a 
tight and conserved regulation across cell types. Furthermore, my data suggests for the first 
time the secretion of non-lipid-modified WNT11 from melanoma cells and supports a possible 
role of WNT11 in melanoma progression. 
5.1 The EVI/WLS ‘destruction complex’ contains ERLIN2, 
FAF2, and UBXN4  
To further elucidate the mechanism by which EVI/WLS is recognised by the ERAD machinery 
and linked to VCP, I performed a screen based on EVI/WLS protein stability after query gene 
knock-down (Figure 11,S1,S2,S3). This led to the identification of three candidates which in-
creased EVI/WLS protein levels upon knock-down and interacted with endogenous EVI/WLS 
protein: ERLIN2, FAF2, and UBXN4 (Figures 12,13,15). 
FAF2 and UBXN4 contain VCP interaction domains and are anchored at the ER mem-
brane by an ‘intramembrane’ domain, which leaves both their N- and C-termini facing the cy-
toplasm (Liang et al., 2006; Meyer & Weihl, 2014; Mueller et al., 2008; Schuberth & Buchber-
ger, 2008). This allows them to hold a firm grip on VCP and to support it during the generation 
of mechanical force by ATP dependent protein extraction from the ER (Hirsch et al., 2009). 
FAF2 was found to be involved in the recently discovered endosome and Golgi-associated 
degradation (EGAD, Schmidt et al., 2019). Accordingly, future studies should consider the pos-
sibility that EVI/WLS can be targeted to the proteasome coming from different organelles than 
the ER. 
However, it cannot be excluded that additional proteins regulate EVI/WLS degradation 
which were not discovered here because of potentially insufficient RNAi mediated knock-down, 
cell type dependency, or variability between biological replicates. Although it is assumed that 
most ERAD related proteins have been identified in yeast and mammals (Christianson & Ye, 
2014), it is impossible to discover novel ERAD associated proteins with a hypothesis driven 
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approach as described here. An unbiased genome-wide screen could potentially identify fur-
ther candidates and add more details to the emerging picture. 
While the ERAD substrate IP3R seems to require a complex of ERLIN2 with ERLIN1 to 
initiate its degradation (Pearce et al., 2007, 2009; Y. Wang et al., 2009), there are also reports 
of ERLIN2 acting independently of ERLIN1, for example during the recognition of HMG-CoA 
reductase (Jo, Sguigna, et al., 2011). Whereas ERLIN2 was identified as a candidate to regulate 
EVI/WLS protein stability, ERLIN1 failed to do so. Furthermore, ERLIN1 did not interact with 
EVI/WLS, although immunoprecipitation experiments confirmed the previously described in-
teraction between ERLIN1 and ERLIN2 (Figures 11,14B,S1). These data indicate that EVI/WLS 
is ubiquitinated and degraded independently of ERLIN1. It is currently unknown if the involve-
ment of ERLIN1 or ERLIN2 depends on properties of the substrate, e.g. general hydrophobicity 
or topology, or additional binding partners that are potentially only present at specific ER sub-
domains. Further studies are required to elucidate this mechanism and the specificity of ER-
LIN2 versus ERLIN1 on EVI/WLS stability. 
Glaeser et al. demonstrated that increased EVI/WLS abundance resulting from the 
knock-down of VCP led to augmented WNT ligand secretion (Glaeser et al., 2018). Hence, it 
will be important in the future to investigate in more detail how these novel components of the 
EVI/WLS ‘destruction complex’ influence cellular WNT secretion and thus WNT signalling in 
general in different cellular models. 
5.1.1   ERLIN2 links EVI/WLS to the Ub machinery 
The presented data indicate an interaction between EVI/WLS and ERLIN2 prior to its ubiquiti-
nation (Figure 21A), suggesting that ERLIN2 is linking EVI/WLS to the ERAD machinery, similar 
to what has been described for HMG-CoA reductase and IP3R (Jo, Lee, et al., 2011; Pearce et 
al., 2007, 2009; Y. Wang et al., 2009). Accordingly, EVI/WLS is the third substrate of regulatory 
ERAD that depends on ERLIN2 for its ubiquitination. Further studies are required to decipher 
the underlying processes of client recognition and to identify additional interaction partners. 
Immunoprecipitation experiments confirmed the interaction of FAF2 and ERLIN2, which 
was reported previously in an extensive screening approach for mapping ERAD component 
interactions (Figure 14, Christianson et al., 2012). Their additional interaction with VCP and 
PORCN indicates either the formation of a large complex at the ER membrane prior to the 
degradation of EVI/WLS or a sequential interaction between these proteins (Figures 13,14). A 
proposed model of this process is depicted in Figure 27. 
 




Figure 27. Proposed sequence of events leading to the extraction of EVI/WLS from the ER membrane 
Side- (left) and top-view (right) of EVI/WLS inserted in the ER membrane. Unubiquitinated EVI/WLS binds ERLIN2 (1), followed by 
its poly-ubiquitination by UBE2J2, UBE2K, UBE2N, and CGRRF1 (2). FAF2 and UBXN4 bind to EVI/WLS and recruit VCP to the 
ER membrane (3). Ubiquitinated EVI/WLS is extracted from the ER membrane by threading it through the lumen of VCP (4). 
However, it is necessary to perform time-resolved experiments to conclusively deter-
mine the order of events at the ER membrane. These kinds of experiments are hindered by the 
constant degradation of EVI/WLS, which obscures a clear-cut starting point as all stages of 
protein translation and degradation are detected at the same time. In the future, these limita-
tions might be overcome by using LGK974 to induce increased EVI/WLS degradation in cells 
with high WNT ligand expression in combination with quantification of Western blot experi-
ments to detect subtle changes over time. 
Furthermore, it will be interesting to analyse how well the described mechanisms are 
conserved in other animals and whether there are parallel mechanisms that are more relevant 
in some organisms than in others. In general, many components of the ERAD machinery are 
conserved from yeast to mammals (Hirsch et al., 2009), and WNT signalling is conserved 
among metazoans (Holstein, 2012), suggesting that the proteins involved in the regulatory 
ERAD of EVI/WLS might also be conserved. 
5.1.2   Is EVI/WLS cleaved and extracted through a channel protein? 
The presented data offers interesting insights into the degradation mechanism of an endoge-
nous substrate of mammalian regulatory ERAD. Still, many open questions remain and espe-
cially the existence of a potential ER membrane channel protein for its dislocation remains 
elusive. Although no such protein could be identified in the screen, this does not exclude that 
one might exist. However, if there was no such channel protein, the alternative could be that 
EVI/WLS would be removed from the ER-membrane by application of brute force generated 
by VCP through the hydrolysis of ATP. Biochemical studies using yeast extracts demonstrated 
the full-length dislocation of the ER-membrane resident isozyme of HMG-CoA after ubiquitina-
tion by Hrd1 and with the help of Cdc48/VCP as energy source. In the same study, the authors 
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showed that Cdc48/VCP and the proteasome, but not Hrd1 as a channel, were required for the 
dislocation of an artificial self-ubiquitinating substrate (SUS) with 8-transmembrane domains 
(Garza et al., 2009). However, it was later discovered that SUS and many other integral mem-
brane ERAD substrates depend on the derlin Dfm1 for their dislocation in yeast (S. Neal et al., 
2018). In general, derlins belong to the rhomboid family, a group of intramembrane proteases, 
which have lost their catalytic activity. Based on recent studies concerning the rhomboid fold 
and its impact on protein diffusion in cellular membranes, it is tempting to speculate that their 
main contribution to ERAD is distorting the lipid bilayer when acting together with channel pro-
teins such as Hrd1 (Kreutzberger et al., 2019; Wu et al., 2020). There is no direct ortholog of 
Dfm1 in mammals and its closest relative is the catalytically active rhomboid protease 
RHBDL4/RHBDD1 (S. Neal et al., 2018). Cleavage by RHBDL4/RHBDD1 is an important step 
in the regulatory ERAD of subunits of the OST complex, underlining the general significance 
of proteolytic processing for ERAD (Knopf et al., 2020). However, recent mass-spectrometry 
analysis of the commonly used cell line HEK293T identified RHBDL4/RHBDD1 as interaction 
partner of ERLIN2 and FAF2, but not of EVI/WLS (Knopf et al., 2020). This is in line with the 
results of my RNAi screen on EVI/WLS abundance, which did not identify RHBDL4/RHBDD1 
as a potential regulator of EVI/WLS stability (Figure 11). Together, these data suggest strongly 
that cleavage by RHBDL4/RHBDD1 is not important for the regulatory ERAD of EVI/WLS. Nev-
ertheless, it is compelling to speculate that the eight-pass transmembrane protein EVI/WLS is 
cleaved within the ER membrane and that the cleaved fragments are then extracted separately. 
Data generated in our lab suggests that EVI/WLS can be proteolytically processed (Kathrin 
Gläser, PhD thesis), but if this occurs in the context of ERAD, or might even be a necessity, 
remains to be elucidated. In addition, no protease has been identified yet that would mediate 
the cleavage of EVI/WLS. 
Overall, it might be possible that not one, but several mechanisms exist in parallel, as 
demonstrated for the prototypic substrate of ERAD, cystic fibrosis transmembrane conduct-
ance regulator (CFTR): single transmembrane domain constructs can be extracted completely 
by VCP, but part of the CFTR proteins were still degraded in a reconstituted cell-free system 
even after the removal of VCP, suggesting VCP-independent ERAD mechanisms (Carlson et 
al., 2006). However, a hitherto undiscovered channel protein and/or potential cleaving enzymes 
seem an elegant and potentially less energy-intensive approach than dislocation of EVI/WLS 
from the ER-membrane just by force generated by VCP. More studies and screening of addi-
tional candidates is required to clarify the underlying mechanisms. 
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5.1.3   Lipid homeostasis is regulated by ERAD components 
The ER is associated with lipid homeostasis, for instance because lipid droplets originate from 
the ER membrane (Olzmann & Carvalho, 2019). Many ERAD-associated proteins have also 
been implicated in lipid droplet biogenesis or turn over, notably ERLIN2, FAF2, UBXN4, and 
VCP (Bersuker et al., 2018; Olzmann et al., 2013; G. Wang, Zhang, et al., 2012). It was even 
proposed that ERAD might preferentially happen at sites of lipid droplet formation and that their 
lipid composition might facilitate the removal of substrate proteins. However, this notion could 
not be confirmed (Christianson & Ye, 2014). Lipid droplets are organelles consisting of a hy-
drophobic core encircled by a phospholipid monolayer (Olzmann & Carvalho, 2019). Hence, 
the localisation of the eight-pass transmembrane protein EVI/WLS to mature lipid droplets is 
rather unlikely from an energy-related perspective. Nevertheless, it is tempting to speculate 
that EVI/WLS is connected to lipid homeostasis or specialised lipid structures, because of its 
interaction with acylated WNT ligands after the transfer of palmitoleic acid by PORCN (Takada 
et al., 2006). It has been demonstrated previously that EVI/WLS, PORCN, and WNTs localise 
to detergent-resistant microdomains with specialised lipid composition in the ER membrane, 
so called lipid rafts (Galli et al., 2016; Zhai et al., 2004). Moreover, studies in Drosophila de-
scribed the dependence of long-range WNT signalling on the lipid raft protein reggie‐1/flotillin‐
2 (Katanaev et al., 2008). Importantly, ERLIN2 is also a major component of lipid rafts (Browman 
et al., 2006) and it will be important to test if ERLIN2 acts as a molecular switch regulating either 
the degradation of EVI/WLS by ERAD or coordinating the events that lead to WNT ligand se-
cretion. ERLIN2 might be involved in both by facilitating crosstalk between proteins and orga-
nelles that harbour EVI/WLS in the presence or absence of WNT ligands, possibly in a PORCN-
dependent manner (Glaeser et al., 2018). 
FAF2 has an important regulatory function for the synthesis of long, unsaturated fatty 
acids by assisting in the VCP- and proteasome dependent degradation of INSIG1. In the ab-
sence of INSIG1, sterol regulatory element-binding protein is activated by proteolysis and me-
diates the transcription of proteins necessary for fatty acid synthesis. In turn, long-chain un-
saturated fatty acids induce the polymerisation of FAF2, thus inhibiting the degradation of IN-
SIG1 and of fatty acid synthesis (H. Kim et al., 2013; J. N. Lee et al., 2010, 2006, 2008). It would 
be interesting to test whether this polymerisation of FAF2 can be mediated by palmitoleic acid 
(C16:1), as well as by oleate (C18:1) and arachidonate (C20:4), which were tested in the study 
by Lee et al., 2010. If yes, this would be exciting to study in the context of EVI/WLS regulation, 
as EVI/WLS might be protected from ERAD by the lipid modification of the WNT ligands. Pal-
mitoleic acid could have a dual function: (i) it could inhibit FAF2 by causing its polymerisation 
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and (ii) its presence on WNT ligands allows their secretion. Of course, several questions have 
to be addressed in the future regarding the localisation of the involved proteins and the delivery 
of lipids to PORCN, WNT, and FAF2. It should also be noted that WNTs reside in the ER lumen 
while FAF2 is attached to the ER membrane from the cytosolic side. 
5.1.4   ERLIN2 and FAF2 are involved in cancer 
Whereas mutations in components of the WNT signalling cascades can be the main drivers of 
malignancies such as colorectal cancer, WNT signalling has rather a modulatory role in other 
tumour entities, for example melanoma (Zhan et al., 2017). FAF2 and ERLIN2 have been impli-
cated in uveal melanoma or breast cancer, respectively, cancer types which are also associ-
ated with deregulated WNT signalling (W. Li et al., 2020; Y. Li et al., 2018; G. Wang, Liu, et al., 
2012; Zhan et al., 2017; Zuidervaart et al., 2007). Only few mechanistic studies analysed the 
functional role of these proteins in tumorigenesis, and they were attributed to a broad range of 
cellular functions, for instance lipid homeostasis, ERAD, or cell cycle regulation (G. Wang, Liu, 
et al., 2012; G. Wang, Zhang, et al., 2012; Xuebao Zhang et al., 2015). It will be interesting to 
test if the underlying mechanisms are connected to the posttranslational regulation of WNT 
secretion and if tumours could be targeted via ERAD. 
In general, ubiquitination, proteasomal degradation, and related processes have been 
implicated in various steps of tumorigenesis of multiple cancer entities, due to their important 
role in many signalling pathways. The described mechanisms are manifold, ranging from reg-
ulating the tumour metabolism to cancer stem cell maintenance, as Ub and related processes 
control protein abundance or act as molecular switches (Deng et al., 2020). In the future, it will 
be important to exploit the specificity of the UPS with regard to the regulation of cellular sig-
nalling to develop novel therapeutic approaches for cancer and other diseases, e.g. by improv-
ing targeted protein degradation through PROteolysis-TArgeting Chimeras (PROTACs, X. Li & 
Song, 2020; X. Sun et al., 2019). 
5.2 UBE2J2, UBE2K, and UBE2N ubiquitinate EVI/WLS 
The E2 Ub conjugating enzyme UBE2J2 and the E3 Ub ligase CGRRF1 have been shown pre-
viously to modify EVI/WLS with Ub, but their knock-down does not completely abolish EVI/WLS 
ubiquitination (Glaeser et al., 2018). This indicates either residual enzyme activity due to in-
complete siRNA-mediated knock-down or that additional E2 and/or E3 proteins ubiquitinate 
EVI/WLS. Here, I show that EVI/WLS is modified by UBE2K with K48-linked Ub (Figures 16,21B) 
and by UBE2N with K63-linked Ub (Figures 18,21C). The yeast homolog of UBE2J2 (Ubc6) 
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was reported to prime substrates with short K11-linked Ub modifications, which are then elon-
gated with K48-linked Ub by different E2s to ensure efficient recruitment of the degradation 
machinery (Mehrtash & Hochstrasser, 2019; Tsuchiya et al., 2018; A. Weber et al., 2016; P. Xu 
et al., 2009). Considering that K11-linked ubiquitination was also found on human EVI/WLS 
(Figure 21A), it is tempting to speculate that UBE2K would elongate these initial modifications 
by UBE2J2 in mammalian cells and allow successful interaction with downstream factors, po-
tentially even without an associated E3 protein (Middleton & Day, 2015; Rodrigo-Brenni & Mor-
gan, 2007; X. Wang et al., 2009). However, it should be noted that IP experiments did not 
confirm an interaction between UBE2K and EVI/WLS (Figure 16D). This might be due to a 
transient interaction between these proteins and/or the stringent cell lysis using Triton X-100, 
which strongly affects the detection of interactions within the ERAD network (Christianson et 
al., 2012). It should be tested whether interaction between EVI/WLS and UBE2K can be ob-
served by using milder detergents for cell lysis, such as digitonin. 
Surprisingly, UBE2G2 was not involved in the ubiquitination of EVI/WLS (Figures 
11,S1), although it was previously connected to the degradation of most other ERAD substrates 
(Leto et al., 2019; Mehrtash & Hochstrasser, 2019). However, only few studies analysed regu-
latory ERAD substrates in great detail and it is conceivable that their ubiquitination mechanism 
differs substantially from the one of misfolded substrates (Printsev et al., 2017). 
5.2.1   The E3 Ub ligase CGRRF1 ubiquitinates EVI/WLS  
Extensive proteomic analyses of ER-membrane associated E3s described CGRRF1, MARCH4, 
and RNF128 as possible candidates to ubiquitinate EVI/WLS (Fenech et al., 2020), but follow-
up experiments only confirmed CGRRF1 (Glaeser et al., 2018). Nevertheless, it is of course 
possible that cytosolic E3s are also involved in the process and screening approaches will be 
necessary to cover the several hundred potential candidates in a systematic way, potentially 
based on known E2/E3 interactions (van Wijk et al., 2009). Beside the effect of cytosolic E3s 
on EVI/WLS protein abundance, their effect on WNT ligand secretion should also be assessed 
in parallel as a potential read-out to determine their involvement in EVI/WLS function. It might 
be worth to investigate MARCH4 and MARCH6 in more detail, possibly in a different cellular 
system, because they affected EVI/WLS in A375 cells to a small degree and MARCH6 is a 
known partner of UBE2J2 (Mehrtash & Hochstrasser, 2019). 
Although SYVN1/HRD1 is highly important for the degradation of many other ERAD 
substrates (Bhattacharya & Qi, 2019), it is apparently not involved in the degradation of 
EVI/WLS. Its knock-down did not regulate EVI/WLS protein levels and there was also no 
 
   5   Discussion 
105 
 
interaction found in IP experiments (Glaeser et al., 2018). Yeast Hrd1 is involved in several 
complexes that mediate the ERAD of ER-luminal or transmembrane proteins (Mehrtash & 
Hochstrasser, 2019). The respective orthologs of components of these SYVN1/HRD1-related 
complexes in the human system (e.g. SEL1L, HERPUD1, or OS9) did also not give strong phe-
notypes in my screen on EVI/WLS protein levels, similar to SYVN1/HRD1 (Figures 11,S1,S2). 
Of course, potential candidates could be missed due to insufficient knock-down. Hence their 
role in EVI/WLS stability could be evaluated again after introducing knock-outs of the respec-
tive gene for example using CRISPR/Cas9 mediated genome engineering. In addition, it might 
be possible that one E3 ligase alone is not sufficient to induce EVI/WLS degradation and that 
instead several E3 ligases might be required to work in concert. It would be possible to perform 
combinatorial knock-down or knock-out experiments to circumvent compensatory mecha-
nisms. 
Additionally, my data did not reveal a specific E3 Ub ligase which cooperates with 
UBE2N to modify EVI/WLS. These results together with published high-throughput studies sug-
gest that the E3 ligase is presumably not an ER-membrane associated protein (Figures 11,S1, 
Fenech et al., 2020b; Glaeser et al., 2018). It should be considered that earlier in-vitro and 
structural studies showed that UBE2N~ubiquitin together with UBE2V2 can adopt an active 
conformation even in the absence of an E3 ligase, suggesting E3-independent Ub chain elon-
gation (McKenna et al., 2001; Pruneda et al., 2011). However, recent sophisticated real-time 
fluorescence resonance energy transfer analysis did not observe Ub transfer events in the 
absence of an E3 (Branigan et al., 2020). 
5.2.2   K63-linked Ub and its possible role in EVI/WLS trafficking 
After associating with WNT ligands in the ER, EVI/WLS shuttles them to the cell surface 
(Bänziger et al., 2006; Bartscherer et al., 2006; Goodman et al., 2006; Routledge & Scholpp, 
2019; J. Yu et al., 2014). Then, EVI/WLS is endocytosed with the help of clathrin and recycled 
back to Golgi and ER in a retromer dependent process (Belenkaya et al., 2008; Port et al., 
2008). If trafficking of EVI/WLS is interrupted, it is transported to the lysosomes for degradation 
(Franch-Marro et al., 2008; Gross et al., 2012; P.-T. Yang et al., 2008). Recently, a study in C. 
elegans found that the knock-out of the K63-specific E2 Ub conjugating enzyme UBC13 also 
disrupted MIG-14/EVI/WLS trafficking and diverted it to lysosomes but they did not investigate 
the ubiquitination status of MIG-14/EVI/WLS (J. Zhang et al., 2018). Here, I demonstrate that 
human EVI/WLS is conjugated with K63-linked Ub chains by UBE2N, the human ortholog of 
UBC13 (Figures 18,21). In humans, the two heterodimers UBE2N-UBE2V1 and UBE2N-
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UBE2V2 have been described to mediate K63-specific ubiquitin linkage. In addition to UBE2N, 
its enzymatically inactive interaction partner UBE2V2 was also required for K63-linked ubiqui-
tination of EVI/WLS (Figure 21). By contrast, the knock-down of UBE2V1 resulted in more var-
iable phenotypes between replicates and requires more in-depth analysis. 
It is exciting to note that the presented data also implies a possible effect of K63-linkage 
on WNT ligand secretion (Figure 18C), in agreement with recent results in worms, where the 
knock-down of UBC13/UBE2N led to defects in Wnt-dependent processes (J. Zhang et al., 
2018). Glaeser et al. also reported increased WNT ligand secretion after the knock-down of 
VCP and the resulting increase of EVI/WLS protein (Glaeser et al., 2018). I did not observe the 
same effect (Figure 18C), most likely due to pleiotropic effects of VCP and the strong effect on 
viability of its knock-down, which is more apparent if the assay is run for longer. Therefore, it is 
possible to observe different effects dependent on the timing of the experiment. In the future, 
it will be important to analyse if increased WNT ligand secretion after depletion of UBE2N or 
UBE2V2 actually results in increased signal transduction in WNT-receiving cells e.g. by TCF-
WNT reporter assays, a notion that was recently challenged in a Drosophila study (Hatori & 
Kornberg, 2020). 
Zhang et al. concluded that ubiquitination by UBC13/UBE2N was important for segre-
gating the retromer and ESCRT-associated microdomains on a common endosome after MIG-
14/EVI/WLS endocytosis to guarantee efficient trafficking in C. elegans (J. Zhang et al., 2018). 
Indeed, it had previously been observed that substrate ubiquitination was important for sorting 
to the SNX3-retromer complex or the ESCRT machinery in yeast (Strochlic et al., 2008) and it 
is in general well established that ESCRT-dependent sorting relies on K63-ubiquitination of the 
cargo (Frankel & Audhya, 2018; Mosesso et al., 2019). However, in the reported cases K63-
linked ubiquitination resulted in lysosomal degradation of the substrates (Cullen & Steinberg, 
2018; Pohl & Dikic, 2019), whereas EVI/WLS seems to be preferentially routed to lysosomes in 
the absence of K63-linkage. Accordingly, intriguing questions arise: why do EVI/WLS protein 
levels increase and not decline after the knock-down of UBE2N if EVI/WLS is delivered to the 
lysosomes? Why does EVI/WLS with K63-linked Ub modification accumulate after the inhibition 
of the proteasome (Figure 21C)? This clearly indicates that EVI/WLS modified with K63-linked 
Ub is degraded by the proteasome and not (only) by lysosomes. It was shown previously that 
EVI/WLS protein levels increase after the inhibition of lysosomes with compounds such as 
bafilomycin A (Glaeser et al., 2018) and it might be interesting to investigate the impact of 
UBE2N on the lysosomal degradation of EVI/WLS. 
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Components of the ESCRT machinery are required for sorting EVI/WLS and WNT lig-
ands to MVBs prior to their release on exosomes (Gross et al., 2012), but intracellular retro-
grade transport of EVI/WLS depends on the retromer complexes. Whether ubiquitination also 
plays a role in the function of retromer is not yet well understood. Stangl et al. reported recently 
that the DUB OTULIN regulated retromer-dependent recycling to the cell membrane, albeit in 
an ubiquitin-independent mechanism (Stangl et al., 2019). Additionally, Hao et al. found that 
K63-linked ubiquitination of the WASH complex regulated F-actin and thus transport by retro-
mer (Y.-H. Hao et al., 2013). Whether any of these mechanisms are involved in the regulation 
of EVI/WLS remains to be analysed. 
Besides retrograde trafficking, K63-linked ubiquitination could also mediate the inter-
nalisation of EVI/WLS from the plasma membrane, which is a well described mechanism for 
the endocytosis of various other proteins (Piper et al., 2014). In this case, removing the K63-
linked ubiquitination should result in the accumulation of EVI/WLS at the plasma membrane in 
the presence of WNT ligands. EVI/WLS surface levels could be tested by surface staining with-
out membrane permeabilisation either directly by fluorescence activated cell sorting or after 
the biotinylation of cell surface proteins and subsequent analysis of EVI/WLS protein levels in 
the surface or intracellular fraction with Western blotting. Using a more advanced approach, it 
might be possible to compare the ubiquitination profiles of EVI/WLS mutant variants that local-
ise either to the plasma membrane (e.g. the Y/AEGL-construct, Gasnereau et al., 2011) or to 
the ER (e.g. after introducing a strong ER-retention motif). Cell fractions could be analysed by 
mass-spectrometry to investigate if the ubiquitination of EVI/WLS is a dynamic process that 
changes according to its intracellular localisation. Importantly, it should be ensured that the 
introduced mutations do not affect possible ubiquitination sites. To gain more insights into the 
possible roles of ubiquitination on EVI/WLS trafficking, it will be important to perform immuno-
fluorescence stainings to investigate the co-localisation of endogenous EVI/WLS with markers 
of the plasma membrane, MVBs, or other organelles after the knock-down of UBE2N. These 
studies should either be performed with tagged proteins or with antibodies that allow the stain-
ing of endogenous EVI/WLS to avoid confounding effects by protein overexpression. 
The involvement of K63-linked Ub in the endocytosis and/or retrograde transport of 
EVI/WLS would imply that it was most relevant in cells with active WNT secretion – otherwise 
EVI/WLS would not localise to the plasma membrane. However, the knock-down of UBE2N led 
to increased EVI/WLS protein levels in HEK293T cells without WNT ligands (Figure 18C). In 
conclusion, many open questions about how UBE2N and K63-linked Ub influence EVI/WLS 
physiology remain, which need to be addressed using additional experiments and with the help 
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of different cellular models. It is likely that the observed phenotypes are results of multiple 
parallel mechanisms and/or indirect effects of the knock-down of UBE2N that are exceedingly 
difficult to disentangle. 
Multiple Ub linkage types present on EVI/WLS provide the opportunity to investigate 
additional layers of its regulation. For example, it has been described that UBE2K together with 
UBE2N builds branched Ub chains with unique downstream signalling properties, such as reg-
ulating NF-κB signalling (Ohtake et al., 2016), and it would be exciting to find such branched 
chains on EVI/WLS as well. It is conceivable that EVI/WLS would be first modified with K63-
linked Ub and only additionally with K48-linked Ub if the protein is destined to be degraded by 
the proteasome (Ohtake et al., 2018). This could be shown indirectly if the knock-down of 
UBE2N resulted in less K48-linked Ub on EVI/WLS, implying that the lack of K63-linked Ub 
chains also led to a reduced availability of sites for K48-linkage. The direct observation of 
branched chains is only possible with mass-spectrometry approaches. However, Ub is usually 
cleaved at R54 between the positions K48 and K63 during routine sample preparation for mass-
spectrometry with trypsin, making it impossible to observe the two branch-points on the same 
peptide (Ohtake et al., 2016). Therefore, either non-trypsin digestion or Ub mutants without 
this cut site are necessary in combination with EVI/WLS protein preparations to directly ob-
serve these modifications using mass-spectrometry. 
5.2.3   Defining the ubiquitination sites of EVI/WLS 
To understand the regulation and the impact of K48- and K63-linked Ub chains on EVI/WLS, it 
is important to determine the ubiquitination sites of EVI/WLS. Publicly available proteomic 
mass-spectrometry data reported several ubiquitination sites in human EVI/WLS, many of them 
within the first luminal loop (Figure 2). At least two records within these datasets found ubiqui-
tination at the positions K61, K208, K217, K410, and K419 (PhosphoSitePlus, Hornbeck et al., 
2015, accessed Oct 2020). Another recently published dataset found an additional ubiquitina-
tion at K12 (Steger et al., 2020). 
However, it is unclear whether this data reflects the whole protein sequence. Some 
ubiquitination sites might not have been identified yet due to their transient nature or because 
EVI/WLS is a multi-pass transmembrane protein and difficult to extract from the membrane. It 
is therefore conceivable that some parts of EVI/WLS are more likely to be recovered using 
mass-spectrometry than others. It is striking that half of the described ubiquitination sites (K61, 
K208, and K217) are at positions that face the ER lumen, but not the cytoplasm or the ubiqui-
tination machinery, according to the structural model of EVI/WLS (Figure 2). Since there is no 
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molecular structure of EVI/WLS available yet, its exact topology and even its number of trans-
membrane domains is still debated (Bartscherer et al., 2006; Jin, Morse, et al., 2010; Korkut et 
al., 2009). Therefore, it should be considered that the described positions might indeed face 
the cytosol and not the ER lumen. However, several lines of evidence contradict this notion: (i) 
two publications performed immunofluorescence staining of V5-tagged EVI/WLS with antibod-
ies targeting the first loop without membrane permeabilisation and found the signal to localise 
either to the plasma membrane (e.g. outside of the cell) or within the Golgi apparatus (e.g. 
luminal) after internalisation (Belenkaya et al., 2008; Franch-Marro et al., 2008). (ii) Immunogold 
staining of electron microscope images using antibodies targeting the loop region also con-
firmed extracellular or luminal localisation (Korkut et al., 2009). (iii) Immunoprecipitation exper-
iments with shortened EVI/WLS constructs demonstrated the localisation of the WNT-binding 
domain within this loop. WNTs are secreted proteins and imported into the ER co-translationally 
(Fu et al., 2009). (iv) N-glycosylation of C. elegans MIG-14/EVI/WLS was found at the amino 
acid positions N158 and N212. These positions are within the loop and their modification infers 
ER localisation. Glycosylation was also predicted for the positions N9 and N345, but their prox-
imity to the ER membrane make an actual modification unlikely due to sterical hinderance (Gly-
coProtDB ID: GPDB0000868, accessed Oct 2020). In conclusion, it is more likely that the lu-
minal positions of EVI/WLS are modified after the respective parts of the protein have been 
extracted from the ER and that the primary ubiquitination sites indeed face the cytoplasm. 
MHC class I heavy chains are also endogenous ERAD substrates that were found to be 
ubiquitinated at ER-facing residues, but not at cytosolic domains. The authors proposed that a 
part of the protein was dislocated before ubiquitination with the help of OS-9, SEL1L and 
SYVN1/HRD1 in a mechanism similar to the retrotranslocation of proteins located entirely 
within the ER lumen. The former luminal domains would then be trapped in the cytosol by 
ubiquitination and the extraction could be completed by VCP (Burr et al., 2013). While this is a 
compelling mechanism that is also supported by recent structural data on the function of yeast 
Hrd1 (X. Wu et al., 2020), there is currently no evidence that supports this hypothesis for 
EVI/WLS as well, especially considering that its dislocation is apparently SYVN1/HRD1 inde-
pendent. 
The predicted primary ubiquitination sites were therefore K410/419. However, expres-
sion of the EVI/WLS-V5 K410/419R mutant variant in HEK293T EVI/WLS knock-out cells did 
not result in a strong upregulation of EVI/WLS protein levels compared to expression of the 
wild type construct (Figure 17), indicating that it is still degraded very efficiently. The strong 
increase of EVI/WLS-V5 K410/419R protein levels after knock-down of VCP additionally 
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suggests that the degradation is mediated via ubiquitination and ERAD, and not by other cellu-
lar degradation pathways (e.g. the lysosomes). This can be due to alternative lysine residues 
that are available for ubiquitination, or it can be a result of ubiquitination of the hydroxylated 
amino acids serine or threonine by UBE2J2 (Cadwell & Coscoy, 2005; X. Wang et al., 2009; A. 
Weber et al., 2016). These oxyester-linked modifications cannot be found with standard mass-
spectrometry approaches because they are pH sensitive and cleaved during routine sample 
preparations; it is therefore not surprising that they do not appear in most proteomic data sets 
(McClellan et al., 2019; A. Weber et al., 2016). Efforts to directly observe non-lysine ubiquitina-
tion on EVI/WLS by comparing high-molecular bands before or after acidic hydrolysis of sam-
ples were unfortunately unsuccessful (data not shown), maybe the effects were concealed by 
the additional presence of pH-insensitive lysine-ubiquitinations. 
Nevertheless, non-lysine ubiquitination could also help to explain why protein levels of 
EVI/WLS-V5 K410/419R were higher than wild type EVI/WLS-V5 after the knock-down of 
UBE2J2 (Figure 17). This observation indicates that the positions K410/419 are indeed im-
portant for ubiquitination. However, they can possibly be functionally replaced by serines or 
threonines in their vicinity in the presence of UBE2J2. In the absence of UBE2J2, the 
K410/419R mutant is not ubiquitinated and degraded efficiently anymore and accumulates. It 
should be noted that the effects of silencing either UBE2K or UBE2J2 do not reflect the strong 
increase of EVI/WLS abundance upon knock-down of VCP, indicating that several additional 
E2 and/or E3 proteins, maybe even in combination, are required for the ubiquitination of 
EVI/WLS. Presumably, this then culminates in the extraction of EVI/WLS from the ER mem-
brane with the help of VCP. Combinatorial knock-down of multiple E2 enzymes will help to 
elucidate the underlying mechanisms and to find potential additionally involved proteins. As 
next steps, it will also be interesting to investigate the presence of non-lysine ubiquitination on 
EVI/WLS by suitable unbiased mass-spectrometry approaches. These require efficient im-
munoprecipitation of either endogenous EVI/WLS or overexpressed EVI/WLS-V5 and custom-
ised sample preparation protocols for mass-spectrometry. It might also be interesting to in-
clude EVI/WLS constructs with multiple mutated ubiquitination sites and depletion of E2 or E3 
proteins in the analysis pipeline. Mutating all possible ubiquitination sites, meaning not only 
lysines but also serines, threonines, and cysteines, would probably result in a malfunctional or 
unexpressed protein and is therefore unlikely to be successful. Nevertheless, it might also be 
interesting to analyse how the lack of ubiquitination sites influence the WNT secretion capacity 
of EVI/WLS to determine their functional relevance. 
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5.3 EVI/WLS is ubiquitinated and degraded in cells with and 
without lipidated WNTs 
It was previously reported that EVI/WLS is a target of regulatory ERAD and that the interaction 
of EVI/WLS with WNT ligands prevented its degradation. This was demonstrated by overex-
pressing WNT ligands in HEK293T cells, a cell line with low endogenous WNT secretion, which 
lead to the stabilisation of EVI/WLS (Glaeser et al., 2018). Here, I show that this effect can be 
reversed by inhibiting PORCN and thus the lipidation of endogenous WNT ligands in A375 
melanoma cells which naturally produce a lot of endogenous WNT5A (Figure 20). LGK974 
treatment decreased EVI/WLS protein levels, but not mRNA expression, compared to DMSO 
control treatment, as EVI/WLS is no longer protected from its degradative fate by the interac-
tion with WNT ligands (Figure 20B,C). The reduced expression of AXIN2 after LGK974 treat-
ment is an indication for decreased canonical/β-catenin dependent WNT-signalling, which can 
be regulated by WNT5A in melanoma cells (Figure 20C, Webster & Weeraratna, 2013). Inhib-
iting the proteasome in addition to LGK974 treatment resulted in an increase of high-molecular 
EVI/WLS bands compared to LGK974 treatment without inhibition of the proteasome, indicat-
ing the presence of ubiquitinated proteins that are no longer degraded. Surprisingly, pro-
teasome inhibition even led to the accumulation of ubiquitinated EVI/WLS in DMSO control 
cells (where lipid-modified WNT ligands are present and actively secreted), indicating a surplus 
production of EVI/WLS and constant turn-over in cells with active WNT signalling (Figure 20D). 
Nevertheless, it should be emphasised that it is difficult to distinguish quantity- from quality-
control ERAD mechanisms in this experiment and it is possible that the ubiquitinated EVI/WLS 
present in the DMSO control after inhibition of the proteasome is indeed misfolded. 
Of the analysed ERAD-associated proteins which could mediate such a ubiquitination 
and degradation in A375 cells, VCP, UBE2J2, and CGRRF1 showed the strongest phenotypes, 
as they did in HEK293T cells (Figure S4, Glaeser et al., 2018). This indicates that the post-
translational regulation of EVI/WLS is conserved between different tissues and developmental 
stages. 
It appears to be a waste of cellular resources to constantly translate and degrade 
EVI/WLS, even in the absence of WNT ligands. Therefore, the question remains why cells would 
have developed such a mechanism. One possible explanation lies in the dynamics of cellular 
signalling: if all proteins necessary for WNT secretion, reception and intracellular signal trans-
duction are present at all times, cells have the ability to react very fast and dynamic to changes 
in WNT ligand expression and signalling without the synthesis of additional proteins. Moreover, 
cells may require a constantly available pool of some proteins for alternative cellular functions, 
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such as β-catenin, which is also involved in adhesive junctions (Peifer et al., 1992). It is con-
ceivable that EVI/WLS also has hitherto undiscovered, WNT-independent functions, as Petko 
et al. described a primate specific splice variant of EVI/WLS that was unable to sustain efficient 
WNT ligand secretion (Petko et al., 2019). However, more research in this area will be neces-
sary in the future to clarify the underlying mechanisms. 
5.4 EVI/WLS protein levels govern melanoma invasiveness 
Malignant melanoma is a skin cancer derived from melanocytes with a very poor prognosis if 
metastasised (Schadendorf et al., 2018). Genetic mutations that drive melanoma development 
and progression are mainly associated with the MAPK signalling pathway (Schadendorf et al., 
2018). Additionally, melanomas also produce a variety of WNT ligands and functional correla-
tions have been established between various WNT pathway components and malignancy (Ga-
jos-Michniewicz & Czyz, 2020). Reduced EVI/WLS protein abundance was detected in human 
melanoma samples compared to healthy skin and nevi and was also associated with metastasis 
formation in a xenograft mouse model (P.-T. Yang et al., 2012). Conversely, WNT5A expression 
is increased in metastatic melanoma compared to non-metastatic lesions and WNT5A is an 
important regulator of melanoma cell invasion (Forno et al., 2008; Weeraratna et al., 2002). 
This controversy is understudied, and it remains unclear how EVI/WLS protein levels are func-
tionally correlated to melanoma invasion, not least due to the lack of reliable cellular models 
for invasiveness that allow the study of multiple conditions in parallel. 
5.4.1 The gelatin degradation assay as an indicator for melanoma cell in-
vasiveness 
One possibility to study cellular invasiveness in-vitro is the gelatin degradation assay, which 
can be used to detect and quantify the proteolytic activity of membrane protrusions in cancer 
cells, so-called invadopodia (Figure 23, Paterson & Courtneidge, 2018). Invadopodia are actin-
based structures that mediate pericellular degradation of the extra-cellular matrix through 
MMPs, such as MMP9 or MMP14 (Jacob & Prekeris, 2015). Importantly, invadopodia and their 
associated proteins, for example SH3PXD2A/TKS5 or CDC42, have been implicated in mela-
noma cell invasion or were found to be overexpressed in melanoma (Iizuka et al., 2016; H. Lu 
et al., 2016; Stengel & Zheng, 2011; Jianwei Sun et al., 2014). MMP14 expression was upreg-
ulated in BRAF p.V600E or NRAS p.Q61R mutant melanoma cell lines compared to cell lines 
without these mutations (Bloethner et al., 2005) and dysregulated MAPK signalling increased 
MMP9 expression (Napoli et al., 2020). Mechanistically, BRAF p.V600E signalling was impli-
cated in the secretion of MMPs and the regulation of actin dynamics through the 
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phosphorylation of cortactin and components of the exocyst vesicle secretion complex by ERK 
(Clark & Weaver, 2008; H. Lu et al., 2016). 
The role of WNT signalling in melanoma and invadopodia formation is not well under-
stood, albeit several studies positively correlated components of the non-canonical WNT/Ca2+ 
signalling pathway, e.g. PKC, CDC42, or Ca2+ release from the ER, to melanoma cell invasion 
(Nakahara et al., 2003; Jianwei Sun et al., 2014; Weeraratna et al., 2002). Furthermore, stabili-
sation of β-catenin promoted invadopodia formation in melanoma cells (Grossmann et al., 
2013) and WNT5A and ROR2 signalling was associated with increased invadopodia activity in 
other cancer entities, such as osteosarcoma (Enomoto et al., 2009). 
5.4.2 WNT11 is secreted independent of PORCN activity and involved in 
invasion 
After setting up the gelatin degradation assay, I established an analysis pipeline to quantify the 
invasive capacity of melanoma cells (Figure 23). To test how inhibition of WNT secretion could 
influence melanoma cell behaviour, I treated RPMI7951 melanoma cells with the PORCN in-
hibitor LGK974 (Figure 24). Western blot analyses confirmed that WNT5A was no longer se-
creted after LGK974 treatment and, accordingly, gelatin degradation by these cells was re-
duced, while migration and proliferation was not significantly affected (Figure 24,28). The pro-
tein levels of EVI/WLS were reduced compared to the DMSO treated control, presumably due 
to the lack of interaction with acylated WNT ligands, as discussed earlier for the cell line A375 
(see 5.3). As a note on the side: this reduction of EVI/WLS protein levels is difficult to recapit-
ulate using siRNAs against WNTs, as melanoma cells express several different WNT ligands 
and it would therefore presumably be necessary to perform combinatorial knock-downs of 
WNTs to see an effect on EVI/WLS abundance. 
Surprisingly, WNT11 was still detected in the supernatant of LGK974 treated cells, al-
beit in lower amounts than in DMSO control cells (Figure 24C). This suggests that WNT11 can 
be secreted independent of PORCN activity. This exciting novel insight is currently under in-
vestigation in various model systems in our lab (Oksana Voloshanenko, personal communica-
tion). It seems as if a part of the WNT11 pool can be secreted independent of PORCN and 
EVI/WLS and is differentially modified, which would also explain the difference in size visible in 
Figure 24C. The two differentially secreted fractions of WNT11 seem to induce distinct down-
stream signalling in their target cells, as EVI/WLS-dependent WNT11 induces non-canonical 
effects like WNT5A and EVI/WLS-independent WNT11 apparently loses its non-canonical char-
acter. It is important to analyse if and how the two subpopulations influence melanoma cell 
invasiveness, e.g. with the help of mutant constructs that can only be secreted EVI/WLS 
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independently or vice versa. Once the two subpopulations and their regulation are better char-
acterised, it will also be interesting to analyse melanoma patient samples to see if they have 
relevant functions in-vivo. 
 
Figure 28. Summary of the observed phenotypes using the gelatin degradation assay 
Compilation of different melanoma cell treatments and their effect on EVI/WLS, WNT5A, and WNT11 protein levels, as well as 
gelatin degradation/invasive capacity (green squares). Upward pointing white arrows indicate increased, downward white arrow 
decreased degradation compared to the control. Data summarised from Figures 24, 25, and 26. 
So far, only limited information on WNT11 and melanoma is available, hence, I exam-
ined the effect of WNT11 knock-down and overexpression on gelatin degradation (Figures 25, 
26). The observed phenotypes are summarised in Figure 28. Surprisingly, the knock-down of 
WNT11 resulted in a significant upregulation of invasive capacity in RPMI7951 and WM793 
melanoma cells, whereas its overexpression had the opposite effect in RPMI7951 cells (Figures 
25,26,28). This was interesting, considering that it counteracts the effects of WNT5A, the 
knock-down of which reduced the invasive capacity of RPMI7951 and WM793 cells (Figure 
26). WNT5A overexpression had no effect, presumably because RPMI7951 cells already se-
crete a lot of WNT5A and signal transduction is already at its maximum (Figures 26,28). 
The role of WNT11 in melanoma was not yet studied in-depth, until a recent paper 
described its involvement in tumour initiation and invasion (Rodriguez-Hernandez et al., 2020). 
They report that WNT11 promotes an amoeboid phenotype in melanoma cells via FZD7 and 
DAAM1. Amoeboid cells are found at the invasive fronts of mouse and human melanomas and 
in metastasis. Their study revealed that siRNA-mediated knock-down of WNT11 in A375M2 
and WM1361 melanoma cells decreased invasion in a 3D assay. In contrast, I showed that 
transfection of siWNT11 induced degradation of extracellular matrix. While the applied assays 
reflect different aspects of the invasive process and different cell lines were used, it is also 
obvious that their invasion assay is very variable, similar to the gelatin degradation assay. Pre-
sumably, their data would profit from more replicates and a stringent statistical analysis. It 
should also be mentioned that there were differences in siRNA knock-down efficiencies 
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comparing the two studies. They still observed 40 % to 50 % of remaining WNT11 mRNA ex-
pression, whereas in my experiments efficiency nearly reached 100 % as WNT11 mRNA levels 
after knock-down were often below detection limit (Figure S5). Furthermore, it would be im-
portant to demonstrate that the observed effects depend on the interaction between WNT11 
and FZD7, and not on the presence of other WNTs in these cell lines, for example WNT5A. 
Overall, further studies are required to investigate the underlying mechanisms and differences, 
but nevertheless the work by Rodriguez-Hernandez et al. provides an important additional link 
between non-canonical/β-catenin-independent WNT signalling and melanoma tumourigenesis. 
In general, it cannot be dismissed that both WNT5A and WNT11 play a role in mela-
noma pathogenesis, given their important role in WNT/PCP signalling and the migration of neu-
ral crest derived cells, such as melanocytes (De Calisto et al., 2005; Y. Yang & Mlodzik, 2015). 
In future studies, it will be important to determine if their apparently opposite effects on mela-
noma cells in the gelatin degradation assay depend on varying levels of secretion, e.g. due to 
differential PTMs (Yamamoto et al., 2013) and their interaction with EVI/WLS, or their engage-
ment with different receptors and further intracellular downstream signal transduction in the 
WNT receiving cell. 
WNT11 was also identified as a tumour suppressor in hepatocellular carcinoma (To-
yama et al., 2010), which would possibly reflect its role in melanoma indicated by my data. 
WNT11 expression was variable and, in most cases, lower than WNT5A expression in human 
melanoma patient samples in the TCGA datasets (309/367 patients, TCGA Research Network, 
accessed Mar 2019). However, WNT11 protein levels and their signalling capacity might be 
regulated at other levels, for example through post-translational mechanisms or by the availa-
bility of receptors at the target cell.  
WNT signalling is an important way of communication between tumour cells and their 
microenvironment. Accordingly, tumour-intrinsic WNT/β-catenin signalling regulates T cell in-
filtration in melanoma (Spranger et al., 2015). Additionally, WNT5A was shown to promote the 
release of immunosuppressive exosomes from melanoma cells in a Ca2+ and CDC42-depent 
mechanism (Ekström et al., 2014). Therefore, and especially in the light of the recent study that 
correlated WNT11 to an invasive cell phenotype (Rodriguez-Hernandez et al., 2020), it will be 
important to characterise WNT-dependent melanoma cell plasticity in the presence of other 
cell types that constitute the microenvironment. WNT11 might be derived from cells in the 
microenvironment and not tumour cells themselves in an in-vivo setting. The expression of 
WNT11 might also be restricted to certain small subpopulations of tumour cells and would 
therefore not be detectable in bulk analysis. Single cell sequencing of tumour and 
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microenvironment might be helpful to determine which cells produce WNT11 and which cells 
carry the according receptors. Furthermore, these results should be confirmed with animal 
models, to prove the in-vivo relevance of WNT11 on melanoma cell invasiveness and migration 
and to evaluate whether the insights gained with the gelatin degradation assay can be trans-
ferred to in-vivo conditions. 
5.4.3 EVI/WLS protein levels regulate melanoma invasiveness 
The effects of knock-down and overexpression of WNT5A and WNT11 (Figures 25,26) are 
coherent within themselves (Figure 28). Unexpectedly, EVI/WLS downregulation increased 
gelatin degradation by melanoma cells, suggesting that lower secretion of WNT ligands makes 
melanoma cells more invasive. In contrast, LGK974 treatment showed a similar effect on WNT 
ligand secretion as the knock-down of EVI/WLS, but decreased gelatin degradation. These 
apparently contradicting phenotypes could be due to differences in WNT ligand acylation, con-
sidering that PORCN is still active in the siEVI/WLS transfected cells, or be due to other WNT 
ligands that the cells might produce and which I did not analyse in these experiments. It should 
be noted that a recent study suggested acylation and secretion independent, cell autonomous 
signalling by WNT3A and WNT4 in several human cancer cell lines (Rao et al., 2019), but fur-
ther studies are required to evaluate this hypothesis. Nevertheless, it should be considered 
that there are possible additional layers of WNT secretion-dependent regulation that remain 
hitherto undiscovered. To gain more insights into the mechanism and to determine how the 
observed phenotypes are connected, it will be important to perform combinatorial knock-
downs or overexpression of EVI/WLS, WNT11, and WNT5A (and possible further candidates). 
These epistasis experiments can clarify if the observed effects are independent or if they act 
in parallel. 
The enhancement of the cells’ invasive capacity after EVI/WLS knock-down is, how-
ever, in line with a previous study correlating reduced EVI/WLS abundance to increased me-
tastasis formation in a xenograft mouse model (P.-T. Yang et al., 2012). The authors explained 
this effect with the EVI/WLS and WNT ligand secretion-dependent activation of WNT/β-catenin 
signalling in melanoma cells, which inhibited melanoma cell proliferation and metastasis. How-
ever, the general role of β-catenin and its regulation in melanoma pathogenesis is under con-
siderable debate and studies showed both its degradation and its stabilisation as response to 
WNT5A signalling (Gajos-Michniewicz & Czyz, 2020; Grossmann et al., 2013). By contrast, I 
did not detect changes in gelatin degradation capacity or in proliferation after knock-down of 
CTNNB1 and cellular migration was slightly enhanced after β-catenin depletion, while it was 
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decreased after knock-down of EVI/WLS (Figure 25). Therefore, my data does not indicate that 
EVI/WLS would regulate melanoma invasiveness through β-catenin, as it was suggested by a 
previous study (P.-T. Yang et al., 2012). There are model and cell line specific differences to 
be considered, such as the variable expression status of WNT receptors in different melanoma 
cell lines, and more experiments are needed to clarify the correlations. 
5.4.4 EVI/WLS and WNT11 induce phenotype switching in melanoma cells 
The knock-down of EVI/WLS or WNT11 induced a profound decrease in proliferation of WM793 
cells compared to transfection of all other siRNAs (Figure 25E). Together with the increased 
gelatin degradation observed upon silencing of EVI/WLS or WNT11 (Figure 25A,B;C), this 
shows that EVI/WLS and WNT11 protein levels can induce switching between a more prolifer-
ative and a more invasive phenotype in these cells. Phenotype switching is an important feature 
of melanoma cells that has emerged as crucial regulator of tumour progression and metastasis 
(Rambow et al., 2019). While it resembles processes involved in epithelial-to-mesenchymal 
transition, it is called differently because melanocytes are not epithelial (Rambow et al., 2019). 
This change in phenotypic characteristics of melanoma cells due to external cues, e.g. hypoxia, 
is primarily associated with varying expression levels of MITF, a key transcriptional regulator in 
melanocytes (Hoek et al., 2006; Kawakami & Fisher, 2017; Michael P. O’Connell et al., 2013; 
Rambow et al., 2019). MITF is not only transcriptionally regulated by WNT/β-catenin signalling, 
but MITF can also interact with β-catenin to induce transcription of target genes (Gajos-Mich-
niewicz & Czyz, 2020). Furthermore, canonical/β-catenin-dependent signalling by WNT3A was 
shown to stabilise MITF post-translationally via the inhibition of its phosphorylation by GSK3 
and the WNT/STOP pathway (Ploper et al., 2015). Conversely, expression of MITF and its target 
genes is downregulated by WNT5A and they are, accordingly, less expressed in melanoma 
cells with an invasive phenotype and high WNT5A expression (Dissanayake et al., 2008; Hoek 
et al., 2008, 2006; Widmer et al., 2012). Albeit my data and previous work by others demon-
strate an important contribution, it remains largely unknown how WNT11, EVI/WLS, and WNT 
secretion are tied to this intricate signalling network. 
A recent review of the existing data on phenotypic plasticity in melanoma suggests that 
the current model should be revised to include many more intermediate stages between the 
‘proliferative – MITF high’ and ‘invasive – MITF low’ state (Rambow et al., 2019). These inter-
mediate states most likely do not represent cells that are transitioning between stages but have 
distinct and probably stable phenotypes. It is likely that many of these states exist in parallel 
and exert different functions in-vivo, for example one could envision that one subpopulation is 
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more proliferative, while another is prone to metastasise, and a third primarily regulates the 
tumour microenvironment. However, this complexity cannot be reflected by single cell lines, 
hence, it will be exciting to further disentangle the WNT-dependent effects on phenotypic di-
versity of melanoma cells. The multi-layered reciprocal regulation of MITF-dependent tran-
scriptional networks and WNT signalling suggests melanocyte lineage-specific, dynamic ge-
netic interactions (Billmann et al., 2018; Rauscher et al., 2019). In the future, it will be important 
to further disentangle this intricate network by analysing melanoma subpopulations in combi-
nation with genetic perturbations of WNT signalling effectors in multiple cellular models, po-
tentially using single-cell sequencing approaches. 
5.4.5 MAPK signalling cooperates with WNT signalling 
Melanoma tumorigenesis is mainly associated with an overactivation of the MAPK signalling 
pathway and the most common driver mutations affect BRAF p.V600 and NRAS p.Q61 (Hodis 
et al., 2012). The BRAF p.V600E mutation was found to promote invadopodia formation and 
invasion in melanoma cells (H. Lu et al., 2016). Notably, melanoma cells with an invasive, 
WNT5A-associated phenotype show decreased sensitivity to BRAF inhibitors and a high ex-
pression of WNT5A correlated with reduced clinical response in melanoma patients treated 
with the BRAF inhibitor vemurafenib (Anastas et al., 2014; Michael P. O’Connell et al., 2013). 
Diverse interactions of the MAPK and WNT/β-catenin signalling pathways in melanoma have 
been described, which most likely depend on tumour stage and genetic background of the 
samples (Gajos-Michniewicz & Czyz, 2020; Zhan et al., 2017). In colorectal cancer, MEK1/2 
inhibition downstream of BRAF induced canonical WNT signalling and stem cell plasticity (Zhan 
et al., 2019), underlining the cooperation of both pathways in other tumour entities as well. 
This data shows how important it is to consider the interactions between different sig-
nalling pathways, especially in a tumour as heterogenous and adaptable as melanoma. Detailed 
and comprehensive understanding of the underlying characteristics of the cancer genome and 
posttranslational regulatory mechanisms are required for the development of novel treatment 
approaches and they can pave the way for combinatorial therapies. Accordingly, it is important 
to extend the insights gained in this thesis by additional studies, not only focusing on WNT but 
especially on the interactions of WNT signalling with other pathways. However, since these 
kind of experiments with potentially hundreds of conditions are difficult to perform in-vivo, 
adapting the gelatin degradation assay to fit a large-scale, plate-based format with an auto-
mated analysis pipeline might contribute to perform genetic interaction screens with a func-
tional read-out in-vitro (Quintavalle et al., 2011). 
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5. 5 Conclusions and future perspectives 
The regulation of protein abundance is a major effect of signal transduction pathways and im-
portant for cellular homeostasis. Various diseases are associated with uncontrolled protein 
synthesis or degradation, among them many cancers. Several components of the WNT signal-
ling pathways are known to be post-translationally regulated with important consequences for 
development and tumourigenesis (Zhan et al., 2017). 
Here, I investigated how the ER-membrane associated protein EVI/WLS, a crucial me-
diator of WNT ligand secretion, is ubiquitinated and delivered to the proteasome. Based on my 
data, I propose a model wherein EVI/WLS interacts with ERLIN2 before it is ubiquitinated by 
UBE2K and UBE2N, as well as by UBE2J2 and CGRRF1. Then, the ER-membrane anchored 
proteins FAF2 and UBXN4 bind to ubiquitinated EVI/WLS and recruit the cytosolic ATPase VCP 
to the ER-membrane. FAF2 and UBXN4 support VCP during the membrane extraction of 









A better understanding of these processes helps to gain insights into how the degra-
dation of mature, properly folded ER-associated proteins can be achieved in general in human 
cells. In the future, it will be important to correlate these findings to substrates of regulatory 
ERAD in other signalling pathways, for example EGFR, which is also ubiquitinated by CGRRF1 
(Y.-J. Lee et al., 2019). It is likely that some regulators of EVI/WLS protein stability are still 
undiscovered and an unbiased, genome-wide screen could not only shed light on the pro-
cesses involved in EVI/WLS degradation, but potentially also discover novel, hitherto unknown 
Figure 29. Summary of the ubiquitination and degradation of EVI/WLS 
It was known previously that EVI/WLS is ubiquitinated by UBE2J2 and CGRRF1 and extracted from the endoplasmic reticulum 
(ER) membrane with the help of VCP (left). My thesis provided evidence that ERLIN2 is an important link between EVI/WLS and 
other ERAD components and potentially helps to recruit the ubiquitination machinery, consisting at least of UBE2K, UBE2N, 
UBE2J2, and CGRRF1. Poly-ubiquitinated EVI/WLS interacts with FAF2 and UBXN4, which recruit VCP to the ER membrane, 
resulting in the dislocation and eventually the proteasomal degradation of EVI/WLS. 
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mediators of ERAD. Furthermore, questions regarding the sites of EVI/WLS ubiquitination, the 
presence of branched Ub chains, or non-lysine ubiquitination remain open and further studies 
using mass spectrometry-based approaches will be needed to address them. Using these 
techniques, it might be possible to discover additional Ub-like proteins that are involved in the 
post-translational regulation of EVI/WLS. These insights will not only lead to a better under-
standing of the posttranslational regulation of EVI/WLS abundance, and thus WNT signalling 
itself, but will be important to develop novel treatment options for WNT-related diseases. 
EVI/WLS protein levels are dysregulated in human malignancies, for example in colo-
rectal cancer or cutaneous melanoma (Glaeser et al., 2018; P.-T. Yang et al., 2012), and it is 
necessary to better understand its relation to tumour progression. Hence, it is important to 
further examine the role of its ‘destruction complex’ in cancer and cellular invasiveness. As a 
first step, the gelatin degradation assay could be used to analyse the effects of knock-down of 
ERLIN2, FAF2, UBXN4, UBE2K, and UBE2N on the invasive potential of melanoma cells. Later, 
it will be important to extend insights generated in this thesis and by others to other cancer 
entities and to non-malignant settings to investigate how well the processes are conserved 
between tissues and other organisms. It will also be necessary to conclusively clarify to what 
extend ubiquitination of EVI/WLS regulates WNT ligand secretion in different systems and if 
this affects canonical or non-canonical WNT ligands differently. 
To better understand how EVI/WLS and other WNT signalling components affect mel-
anoma cell invasiveness, I used the gelatin degradation assay as an in-vitro tool to visualise 
cellular proteolytic activity. Thus, I provided evidence in melanoma cells that EVI/WLS and 
WNT11 are involved in the remodelling of the microenvironment. Since my data indicate op-
posite effects of the two non-canonical WNT ligands WNT5A and WNT11 in melanoma pathol-
ogy, epistasis experiment should be performed to elucidate the connection between the ob-
served phenotypes and possibly also to examine how they are linked to MITF expression and 
phenotype switching. If the effect of WNT11 can be validated in these studies, it will be im-
portant to use animal models to further analyse how it influences melanoma malignancy in-vivo 
and the expression of WNT11 should be better characterised in patient samples. Here, it will 
be important to consider the presence of multiple tumour cell subpopulations, as WNT11 might 
only be relevant for some of them. In this case, single cell sequencing techniques will help to 
disentangle WNT11 producing and receiving cells. 
In this context, the lipidation independent secretion of WNT11 from melanoma cells that 
I observed is of upmost importance and it is necessary to further characterise the mechanisms 
of PORCN and EVI/WLS-independent WNT ligand processing. It will be interesting to elucidate 
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the mechanism of this alternative secretion route, to investigate how well it is conserved across 
organisms, and how it influences the function of WNT ligands. These analyses will also further 
the understanding of how posttranslational regulation influences the WNT signalling pathways. 
Importantly, many compounds targeting WNT signalling in clinical trials affect the classical WNT 
secretion route. It should be clarified if this treatment could potentially aggravate melanoma 
cell invasiveness by promoting the PORCN or EVI/WLS-independent secretion of WNT ligands 
with potentially carcinogenic potential. 
In conclusion, EVI/WLS is a substrate of ERAD in cells with and without endogenous 
WNT ligand expression and its ubiquitination is potentially important for WNT ligand secretion. 
EVI/WLS abundance also regulates many human diseases. In the future, it will be important to 
better characterise the underlying processes and relate them to cancer progression and po-
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6.4.1   Abbreviations 
Table 21. Abbreviations (Abbr.) 
Abbr. Designation 
Abbr. Abbreviations 
ADP Adenosine diphosphate 
AIDA AXIN interactor, dorsaliza-
tion-associated protein  
AMFR/ 
GP78 
Autocrine motility factor re-
ceptor 
AMP Adenosine monophosphate 
AP-2 Adaptor protein 2  
APC Adenomatous polyposis coli  
APF-1 Active principle of fraction 1 
ARF ADP-ribosylation factor  
Asi Amino acid sensor-inde-
pendent 
ATCC American Type Culture Col-
lection 
ATF2 AMP-dependent transcrip-
tion factor 2 
ATG Autophagy related genes 
ATP Adenosine triphosphate  
ATP9A Probable phospholipid-
transporting ATPase IIA 
ATXN3 Ataxin 3 
AXIN Axis inhibition protein  
BAG6 BCL2-associated athano-
gene 6 
BCA Bicinchonic acid 
BCL9 B-cell lymphoma 9  
BiP Binding ig protein 
Bp Base pairs 
BSA Bovine serum albumin 




CBL Casitas B-lineage lym-
phoma proto-oncogene  





cDNA Complementary DNA 
CELSR Cadherin EGF LAG seven-
pass G-type receptor  
CFTR Cystic fibrosis transmem-
brane conductance regula-
tor 
CGRRF1 Cell growth regulator with 
RING finger domain 1 
CHX Cycloheximide 
CK Casein kinase 
CLR Calreticulin 
CNX Calnexin 
COP Coat protein complex 
Cq Quantification cycles 
CRD Cysteine-rich domain 
CRISPR Clustered regularly inter-





CTNNB1 β-catenin gene 
Ctrl Control 
Cue1 Coupling of Ub conjugation 
to ER degradation 1 






DKFZ German Cancer Research 
Center 
DKK Dickkopf 
DMEM Dulbecco’s modified Eagle’s 
medium 
DMSO Dimethyl sulfoxide 
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DNA Deoxyribonucleic acid 
Doa10 Degradation of α2 protein 
Dr. rer. 
nat. 
Doctor rerum naturalium 
DTT Dithiothreitol 
DUB Deubiquitinating enzyme 
DVL Dishevelled 





e.g. Exempli gratia, for example 
EGAD Endosome and Golgi‐asso-
ciated degradation 
EGF Epidermal growth factor 
EGFR Epidermal growth factor re-
ceptor  
ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ERGIC2 ER-Golgi intermediate com-
partment protein 2 
ERK Extracellular signal-regula-
ted kinase 
ERLEC1 ER lectin 1 
ERLIN ER lipid raft associated 
ESCRT Endosomal sorting com-
plexes required for 
transport 
EVI Evenness interrupted 
FAF2 Fas associated factor family 
member 2 
FCS Fetal calf serum 
FZD Frizzled 
G protein Guanine nucleotide-binding 
protein 
GPCF Genomics and Proteomics 
Core Facility  
GRB2 Growth factor receptor-
bound protein 2 
GSK3 Glycogen synthase kinase-3 
gt Goat 
HECT Homologous to E6AP car-
boxy-terminus  
Abbr. Designation 
HEK Human embryonic kidney 
HER2 Human epidermal growth 
factor receptor 2 
HERPUD Homocysteine inducible ER 
protein with Ub like domain 
HMG-CoA β-hydroxy β-methylglutaryl 
coenzyme A 
HOPS Homotypic fusion and pro-
tein sorting 
Hrd HMG-CoA reductase degra-
dation protein 
SYVN1 Synoviolin 1 
HRP Horse radish peroxidase 
HSC70 Heat shock protein 70 kDa 
ID Identifier 
IF Immunofluorescence 
IgG (H+L) Gamma immuno-
globins heavy and light 
chains 
ILV Intraluminal vesicles 
INSIG Insulin-induced gene 1 
IP Immunoprecipitation 
IP3 Inositol 1,4,5-trisphosphate  
IP3R IP3 receptor 
JNK JUN N-terminal kinase  
kDa Kilodalton 
KO Knock-out 
LB Lysogeny broth 
LEF Lymphoid enhancer factor  
LGR4/5 Leucine-rich repeat contain-
ing G protein-coupled re-
ceptor 4/5 
LRP5/6 Low-density lipoprotein-re-
ceptor-related proteins 5/6  
MAPK Mitogen-activated protein 
kinase  
MARCH Membrane associated 
RING-CH-type finger 
MHC Major histocompatibility 
complex 
MIQE Minimum Information for 
Publication of RT-qPCR Ex-
periments 
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MRH Mannose 6-phosphate re-
ceptor homology  
ms Mouse 
MVB Multivesicular body 
NA Not applicable 
NEDD8 Neural precursor cell ex-
pressed developmentally 
down-regulated protein 8  
NEM N-ethylmaleimide 
NFAT Nuclear factor of activated T 
cells 
NGLY N-Glycanase 1 
NLK Nemo-like kinase  
NPLOC4 Nuclear protein localization 





ORF Open reading frame 
OS9 Osteosarcoma 9, ER lectin 
OST Oligosaccharyltransferase 
p. Protein sequence 
PBS Phosphate buffered saline 
PCP Planar cell polarity 
PCR Polymerase chain reaction 
PD-1 Programmed cell death pro-
tein 1 
PDB Protein data bank 
PD-L1 Programmed cell death lig-
and 1  
PFA Paraformaldehyde 
pH Pondus Hydrogenii 
PhD Doctor of Philosophy 
PIP2 Phosphatidylinositol-4,5-
bisphosphate 
PK Prickle-like protein  
 
Abbr. Designation 
PKC Protein kinase C 
PLC Phospholipase C 










PTK Protein tyrosine kinase 7 
PTM Post-translational modifica-
tions  
RAB RAS-associated binding  
RAD23 RAD23 homolog, nucleotide 
excision repair protein 
RAS Rat sarcoma 
rb Rabbit 
RBR RING between RING  
RHBDD Rhomboid domain contai-
ning 1 
Rho RAS homolog family 
RING Really interesting new gene 
RNA Ribonucleic acid 
RNF RING finger protein 
ROCK Rho-associated protein ki-
nase  
ROR Receptor tyrosine kinase 
like orphan receptor 
RPMI Roswell Park Memorial Insti-
tute 
RSPO R-Spondin  
RT-qPCR Reverse-transcription quan-
titative PCR 
RYK Receptor like tyrosine 
kinase 
S.O.C. Super optimal broth with ca-
tabolite repression 
SAR1 Secretion associated RAS 
related GTPase 1 
SDS Sodium dodecyl sulfate 
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SEL1L Suppressor of lin-12-like 
protein 1 




SH3 and PX domains 2A 
siRNA Small interfering ribonucleic 
acid 
SNARE Soluble N-ethylmaleimide-
sensitive factor attachment 
protein receptor  
SNX3 Sorting nexin 3 
SOST Sclerostin 
SPP Signal peptide peptidase 
SUMO Small Ub-like modifier  
SUS Self-ubiquitinating substrate 
SWIM Secreted wingless-interact-
ing molecule 
TBS Tris-buffered saline 
TBST TBS with Tween-20 
TCEP Tris-(2-carboxyethyl)-phos-
phin 
TCF T cell factor  
TCGA The Cancer Genome Atlas 
TCRα T cell receptor α  
TERT Telomerase reverse-tran-
scriptase  
TLE Transducin-like enhancer 
protein 
TMED Transmembrane p24 traf-
ficking proteins 
TMUB1/2 Transmembrane and Ub like 
domain containing 1/2 
TNF Tumour necrosis factor  
TRAF6 TNF receptor-associated 
factor 6 
TRC35 Transmembrane domain 









UBAC2 UBA domain containing 2 
UBC Ub-conjugating domain 
UBD Ub-binding domain 
UBE2 Ub conjugating enzyme E2 
UBE4B Ubiquitination factor E4B 
UBQLN2 Ubiquilin 2 
UBX Ubiquitin regulatory X 
UBXN4 UBX domain protein 4 
UBXN6/ 
UBXD1 
UBX domain protein 6 
UFD1 Ub recognition factor in E-
RAD 1 
ULK1 Unc-51-like kinase 1  
UPL Ub-protein ligase 
UPS Ub-proteasome system  
USA United States of America 
Usa1 U1 SNP1-associating pro-
tein 1 
USP Ub-specific protease 
UV Ultraviolet 
VANGL Vang-like protein  
VCP Valosin-containing protein 
VCPIP1 VCP interacting protein 1 
VIM/VBM VCP-interacting/binding mo-
tifs  
WB Western blot 
Wg Wingless 
WGA Wheat germ agglutinin  





tion of proteins 
YOD1 YOD1 deubiquitinase 
ZNRF3 Zinc and RING finger 3  
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6.4.2   Parameter & Units 
Table 22. Parameter & Units 
Parameter Unit Symbol Comments 
Amount of substance Mole mol 1 mol = 6.022x 1023 particles 
Atomic mass Dalton Da No SI unit, 1 Da ~ 1.660 538 92 x 10−27 kg 
Centrifugation force Gravity x g Here: used to indicate centrifugation speeds  
Concentration Molarity M Mol/l or g/l 
Enzyme activity Unit U Amount of enzyme converting 1 µl sub-
strate/min 
Mass Gram g - 





S Relates to a particle's size 
Temperature Kelvin K 1 K = 273 °C; RT = 20 - 25 °C  
Time Second s, sec 1 day (d) = 24 h; 1 hour (h) = 60 minutes 
(min); 1 min = 360 s  
Voltage Volt V - 
Volume Liter l 1 l = 1 dm³ 
 
Table 23. Amino acids and IUPAC codes              Table 24. Nucleotides 
 
  
      Table 25. Prefixes for units 




Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Tyr W 
Tyrosine Tyr Y 
Valine Val V 













giga G 109 
mega M 106 
kilo k 103 
deci d 10-1 
centi c 10-2 
milli m 10-3 
micro µ 10-6 
nano n 10-9 
pico p 10-12 
I 
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Supplementary Figure S1. Western blots to Figure 1 ‘siRNA-based mini-screen identifies novel candidates involved in the 
degradation of EVI/WLS in HEK293T cells’ 
EVI/WLS protein levels were analysed after siRNA mediated knock-down of target genes. Increased EVI/WLS protein levels com-
pared to siControl/siLuciferase treatment indicated the candidate’s possible involvement in EVI/WLS’s ERAD p rocess. HEK293T 
wild type cells were treated with the indicated siRNAs for 72 h. Then, total cell lysates were analysed by SDS-PAGE and Western 
blotting for the specified proteins. VINCULIN and β-ACTIN served as loading controls. Untreated samples or samples treated with 
transfection reagent only (mock), non-targeting siRNA (siControl), or siLuciferase were used as negative control. siVCP was used 
as positive control. The experiments shown in A & B were performed by Julie Haenlin, the experiment shown in C was performed 
by Annika Lambert. kDa = kilodalton 
 




Supplementary Figure S2. The knock-down of DERL3, UBE4A, UBAC2, TMUB2, NGLY1, RAD23B, SEL1L, or USP50 by sin-
gle siRNAs did not show consistent upregulation of EVI/WLS 
EVI/WLS protein levels did not differ from the control or varied between biological replicates and single siRNAs against the candi-
dates investigated in A - H. HEK293T wild type cells were treated with the indicated siRNAs for 72 h. Each gene’s mRNA was 
targeted by either single siRNAs or an equimolecular mix of all four respective siRNAs (pool) to analyse their effect on EVI/WLS 
protein level. Total cell lysates were analysed by SDS-PAGE and Western blotting for the specified proteins. VINCULIN or β-ACTIN 
served as loading controls. Samples treated with transfection reagent only (mock), non-targeting siRNA (siControl), or siLuciferase 
were used as negative control, siVCP as positive control. The experiments shown here were performed by Annika Lambert. West-
ern blots represent an example of three independent experiments. kDa = kilodalton 
 




Supplementary Figure S3.The knock-down of UBXN6, UFD1, or NPLOC4 by single siRNAs did not show consistent upreg-
ulation of EVI/WLS 
EVI/WLS protein levels did not differ from the control or varied between biological replicates and different single siRNAs af ter 
treatment with single or pooled siRNAs against the candidates investigated here (A, C, E). mRNA expression analyses demon-
strated mostly efficient gene silencing by pooled or single siRNAs with little effects on other investigated mRNAs (B, D, F). 
HEK293T wild type cells were treated with the indicated siRNAs for 72 h. Each gene’s mRNA was targeted by either single siRNAs 
or an equimolecular mix of all four respective siRNAs (pool) to analyse their effect on EVI/WLS protein level or mRNA express ion. 
Samples treated with transfection reagent only (mock) and non-targeting siRNA (siControl) were used as negative control, siVCP 
as positive control. The experiments shown here were performed by Julie Haenlin.  
A, C, E. Total cell lysates were analysed by SDS-PAGE and Western blotting for the specified proteins. VINCULIN served as 
loading control. Western blots are representative of three independent experiments. kDa = kilodalton 
B, D, F. Total cellular RNA was transcribed to cDNA and used for mRNA expression analyses by RT-qPCR. Target gene expression 
was normalised to siControl treatment and GAPDH served as reference gene. Individual data points from three independent ex-
periments are shown. 
 




Supplementary Figure S4. EVI/WLS is degraded with the help of VCP, CGRRF1, and UBE2J2 in A375 melanoma cells 
Knock-down of VCP, CGRRF1, or UBE2J2 prevented degradation of EVI/WLS after LGK974 treatment. A375 melanoma cells were 
treated with LGK974 (10 µM) or equivalent volumes of DMSO as solvent control with daily medium changes. 24 h after start of 
compound treatment, cells were additionally transfected with siRNAs, as indicated. Samples treated with transfection reagent only 
(mock) and non-targeting siRNA (siControl) were used as negative control, siVCP as positive control. Again 72 h later, total cell 
lysates were analysed by SDS-PAGE and Western blotting for the specified proteins. β-ACTIN served as loading control. Western 
blots are representative of three independent experiments. kDa = kilodalton 
 
 




Supplementary Figure S5. siRNA mediated knock-down of targets is efficient in melanoma cells 
RPMI7951 or WM793 melanoma cells were treated with the indicated siRNAs for 72 h. Each gene’s mRN A was targeted by either 
single siRNAs or an equimolecular mix of the single siRNAs (pool). Samples treated with transfection reagent only (mock) or non-
targeting siRNA (siControl) were used as negative control. 
A, B, C. After pre-treatment with siRNAs, total cellular RNA was transcribed to cDNA and used for mRNA expression analyses by 
RT-qPCR. Target gene expression was normalised to siControl treatment (Ctrl) and GAPDH served as reference gene. Individual 
data points from at least two independent experiments are shown with mean and confidence interval (orange), where applicable. 
WNT11 values shown as 0 were below detection limit.  
D, E. After pre-treatment of RPMI7951 cells with siRNAs, secreted proteins were precipitated from the supernatant using Blue 
Sepharose. Eluates and total cell lysates were analysed by SDS-PAGE and Western blotting for the specified proteins. VINCULIN 
or HSC70 served as loading control. The experiment shown in E was performed by Annika Lambert. Western blots are repre-
sentative of three independent experiments. kDa = kilodalton 
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7.2   Supplementary table 
Supplementary Table 1. Genes investigated for EVI/WLS protein stability and phenotypes in HEK293T and A375 cells 













UBE2D1 7321 P51668 HEK293T - this work 
UBE2G1 7326 P62253 HEK293T - this work 
UBE2G2 7327 P60604 HEK293T - Glaeser 
   A375 -/+ this work 
UBE2J1 51465 Q9Y385 HEK293T - Glaeser 
      A375 - this work 
UBE2J2 118424 Q8N2K1 HEK293T ++ Glaeser 
   A375 ++ this work 
UBE2K 3093 P61086 HEK293T ++ this work 
UBE2N/UBC13 7334 P61088 HEK293T +/++ this work 
UBE2U 148581 Q5VVX9 HEK293T - Glaeser 
      A375 - this work 
E3 Ub 
ligases 
AMFR/GP78/RNF45 267 Q9UKV5 HEK293T -/+ Glaeser 
   A375 + this work 
CGRRF1/ 
RNF197 10668 Q99675 HEK293T ++ Glaeser 
      A375 ++ this work 
HRD1/SYVN1 84447 Q86TM6 HEK293T - Glaeser 
      A375 - this work 
MARCH4/ 
RNF174 57574 Q9P2E8 HEK293T - Glaeser 
   A375 +/++ this work 
MARCH6/TEB4/ 
RNF176 10299 O60337 HEK293T + Glaeser 
      A375 -/+ this work 
RNF5 6048 Q99942 HEK293T -/+ Glaeser 
   A375 + this work 
RNF24 11237 Q9Y225 HEK293T -/+ this work 
RNF122 79845 Q9H9V4 HEK293T -/+ this work 
RNF128 79589 Q8TEB7 HEK293T - Glaeser 
      A375 -/+ this work 
RNF139/TRC8 11236 Q8WU17 HEK293T + Glaeser 
   A375 - this work 
RNF170 81790 Q96K19 HEK293T - Glaeser 
      A375 - this work 
UBE4B/UFD2 10277 O95155 HEK293T - this work 
Continued on the next page  
 
   7   Appendix 
VII 
 













ERLEC1 27248 Q96DZ1 HEK293T -/+ this work 
ERLIN1/SPFH1 10613 O75477 HEK293T - this work 
ERLIN2/SPFH2 11160 O94905 HEK293T +/++ this work 
OS9/ERLEC2 10956 Q13438 HEK293T - this work 
SEL1L/HRD3 6400 Q9UBV2 HEK293T + this work 






DERL1 79139 Q9BUN8 HEK293T + this work 
   A375 - this work 
DERL2 51009 Q9GZP9 HEK293T + this work 
DERL3 91319 Q96Q80 HEK293T +/++ this work 
FAF2/ETEA/UBXD8 23197 Q96CS3 HEK293T +/++ this work 
HM13/SPP 81502 Q8TCT9 HEK293T + this work 
      A375 - this work 
NPLOC4/NPL4 55666 Q8TAT6 HEK293T +/++ this work 
RHBDD1/ 
RHBDL4 84236 Q8TEB9 HEK293T + this work 
      A375 - this work 
UBAC2 337867 Q8NBM4 HEK293T + this work 
UBXN4/ERASIN/UBXD2 23190 Q92575 HEK293T +/++ this work 
UBXN6/ 
UBXD1 80700 Q9BZV1 HEK293T +/++ this work 
UFD1/UFD1L 7353 Q92890 HEK293T +/++ this work 
VCP/P97/CDC48 7415 P55072 HEK293T ++ Glaeser 






SCYTHE 7917 P46379 HEK293T - this work 
HERPUD1/HERP 9709 Q15011 HEK293T + this work 
NGLY/PNG1 55768 Q96IV0 HEK293T + this work 
RAD23A 5886 P54725 HEK293T -/+ this work 
RAD23B 5887 P54727 HEK293T -/+ this work 
TMUB1/HOPS 83590 Q9BVT8 HEK293T - this work 
TMUB2 79089 Q71RG4 HEK293T +/++ this work 





ATXN3 4287 P54252 HEK293T - this work 
USP13 8975 Q92995 HEK293T - this work 
USP19 10869 O94966 HEK293T + this work 
USP25 29761 Q9UHP3 HEK293T - this work 
USP50 373509 Q70EL3 HEK293T +/++ this work 
VCPIP1 80124 Q96JH7 HEK293T - this work 
YOD1/OTUD2 55432 Q5VVQ6 HEK293T - this work 
Ub: Ubiquitin; - no effect, + low/variable upregulation, ++ consistent upregulation; Glaeser: Glaeser et al., 2018, PMID: 29378775 
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Publications 
Dix CL, Matthews HK, Uroz M, McLaren S, Wolf L, Heatley N, Win Z, Almada P, Henriques R, 
Boutros M, Trepat X, Baum B (2018). The Role of Mitotic Cell-Substrate Adhesion 
Re-modeling in Animal Cell Division. Developmental Cell, PMID: 29634933 
Wolf L, Lambert A, Haenlin J, Boutros M. EVI/WLS is ubiquitinated by multiple E2 enzymes 
and linked to ERAD by ERLIN2. In preparation 
Voloshanenko O, Aponte D, Seidl C, Wolf L, Kranz D, Ivanova A, Rindtorff N, Augustin I, Russel 
R, Niehrs C, Brügger B, Boutros M. Molecular determinants in Wnts for canonical 
and non-canonical signaling. In preparation 
Rauscher B, Henkel L, Heigwer F, Wolf L, Erdmann G, Boutros M. A Pan-Cancer Analysis of 
Tumor Cell Lineage Dependencies. In preparation 
 
Oral presentations 
7th Anglo-French-German Workshop on Skin Cancer Biology, 2018, Mannheim, Germany 
Identification of genes linked to aberrant Wnt signalling in melanoma, Wolf L 
5th Anglo-German Workshop on Skin Cancer Biology, 2016, London, United Kingdom 
Identification of genes linked to aberrant Wnt signalling in melanoma, Wolf L 
 
Poster presentations 
DKFZ FSP-B Retreat, 2020, Kloster Schöntal, Germany 
Gone with the WNT – WNT ligand dependent endoplasmic reticulum associated 
degradation (ERAD) of EVI/WLS, Wolf L, Lambert A, Haenlin J & Boutros M 
EMBO Workshop: The ubiquitin system, 2019, Cavtat, Croatia  
Gone with the WNT – WNT ligand dependent endoplasmic reticulum associated 
degradation (ERAD) of EVI/WLS, Wolf L, Lambert A, Haenlin J & Boutros M 
Gordon Research Conference: Wnt signaling, 2019, Mount Snow, USA 
Gone with the WNT – WNT ligand dependent endoplasmic reticulum associated 
degradation (ERAD) of EVI/WLS, Wolf L, Lambert A, Haenlin J & Boutros M 
6th Heidelberg Forum For Young Life Scientists, 2019, Heidelberg, Germany 
 Gone with the Wnt – Wnt ligand dependent stabilization of EVI/WLS, Wolf L, Lam-
bert A, Gläser K & Boutros M 
Ubiquitin & Friends, 2019, Vienna, Austria 
 Gone with the WNT – WNT ligand dependent endoplasmic reticulum associated 
degradation (ERAD) of EVI/WLS, Wolf L, Lambert A, Gläser K & Boutros M 
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European Wnt Meeting, 2018, Heidelberg, Germany 
Feel the Wnt on your Skin - How Wnt Signalling Shapes Melanoma’s Invasive Po-
tential, Wolf L & Boutros M 
DKFZ PhD Poster Presentation, 2017, Heidelberg, Germany 
 Having their Feet on the Ground: Ect2 Independent Cytokinesis in RPE1 Cells De-
pends on Adhesion and Daughter Cell Respreading, Wolf L, Dix C, Matthews H, 
Boutros M & Baum B 
Hallmarks of Skin Cancer Conference, 2017, Heidelberg, Germany 
 Having their Feet on the Ground: Ect2 Independent Cytokinesis in RPE1 Cells De-
pends on Adhesion and Daughter Cell Respreading, Wolf L, Dix C, Matthews H, 
Boutros M & Baum B 
22nd DKFZ PhD Retreat, 2017, Weil der Stadt, Germany 
 Daughter Cell Respreading and Adhesion Are Required for Ect2 Independent Cy-
tokinesis in RPE1 cells, Wolf L, Dix C, Matthews H, Boutros M & Baum B 
5th Heidelberg Forum For Young Life Scientists, 2017, Heidelberg, Germany 
 Daughter Cell Respreading and Adhesion Are Required for Ect2 Independent Cy-
tokinesis in RPE1 cells, Wolf L, Dix C, Matthews H, Boutros M & Baum B 
DKFZ FSP-B Retreat, 2015, Kloster Schöntal, Germany 
A high-content screening approach to identify Wnt dependent invasion/metasta-
sis mechanisms in malignant melanoma, Wolf L & Boutros M 
4th Anglo-German Workshop on Skin Cancer Biology, 2015, Heidelberg, Germany  
A high-content screening approach to identify Wnt dependent invasion/metasta-
sis mechanisms in malignant melanoma, Wolf L & Boutros M 
 
Student supervision 
Lambert A (2020), ERLIN2, UBXN4 and FAF2 are involved in ER- associated protein deg-
radation of the Wnt cargo receptor EVI in human cells. Master thesis, Faculty of Sci-
ence, University of Tuebingen 
Haenlin J (2019), Ubiquitin dependent ER associated degradation and localisation of EVI 
in human cells. Bachelor thesis, Faculty of Biosciences, Heidelberg University 
  
 
7   Appendix 
X 
 
7.4   Danksagung 
Viele haben zum Gelingen dieser Arbeit beigetragen, mich inspiriert, motiviert, unterstützt und 
durch ihr Mitwirken an den vielen großen und kleinen Projekten meine Zeit als Doktorandin 
unvergesslich gemacht – ich möchte sie hier nicht ungenannt lassen. Alle, die ich versäumt 
habe zu erwähnen mögen mir verzeihen und sich trotzdem bedankt fühlen. 
Michael Boutros: meine Zeit als Doktorandin in deinem Labor wird für mich immer be-
sonders bleiben. Nur durch deine Unterstützung in den vielen Phasen meiner Projekte war es 
mir möglich, mich während meines Aufenthalts in London, der HOSC2017 Konferenz, und 
meinen zahlreichen außerwissenschaftlichen Aktivitäten persönlich und wissenschaftlich wei-
terzuentwickeln. Ich bin dankbar für die wissenschaftliche Freiheit, die Ressourcen, und die 
vielen Konferenzen, die ich besuchen durfte. Und für das Ubiquitin-Projekt, auch wenn ich das 
zunächst nicht gedacht hätte. Durch dein Feedback und deine Ideen inspirierst du uns alle zu 
immer besserer Arbeit, auch wenn der Weg manchmal mühsam ist. 
Michael Boutros, Buzz Baum, Viktor Umansky und Iris Augustin: für eure wissenschaft-
liche Unterstützung, die Anregungen und Ideen während meiner TAC Treffen und natürlich 
zusätzlich Britta Brügger und Irmi Sinning dafür, Teil meiner Prüfungskommission zu sein. 
Thomas Sommer, dem Sommer Lab, Sina Barysch und Ron Kopito: für sehr wertvolle 
Einsichten in das Ubiquitin-Feld und gute Ideen und Hilfestellungen für mein Projekt. 
Dem RTG2099, ganz besonders Sergij Goerdt, Cyrill Géraud, Jochen Utikal, Viktor Um-
ansky und Adrian Hayday: für die initiale Finanzierung meines Projektes, die vielen unvergess-
lichen und inspirierenden Aufenthalte in London und die gute Zusammenarbeit während mei-
ner Zeit in der MD und PhD Doktorandenvertretung des RTG2099. Auch, wenn wir nicht immer 
einer Meinung waren, die HOSC2017 bleibt unvergessen! Außerdem den vielen anderen Mit-
streitern des RTG2099, besonders Ashik Ahmed Abdul Pari, Katharina Kober und Georg Sed-
lmeier. Und Olga Strobl-Freidekind, Lisa Jakobi und Martina Nolte-Bohres für die viele organi-
satorische Unterstützung. 
Der DKFZ Graduate School, Lindsay Murrells und ihrem Team: für die gute Zusammen-
arbeit während meiner Zeit im PhD Council, und davor und danach und immer. 
Den vielen großartigen Kollegen von B110: ihr habt lange gewartet und ich hab lange 
gebraucht, aber durch eure persönliche und wissenschaftliche Unterstützung, den Austausch, 
die tiefsinnigen Gespräche, die Kinder Schoko-Bons und die vielen witzigen Momente verging 
die Zeit wie im Flug. Ich teile viele Erinnerungen mit euch, die man auch mit einem Glitzi 
Schwann nicht wegwischen kann, wir brauchen aber doch noch eine B110 Playlist. An meine 
 
   7   Appendix 
XI 
 
Mitleidenden des Hot-Offices: es wird keine Klimaanlage kommen. Vor allem möchte ich mich 
bei Dominique Kranz und Oksana Voloshanenko für die viele Hilfe im Labor und bei der Kor-
rektur der Doktorarbeit bedanken. Außerdem für unschätzbare Unterstützung im Labor und in 
allen Lebenslagen bei: Katharina Kober, Josephine Bageritz, Maja Funk, Luisa Henkel, Fillip 
Port, Michaela Holzem, Antonia Schubert, Kathrin Gläser, Benedikt Rauscher, Florian Heigwer, 
Bojana Pavlovic, Christian Scheeder, Alena Ivanova, Jan Winter, Giulia Ambrosi, Tianzuo Zhan, 
Siu Wang Ng, Diego Aponte, Jan Gleixner, Jun Zhou, Erica Valentini, Siamak Redhai, John 
Hawkins, Kim Boonekamp, Shiv Bahuguna, Katharina Imkeller, Niklas Rindtorff und unseren 
vielen Studenten, Angestellten und Laborgästen: Markus Brown, René Riedke, Arek Kendirli, 
Phillip Gmach, Schayan Yousefian, Elena Tonin, Zeynep Aydin, Michaela Wölk, Nancy Klemm, 
Alessio Falzone, Leo Bamberg, Michael Endres, Niklas Krauße, Jenny Hundshammer, Manuela 
Urban, um nur ein paar wenige zu nennen (die Namen sind außerdem in willkürlicher Reihen-
folge, es sind zu viele). Ulrike Hardeland, Angelika Manz, Felicitas Olschowsky: für immerwäh-
rende Unterstützung mit Organisatorischem, vor allem auch während der HOSC2017 Konfe-
renz und im Zusammenhang mit dem RTG2099. Claudia Blass, Claudia Strein, Barbara 
Schmidt, Thilo Miersch: für die vielen großen und kleinen Hilfen, die das Leben in B110 so viel 
einfacher und besser machen. Den Medizinern am Schreibtisch neben mir, Thomas Worst, 
Niklas Westhoff, Christian Galata: tut mir leid, dass ich immer euren Schreibtisch belagert habe. 
Die Mauer aus Ordnern, die Niklas gebaut hat, war aber trotzdem nicht ok. Dharanija: für ein 
unvergessliches Musikerlebnis. 
Katharina Kober: unsere gemeinsame Zeit in B110 werde ich nie vergessen. Wir haben 
viel zusammen durchgestanden und uns immer gut ergänzt, nicht nur deshalb ist die 
HOSC2017 so außergewöhnlich gut gelungen. 
Annika Lambert, Julie Haenlin, Lelia Wagner und Ridzky Yuda: für das Krebszellku-
scheltier, die Enton Karte, die Super Mario Kette, den Schlüsselanhänger, die viele Schokolade 
und andere Süßigkeiten. Aber vor allem für die vielen lehrreichen und witzigen Momente, eure 
Initiative, Ideen, Fragen und die viele Arbeit für unsere Projekte. 
Den Zentralen Einheiten am DKFZ, vor allem der Lichtmikroskopie und der Genom- und 
Proteomforschung: für wertvolle Unterstützung durch kompetente Beratung und Hilfe wann 
immer nötig. Mein Dank gilt vor allem Manuela Brom und Damir Krunic, dem ich mal ein Glas 
Wasser gereicht habe. 
Den vielen Leute, die ich am DKFZ kennengelernt habe: was für eine großartige Zeit 
wir hatten! Vor allem hervorheben möchte ich Sebastian Kruse – mit unseren Party Plänen in 
Straßburg hat meine Zeit in den PhD Council Teams begonnen. Und die unvergleichliche Mira 
 
7   Appendix 
XII 
 
Bujupi, die das Beste an unserer Reise durch Indien war. Besonders möchte ich auch den 
Doktoranden aus der Winter Selection 2015 dafür danken, dass sie mir den Start in Heidelberg 
so einfach gemacht haben. Und den vielen Freunden, bei denen ich mich viel zu selten melde: 
Ashik, Sharavan, Jan, Fereydoon, Laura, Meli, Sara, Juliane … 
Den PhD Council Mitgliedern 2016/2017 und 2017/2018: Isabelle Everlien, Felix Frau-
hammer, Britta Ismer, Manasi Ratnaparkhe, Jacqueline Taylor und besonders Maria Bonsack, 
Florian Köhler, Michael Persicke und Ginny Valinciute. Außerdem den vielen Mitgliedern un-
serer Teams, ganz besonders natürlich dem unermüdlichen Party Team – ich habe euch viel 
abverlangt! Meine Zeit in der Doktorandenvertretung des DKFZ war mit die schönste, lustigste, 
lehrreichste, lohnendste, aber auch anstrengendste Phase als Doktorandin überhaupt. Ich bin 
dankbar für die vielen Projekte, die wir zusammen gemeistert haben und dass ich nicht bei 
jedem Treffen von Michaels Freundschaftsliste gestrichen wurde. Zusammen haben wir viel 
für die Doktoranden erreicht und die besten Partys geschmissen, die das DKFZ je gesehen 
hat. Bedanken möchte ich mich auch bei den Council Mitgliedern vor und nach uns, deren Zeit 
zwar bei Weitem nicht so cool war wie unsere, aber mit denen die Zusammenarbeit immer 
spaßig und produktiv war. 
Buzz Baum und sein Labor in London, vor allem Christina Dix und Helen Matthews: für 
den herzlichen Empfang und die tolle Arbeitsatmosphäre. Mal wieder eine großartige Zeit in 
London, die mir viele schöne Erinnerungen und neue Eindrücke beschert hat. Buzz, du bist 
einer der besten und inspirierendsten Gruppenleiter, mit denen ich bisher arbeiten durfte. 
Frédéric Chevessier: alles im Labor habe ich von dir gelernt und mein innerer Fred sagt 
mir, was zu tun ist. Zumindest hat jetzt niemand anderes mehr meinen Kittel an. 
Den Leuten, die ich in London wieder getroffen habe, vor allem Gabi Carreno, Sara 
Pozzi und Mario Gonzalez Meljem: für eine schöne Zeit, an die ich oft und gerne zurückdenke. 
Der Ananas: für wertvolle Nährwertangaben und treue Begleitung. 
Marius Bruer und Iman Meziane: das L.I.M Team ist das Beste! 
Meinen Mitbewohnern: für sinnvolle und weniger sinnvolle Unterhaltungen und vor al-
lem Sarah für gute Gesellschaft während des Lockdowns. 
Meinen Freunden aus der Schulzeit und ihren Familien: ich hoffe, wir bleiben in Kontakt. 
Den Dragonball Leuten: Pizza essen und bis drei zählen kann man eben nur, wenn auch 
eine Studentin der Musikwissenschaften dabei ist … 
Christopher Dächert: für unzählige schöne Restaurant-, Kino- und Theaterbesuche, ge-
meinsames Kochen und Trinken. Und ja, ich habe diesen Text von dir kopiert. 
 
   7   Appendix 
XIII 
 
Den Adequate tools: eine Ananas: 3,99 €, eine halbe Makrele: 30 Kronen, ein Corona-
Pitcher Murphy‘s: 5,70 €, Freunde mit demselben Humor: unbezahlbar. Vor allem Andi Wild für 
seine dummen (?) Kommentare zu meiner Einleitung, die die letzten Korrekturen viel leichter 
gemacht haben. 
Elfriede und Wolfgang Feyerabend, Hilde und Bill Lingenfelter: für die Erinnerungen. 
Erika Lachmann und Ullrich Wolf: hoffentlich bis bald. 
Meinen Eltern: für alles. 
 




7   Appendix 
XIV 
 
7.5   Acknowledgements 
Many contributed to this work directly or indirectly by motivating, inspiring, and supporting me 
throughout the many projects during my time as a PhD student/doctoral researcher. They 
made this journey so extraordinary and unforgettable and I do not want to leave them unmen-
tioned. And my regards to all the people I forgot to list. 
Michael Boutros: my time as a PhD student in your lab will always remain special to me. 
Only your support made it possible to improve myself personally and scientifically during my 
time in London, the HOSC2017 conference, and my countless extra-curricular activities. I am 
thankful for the scientific freedom, the resources, and the many conferences I attended. And 
for suggesting the ubiquitin project, although I wouldn’t have though that in the beginning. Your 
feedback and ideas inspire all of us to do better work, although it might be tedious at times. 
Michael Boutros, Buzz Baum, Viktor Umansky and Iris Augustin: for your scientific sup-
port, ideas, and suggestions during my TAC meetings, and of course Britta Brügger and Irmi 
Sinning for being part of my Doctoral Defense Examination Commission. 
Thomas Sommer, the Sommer Lab, Sina Barysch and Ron Kopito: for very helpful in-
sights into the ubiquitin field and good ideas and suggestions for my project. 
The RTG2099, especially Sergij Goerdt, Cyrill Géraud, Jochen Utikal, Viktor Umansky 
and Adrian Hayday: for the initial financing of my project, the many unforgettable and inspiring 
visits to London, and the great collaboration during my time as MD and PhD representative of 
the RTG2099. We did not always agree, but the HOSC2017 was extraordinary. Furthermore, 
all the people I met through the RTG2099, notably Ashik Ahmed Abdul Pari, Katharina Kober 
and Georg Sedlmeier. And Olga Strobl-Freidekind, Lisa Jakobi and Martina Nolte-Bohres for 
organisational help. 
The DKFZ Graduate School, Lindsay Murrells and her team: for the great collaboration 
during my time in the council and before, and after, and always. 
The many brilliant colleagues at B110: I took a long time, but time flew thanks to your 
personal and scientific help, the exchange, the meaningful conversations, the Kinder Schoko-
Bons and the many laughs we shared. I owe many fond memories to you that cannot be wiped 
away, but we still need a B110 playlist. To my fellow inhabitants of the hot office: AC is not 
going to come. I especially would like to thank Dominique Kranz and Oksana Voloshanenko for 
their help in the lab and for feedback to this thesis. Moreover for support in the lab and life by 
Katharina Kober, Josephine Bageritz, Maja Funk, Luisa Henkel, Fillip Port, Michaela Holzem, 
Antonia Schubert, Kathrin Gläser, Benedikt Rauscher, Florian Heigwer, Bojana Pavlovic, 
 
   7   Appendix 
XV 
 
Christian Scheeder, Alena Ivanova, Jan Winter, Giulia Ambrosi, Tianzuo Zhan, Siu Wang Ng, 
Diego Aponte, Jan Gleixner, Jun Zhou, Erica Valentini, Siamak Redhai, John Hawkins, Kim 
Boonekamp, Shiv Bahuguna, Katharina Imkeller, Niklas Rindtorff and our many students, em-
ployees, and guests: Markus Brown, René Riedke, Arek Kendirli, Phillip Gmach, Schayan 
Yousefian, Elena Tonin, Zeynep Aydin, Michaela Wölk, Nancy Klemm, Alessio Falzone, Leo 
Bamberg, Michael Endres, Niklas Krauße, Jenny Hundshammer, Manuela Urban, just to name 
few in a random order. Ulrike Hardeland, Angelika Manz, Felicitas Olschowsky: for all the help 
with organisational matters, even throughout HOSC2017 and connected to the RTG2099. 
Claudia Blass, Claudia Strein, Barbara Schmidt, Thilo Miersch: for all the many things you do 
that make B110 life so much better. The MDs at the desk next to mine, Thomas Worst, Niklas 
Westhoff, Christian Galata: I’m sorry to have occupied so much of your desk space. Still, it was 
not ok of Niklas to build a wall out of folders. Dharanija: for a very special music experience. 
Katharina Kober: I’m never going to forget our time at B110. We went through a lot 
together and in the end it turned out great, especially HOSC2017. 
Annika Lambert, Julie Haenlin, Lelia Wagner and Ridzky Yuda: for the cancer soft toy, 
the psyduck card, the Super Mario necklace, the keychain and the many sweets. But most of 
all for the many educational and funny moments, your initiative, ideas, questions, and all the 
hard work you put into our projects. 
The DKFZ Core facilities, especially light microscopy and genomics and proteomics: for 
invaluable help and proficient consulting whenever necessary. I would like to thank Manuela 
Brom and Damir Krunic, whom I once handed a glass of water. 
The many people I met at DKFZ: what a great time we had! I would like to mention 
Sebastian Kruse, our talk about parties in Strasbourg initiated my Council career. And the ex-
traordinary Mira Bujupi, who was the best during our travels through India. Further, I would like 
to thank the people from the PhD Winter Selection 2015 for making my start in Heidelberg so 
easy and the many friends who I contact too rarely: Ashik, Sharavan, Jan, Fereydoon, Laura, 
Meli, Sara, Juliane, … 
The PhD Council Members 2016/2017 and 2017/2018: Isabelle Everlien, Felix Frau-
hammer, Britta Ismer, Manasi Ratnaparkhe, Jacqueline Taylor and especially Maria Bonsack, 
Florian Köhler, Michael Persicke and Ginny Valinciute. Moreover, all the members of our teams, 
most notably the tireless Party Team – I asked a lot! My time as a PhD Student representative 
was amongst the best, funniest, most educational, most rewarding, but also most exhausting 
periods as a PhD student. I’m thankful for all the projects we pursued together and that I wasn’t 
 
7   Appendix 
XVI 
 
crossed off Michael’s friendship list in every meeting. Together, we accomplished a lot and we 
had the best parties ever at DFKZ! I would also like to thank the council members before and 
after us. Although your terms were less cool than ours, the teamwork was always great. 
Buzz Baum and his lab in London, especially Christina Dix and Helen Matthews: for the 
great start and the wholesome work environment. Once more, a great time in London with fond 
memories and new impressions. Buzz, you are one of the best and most inspiring PIs I ever 
had the pleasure to work with. 
Frédéric Chevessier-Tünnesen: everything I know in the lab I learned from you and my 
inner Fred always tells me what to do. At least nobody else wears my lab coats anymore. 
All the people I met again in London, especially Gabi Carreno, Sara Pozzi and Mario 
Gonzalez Meljem: for a great time I like to recall. 
The pineapple: for valuable nutrition facts and loyal company. 
Marius Bruer and Iman Meziane: L.I.M is the best! 
My flat mates: for meaningful and less meaningful conversations and especially Sarah 
for the good company during the Lockdown. 
My friends from school and their families: I hope we stay in touch. 
The Dragonball people: eating pizza and counting to three is only possible, if there is 
also a student of musicology present… 
Christopher Dächert: for countless nice visits to restaurants, the movies, and the thea-
tre, and for cooking and eating together. And yes, I copied this text from you. 
The adequate tools: a pineapple: 3.99 €, half a mackerel: 30 Danish kroner, a Corona-
Pitcher Murphy‘s: 5.70 €, friends with the same sense of humour: priceless. Especially Andi 
Wild for his stupid (?) comments on my introduction, which made the last corrections so much 
better. 
Elfriede and Wolfgang Feyerabend, Hilde and Bill Lingenfelter: for the memories. 
Erika Lachmann and Ullrich Wolf: see you soon. 
My parents: for everything. 
 
Everything will be all right in the end. If it's not all right, then it's not yet the end. 
Unknown  
 
   7   Appendix 
XVII 
 




Eidesstattliche Versicherung gemäß § 8 der Promotionsordnung für die Naturwissenschaftlich-
Mathematische Gesamtfakultät der Universität Heidelberg 
 
1. Bei der eingereichten Dissertation zu dem Thema: 
Ubiquitin-dependent regulation of the WNT cargo protein EVI/WLS 
handelt es sich um meine eigenständig erbrachte Leistung. 
 
2. Ich habe nur die angegebenen Quellen und Hilfsmittel benutzt und mich keiner unzu-
lässigen Hilfe Dritter bedient. Insbesondere habe ich wörtlich oder sinngemäß aus an-
deren Werken übernommene Inhalte als solche kenntlich gemacht. 
 
3. Die Arbeit oder Teile davon habe ich bislang nicht an einer Hochschule des In- oder 
Auslands als Bestandteil einer Prüfungs- oder Qualifikationsleistung vorgelegt. 
 
4. Die Richtigkeit der vorstehenden Erklärungen bestätige ich. 
 
5. Die Bedeutung der eidesstattlichen Versicherung und die strafrechtlichen Folgen einer 
unrichtigen oder unvollständigen eidesstattlichen Versicherung sind mir bekannt. 
 
Ich versichere an Eides statt, dass ich nach bestem Wissen die reine Wahrheit erklärt und 
nichts verschwiegen habe. 
 
Heidelberg, den 24. November 2020   
  
………………………………….. 
    Lucie M. Wolf, M.Sc. 
  
 
7   Appendix 
XVIII 
 
7.7   Declaration on scientific standards 
 
COMBINED FACULTY OF NATURAL SCIENCES AND MATHEMATICS 
 
Sworn Affidavit according to § 8 of the doctoral degree regulations of the Combined Faculty of 
Natural Sciences and Mathematics 
 
1. The thesis I have submitted entitled: 
Ubiquitin-dependent regulation of the WNT cargo protein EVI/WLS 
is my own work. 
 
2. I have only used the sources indicated and have not made unauthorised use of 
services of a third party. Where the work of others has been quoted or reproduced, 
the source is always given. 
 
3. I have not yet presented this thesis or parts thereof to a university as part of an 
examination or degree. 
 
4. I confirm that the declarations made above are correct. 
 
5. I am aware of the importance of a sworn affidavit and the criminal prosecution in 
case of a false or incomplete affidavit. 
 
I affirm that the above is the absolute truth to the best of my knowledge and that I have not 
concealed anything. 
 
Heidelberg, 24th November 2020    
  
………………………………….. 
    Lucie M. Wolf, M.Sc. 
 
